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General introduction 
Esophageal cancer is the 8th most common type of malignancy and the 6th most 
common cause of cancer mortality in the world.1 Worldwide more than 400,000 
patients are newly diagnosed with esophageal cancer each year. The majority of 
patients (>90%) is diagnosed with the two most common histological subtypes: 
squamous cell carcinoma or adenocarcinoma of the esophagus. Esophageal squamous 
cell carcinoma arises from dysplastic squamous epithelium, usually as a result of 
chronic irritation. Substantial alcohol intake, especially in combination with smoking, 
greatly increases the risk of squamous cell carcinoma and accounts for more than 90 
percent of all cases of squamous cell carcinoma of the esophagus in the developed 
world.2 Patients with recurring symptoms of reflux have an eightfold increase in the 
risk of developing esophageal adenocarcinoma.3 Ongoing gastroesophageal reflux 
results in the replacement of normal squamous epithelium by a columnar-lined 
esophagus, which is characterized by the presence of intestinal metaplasia.4, 5 This 
so-called Barrett’s esophagus is the precursor lesion of esophageal adenocarcinoma, 
that develops through a metaplasia – dysplasia – carcinoma sequence.6 
The incidence of esophageal cancer is rising in the Western world, mainly due 
to the increase in adenocarcinomas in the distal esophagus and around the 
gastroesophageal junction over the past decades.7 In The Netherlands, approximately 
1,500 new patients are diagnosed with esophageal cancer annually. Frequently, 
patients are seen at an advanced stage of the disease. Symptoms such as dysphagia 
and odynophagia develop when the tumor is large and obstructing the esophageal 
lumen. Moreover, esophageal cancer is an aggressive disease with early lymphatic 
and hematogenous dissemination. Hence, less than half of the newly diagnosed 
patients are eligible for curative therapy due to tumor invasion into adjacent organs 
such as heart and major airways, or due to the presence of distant metastases.8, 9
After having established the diagnosis esophageal cancer, an assessment of patient’s 
fitness for major surgery and tumor staging need to be performed. The staging 
of esophageal cancer is generally based on the tumor-node-metastasis (TNM) 
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classification developed by the Union Internationale Contre le Cancer (UICC) and the 
American Joint Committee on Cancer (AJCC).10 The T-stage represents the depth of 
tumor infiltration through the esophageal wall, the N-stage describes the absence 
(N0) or presence (N1) of locoregional lymph node metastases, and the M-stage 
reflects potential distant metastases. The T-stages are shown in Figure 1. Endoscopic 
ultrasonography (EUS) has shown to be superior to other imaging modalities in 
staging patient’s preoperative depth of tumor growth (T-stage) and involvement of 
lymph nodes (N-stage).11-14 CT-scanning of chest and abdomen as well as external 
ultrasound of the neck are used for the detection of distant metastases, which often 
comprise involved supraclavicular and cervical lymph nodes and liver metastases.11 
Figure 1. T-stages of esophageal cancer according to the TNM-classification. A T1-tumor is 
limited to the mucosa (T1a) or submucosa (T1b). In case the tumor infiltrates into the muscularis 
propria or through the muscle layer, the lesion is called a T2 or a T3 tumor, respectively. When 
an adjacent organ is invaded, the tumor is staged as T4.
The treatment of patients with esophageal cancer is highly complex and requires an 
interdisciplinary approach with surgeons, gastroenterologists, medical and radiation 
oncologists, and pathologists.8 In the past decade this treatment became more 
tailored to the individual patient.15 In patients with early esophageal cancer, recent 
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advances in endoscopy have changed the indication for surgery. These patients with 
lesions limited to the mucosa (T1a tumors) can now be treated with endoscopic 
mucosal resection (EMR) in experienced centers.16-18 In patients with locally advanced 
esophageal cancer, the role of surgery has also evolved. Surgical therapy varies 
from transthoracic esophagectomy (TTE) with extended lymphadenectomy to less 
invasive surgical techniques such as transhiatal esophagectomy (THE) and minimally 
invasive esophagectomy (MIE). A large randomized controlled trial (RCT) indicated 
that patients with adenocarcinoma of the (distal) esophagus may have a survival 
benefit after TTE, whereas in patients with tumors located at the gastroesophageal 
junction a THE may be sufficient.19, 20
Esophagectomy is associated with a high operative risk.20, 21 Although operative 
mortality is below 5% in high volume centers20, 22, esophageal resection is still 
accompanied by substantial morbidity. Early postoperative complication rates 
vary between 40% and 80%, depending on the applied criteria and on the extent 
of resection.20, 23, 24 Predicting the severity of complications after esophagectomy 
may supply important information for both patient and surgeon. The impact of 
postoperative complications on quality of life plays an important role in decision 
making whether to proceed with an operation in an individual patient with 
esophageal cancer. Furthermore, the prediction of severity of complications in the 
preoperative phase may help in informing patients and in choosing the extent of 
the operation. It is now widely recognized that certain high-risk surgical procedures 
have lower mortality and morbidity rates when performed in high-volume centers, 
which is also true for esophageal cancer surgery.25, 26 For continuous improvement 
of esophagectomy outcome, an optimal treatment strategy for the individual 
patient should be based on proper patient selection by means of preoperative risk 
assessment as well as accurate staging of patient’s TNM-stage and tumor location.
Nevertheless, the prognosis for patients with esophageal cancer who undergo 
esophagectomy with a curative intent rarely exceeds 40%.27, 28 In order to improve 
long-term survival, the role of neoadjuvant chemoradiotherapy has been investigated 
recently in a large multicenter RCT29, of which the long-term results have not been 
published yet.
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Outline of the thesis
This thesis includes studies that address various aspects of esophageal cancer: 
etiology, diagnosis, staging and treatment. The thesis is divided into three parts: part 
A – pathogenesis of Barrett’s adenocarcinoma, part B – optimization of staging and 
part C – preoperative risk assessment and surgical treatment. 
Part A – Pathogenesis of Barrett’s adenocarcinoma
Over the last decade increasing evidence has indicated that not all cells within a 
tumor have the same proliferative and tumorigenic ability, but only a (small) subset of 
the population, named cancer stem cells (CSCs). This cancer stem cell model assumes 
that only this subpopulation of cells has the capacity to sustain tumor growth. In 
chapter 1 an overview is given of the current evidence for the existence of CSCs in 
malignancies, and its potential implications for treatment of solid tumors. Several 
markers have been employed to isolate CSCs from various malignancies, though 
not from esophageal adenocarcinoma. We tested whether Barrett’s esophagus 
and esophageal adenocarcinoma might serve as a model for the CSC concept. The 
results of this study are described in chapter 2. In chapter 3 an overview is given 
of the pathogenesis of Barrett’s metaplasia and its progression towards esophageal 
adenocarcinoma. The risk factors for the development of Barrett’s esophagus are 
reviewed as well as the different theories concerning the cell of origin of Barrett’s 
metaplasia. Also, a summary is given of the tumorigenic steps that are involved in the 
development of esophageal adenocarcinoma. Chapter 4 comprises a short report in 
which the reproducibility of a non-invasive mouse model of Barrett’s esophagus has 
been investigated. 
Part B – Optimization of staging 
Accurate determination of patient’s TNM-stage and tumor location is essential in 
the preoperative phase in order to determine a treatment strategy for the individual 
patient, in particular therapeutic decisions with regard to the optimal surgical 
approach and possible application of neoadjuvant therapy. In chapter 5 the results are 
shown of the study in which the accuracy for determining the location of the primary 
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tumor according to the Siewert classification as well as the lymph nodal status per 
station were investigated prospectively. The preoperative assessment by endoscopy/
EUS and CT-scanning are compared with the histopathologic findings in the resection 
specimen (gold standard). In chapter 6 a study on the feasibility of application of 
the sentinel node procedure in adenocarcinomas of the distal esophagus and GEJ is 
presented, with a focus on its value in the clinical setting. 
In 2001 the Japanese Society of Esophageal Disease introduced its classification in 
which early cancers are subdivided in six successive layers of the mucosa (m1, m2, 
m3) or submucosa (sm1, sm2, sm3). Subdivision in six, rather than two categories has 
been shown helpful in directing patients to the most optimal treatment strategy. In 
general, current treatment options for early esophageal cancer vary from endoscopic 
mucosal resection (EMR) in mucosal lesions to surgical resection with extended 
or regional lymphadenectomy in submucosal tumors. In chapter 7 we attempt to 
address the question whether the presence of occult metastases in patients with m3 
and sm1 adenocarcinomas will influence the decision to undertake an endoscopic 
or surgical resection. In chapter 8, we evaluate the reproducibility of the Japanese 
classification of early esophageal cancer. The inter- and intraobserver variation 
among gastrointestinal pathologists in grading early oesophageal adenocarcinoma 
according to the criteria proposed by the Japanese Society for Esophageal Disease is 
analyzed on surgical resection specimens.
Part C – Preoperative risk assessment and surgical treatment
Individual preoperative risk assessment is essential for a proper patient selection in 
the preoperative phase. In chapter 9 patients’ preoperative risk assessment and the 
potential risk factors that can be taken care of both preoperatively and intraoperatively 
in order to prevent postoperative complications in patients with esophageal cancer 
are reviewed. Predictive factors such as age, pulmonary and cardiovascular condition, 
nutritional status, and neoadjuvant chemo(radio)therapy are discussed. In chapter 
10 and 11 the prognostic value of body mass index and of delay in diagnostic work-
up on short-term and long-term outcome after resection of esophageal cancer are 
studied, respectively. Furthermore, a recently developed nomogram predicting the 
occurrence and severity of complications in esophagectomy patients is validated 
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externally in a large cohort of patients who underwent esophagectomy for cancer in 
an independent high-volume center. These results are shown in chapter 12. Finally, 
an international study is reported in chapter 13, which focuses on the best surgical 
treatment for early esophageal cancer with submucosal tumor infiltration (T1b). The 
short-term and long-term outcome of patients who underwent esophagectomy for 
T1b cancer through a transthoracic approach with extended lymphadenectomy is 
compared retrospectively to those of patients in whom a transhiatal esophagectomy 
was performed with regional lymph node dissection only.
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Abstract
There is increasing evidence that a variety of human cancers is maintained 
by a subset of cells, the so-called cancer stem cells (CSCs), which sustain 
tumor growth, underlie its malignant behavior, and possibly initiate distant 
metastases. Notwithstanding the ongoing debate on the operational 
definition of CSCs, there is little doubt that at least some tumors share the 
hierarchical organization characteristic of normal tissues with multipotential 
progenitors as well as more differentiated cell types. Likewise, CSCs are 
characterized by the two main properties of normal stem cells: self-renewal 
(i.e. the capacity to retain their stem cell identity after each cell division) 
and the ability to differentiate into more specialized cell lineages. Also, CSCs 
seem to be intrinsicly resistant to DNA damaging agents, which make them 
resistant to chemo- and radiotherapy. As such, the very existence of CSCs 
has vast clinical implications and opens new avenues with regard to cancer 
treatment. The development of tailor-made CSC-targeted therapies may 
entail great promises: direct eradication by means of therapies directed at 
CSC-specific surface markers, inhibition of self-renewal signaling pathways 
that are crucial for CSCs, reversal of the intrinsic resistance of CSCs to chemo- 
and radiotherapy, and induction of terminal differentiation. 
Here, we review and evaluate the current evidence for the existence of CSCs 
and the implications on the present management and treatment of cancer, 
including surgical therapy.
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1
Introduction
Until recently, the knowledge of tumor development favored the consecutive 
accumulation of genetic and epigenetica events at tumor suppressor genes and 
oncogenes in cells leading to the malignant phenotype. A number of cellular changes 
such as resistance to programmed cell death (apoptosis), insensitivity to growth-
inhibitory signals, limitless replication and cell division, and growth induction of 
new blood vessels (angiogenesis), provide growth advantage to tumor cells.1 In this 
‘textbook’ model all cells within a certain tumor share these selective advantages 
and as such have similar tumor-propagating capacities. However, this model does not 
take into account the morphological and functional heterogeneity that characterizes 
most cancers. Over the last decade increasing evidence has indicated that only a 
(small) subset of tumor cells, the so-called cancer stem cells (CSCs), has tumorigenic 
properties together with the capacity to self-renew and differentiate.2-4 Hence, CSCs 
may represent the driving force behind tumor growth, malignant behavior, and 
dissemination. 
These alleged characteristics of CSCs have attracted interest from outside the 
scientific and medical community mainly because of the prospect that they might 
provide a unique target for cancer treatment. However, many questions need yet to 
be answered concerning the very existence of CSCs, their operational definition, and 
their applicability in the treatment of cancer.
Cancer stem cells: definition and controversies
The first evidence for the concept of CSCs came from hematologic malignancies. 
In 1997, John Dick and colleagues identified a subpopulation of human leukemia 
cells that was enriched for tumor initiating abilities: only a small subset of cells 
(earmarked by expression of the cell-surface markers CD34+CD38- b) was able to 
recapitulate human leukemia when injected into immunodeficient mice (NOD-SCID 
a Epigenetics is the study of inherited changes in gene expression caused by mechanisms 
other than changes in the underlying DNA sequence (mutations).
b CD-markers (‘cluster-of-differentiation’-markers) are cell-surface markers. The marker 
expression CD34+CD38- refers to the presence of marker CD34 and the absence of marker 
CD38 on the surface of the cell.
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micec), in contrast to other tumor cells.5 In specific, as few as 5,000 CD34+CD38- 
cells were able to initiate tumor growth, whereas as many as 500,000 cells of the 
remaining tumor cell population failed to engraft. Furthermore, analysis of the 
engrafted mice demonstrated that CD34+CD38- cells could expand and differentiate 
into a heterogeneous leukemic cell population reminiscent of the patient’s primary 
disease.6 In other words, tumor cells with expression of cell-surface markers other 
than CD34+CD38- were again detected in the transplanted tumors, in ratios similar to 
those observed among leukemic cells directly isolated from the patient. CD34+CD38- 
cells were then isolated a second time (now from the tumor engrafted in NOD-SCID 
mice) and injected into secondary recipient animals. Once again, only the newly 
isolated CD34+CD38- cells were enriched in tumor propagating capacities when 
compared to other tumor cells. These studies provided experimental support for the 
capacity of this subset of cancer cells to self-renew and differentiate: two intrinsic 
features of stem cells in general. Accordingly, the term cancer stem cells (CSCs) is 
often employed. Alternatively, the name tumor initiating cells (TICs) has also been 
used although it only reflects their engrafting potential and does not encompass 
the ability of these cells to recapitulate the diversity of the patient’s primary tumor 
(differentiation). As the latter has been shown to vary considerably depending on 
the experimental set up and the type of recipient animal employed4, 7, we will here 
use the CSC acronym as it appropriately refers to the stem-like characteristics (self-
renewal and differentiation) essential for tumor maintenance and growth.  
Definition of cancer stem cells
CSCs have been defined as a distinct subpopulation of tumor cells able to propagate the 
primary malignancy when engrafted in immunodeficient mice at low multiplicities.2, 
8 The transplanted tumors recapitulate the complexity and heterogeneity of the 
patient’s primary tumor. As illustrated by the original study by John Dick, these cells 
are thought to encompass the two main properties of normal tissue stem cells: 
self-renewal and differentiation.2, 8 Self-renewal refers to the capacity of a stem cell 
c NOD-SCID mice are non-obese diabetic severe combined immunodeficient mice, which lack 
both B- and T-cell activity. Immunodeficient mice are required for these experiments as the 
transplantation of human cells into mice with an intact immune system will cause a rejection 
of the human cells.
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to divide while still retaining its ability to generate multiple cell lineages. This can 
be achieved by symmetric and asymmetric cell divisions. When a stem cell divides 
asymmetrically two different daughter cells are produced: one retains the stem cell 
properties (self-renewal) while the second is committed to become a specialized 
cell (differentiation).9 Alternatively, symmetric cell divisions will result into two 
identical daughter stem cells. In both scenarios, stem cells retain their identity 
after each cell division thus preventing their own exhaustion. While symmetric and 
asymmetric cell divisions are finely tuned and balanced within a stem cell niched to 
control tissue homeostasis, CSCs seem to have lost some of the control mechanisms 
thus resulting in a partially heterogeneous tumor mass when transplanted in 
immunodeficient recipient animals. Self-renewal and differentiation in CSCs are best 
assayed by serial transplantations (Figure 1): after isolation of the CSC-enriched cell 
population (earmarked by expression of a specific combination of CD-markers) from 
the patient’s tumor and its injection into immunodeficent mice, a tumor is formed 
that recapitulates the diversity of the primary lesion. From the transplanted tumor, 
CSC isolation and transplantation can be serially repeated for multiple rounds with 
similar results (‘serial transplantability’). At a consensus meeting, CSCs have indeed 
been defined as those cells within a tumor that possess the capacity to self-renew 
and to generate the heterogeneous cell population that comprises the primary 
tumor.8 Hence, to date, the gold standard and operational definition of CSCs is the 
transplantation assay that assesses their ability to establish tumor growth when 
injected at low multiplicities into immunodeficient mice.5, 6 
Recently, it has been shown that intestinal cancer is triggered only when specific 
mutations occur in normal stem cells but not in progenitor (transient-amplifying) 
cells.10 However, the cell of origine of the tumor is a distinct issue than the cancer 
stem cell concept.11 CSCs are the cells that maintain the tumor mass but do not 
necessarily originate from the transformation of normal stem cells, and may also 
arise from progenitors or more differentiated cells that have acquired self-renewing 
capacity.12 
d A stem cell niche is the microenvironment in which stem cells are found, which interacts with 
stem cells to regulate stem cell fate.
e The cell of origin is the cell that undergoes the first and rate-limiting mutation event (first hit) 
and thus initiates tumor formation.
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Figure 1. Schematic presentation of the transplantation assay applied in the study of cancer 
stem cells and the concept of serial transplantability.
Identification of cancer stem cells in solid tumors
Breast cancer represents the first solid malignancy from which CSCs were identified 
and prospectively isolated. A CD44+CD24-/low cell population (comprising 1-10% of the 
bulk of the tumor) was identified to be significantly enriched for tumor propagating 
abilities. As few as 200 CD44+CD24-/low breast cancer cells were capable of forming 
tumors when implanted into NOD-SCID animals.13 In contrast, 20,000 cells that did 
not express these markers were unable to initiate tumor growth. Consistent with 
the CSC model, the CD44+CD24-/low cell population was able to generate tumors that 
recapitulated the phenotypic heterogeneity of the primary cancer. Therefore, this 
study reported for the first time the identification of a CSC population in a solid tumor 
that was able to self-renew, proliferate and differentiate in order to regenerate the 
phenotypically heterogeneous primary tumor when injected into immunodeficient 
mice. 
By following similar transplantation approaches, cell-surface antigens that earmark 
tumorigenic populations capable of transferring and recapitulating human disease 
into immunodeficient animals have been characterized in various other human 
malignancies. These include predominantly CD-markers that have proved useful for 
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the prospective isolation of subsets of live tumor cells enriched in CSCs (Table 1). 
Some of these cell-surface markers (e.g. CD133 or CD44) have been found to identify 
CSCs in a broad spectrum of cancers, though it is yet not known whether they also 
play a functional role in regulating CSCs.
Table 1. Cell-surface phenotype of CSCs identified in solid tumors. 
Tumor type CSC marker Reference(s)
Breast CD44+/CD24-/low 13
Brain CD133+ 55
Colon CD133+
EpCAMhigh/CD44+/CD166+
17, 18
56
Pancreas CD44+/CD24+/EpCAM+
CD133+
57
41
Lung CD133+ 58
Liver CD90+CD45- 59
Melanoma ABCB5+ 50
Transplantation assay - a guide for skeptics? 
To date, the transplantation assayf in immunodeficient mice represents the only 
operational definition of CSCs. As mentioned above, in this assay tumors are 
surgically resected from patients and then reduced into single cell suspensions by 
enzymatic digestion and mechanic dissociation. These suspensions are analyzed by 
means of flow cytometry (Fluorescence Activated Cell Sorting – FACS) to evaluate 
the expression of specific cell-surface antigens, and to sort the different tumor cell 
subpopulations to allow in vitro (cell culture) and in vivo (transplantation) analysis. 
Transplantations can either be performed subcutaneously or orthotopicallyg. 
Notwithstanding the merits of the operational definition by transplantation assays, 
it is important to recognize that CSC identification efforts that rely exclusively on 
tumorigenicity assays of sorted cancer cell subpopulations have clear limitations. An 
important question is whether the use of immunodeficient mice is a reliable model 
for studying human cancer. This method does not take into account the extent to 
which tumor growth might be positively or negatively affected by the macro- and 
f The transplantation assay is the experimental standard for identification of CSCs: a distinct 
subpopulation of tumor cells can be identified that has the ability to propagate and recapitulate 
the complexity and heterogeneity of the primary tumor when engrafted in immunodeficient 
mice.
g An orthotopic injection is an injection of tumor cells in the tissue/organ of origin; e.g. 
injection of a breast cancer-cells into the mammary fat-pad of the mouse.
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micro-environment provided by the host animal. The presence of residual immune 
function in the recipient animals can significantly influence the efficiency of human 
cell engraftment. For example, NOD-SCID mice showed improved engraftment 
rates with leukemia cells when compared to SCID mice, which also lack B- and T-cell 
activity though to a lesser extent.5, 6 NOD-SCID mice still retain natural killer (NK) cell 
activity, which is thought to reject most transplanted human cells.14 Accordingly, it 
was shown that the lack of NK-, B- and T-cell activity (as established in the so-called 
NOD-SCID-IL2Rγ-null mice) has dramatic effects on tumor engraftment rates and 
on the estimated frequency of tumor initiating cells: approximately one in a million 
melanoma cells form tumors in ‘conventional’ NOD-SCID mice compared to one in 
four in NOD-SCID-IL2Rγ-null mice.7 Hence, depending on the type of immunodeficient 
recipient animals employed, transplantation assays can lead to large variations in the 
estimate of the frequency of tumorigenic cancer cells. 
Another factor that affects tumor initiating cell estimates is represented by the 
transplantation site. Striking differences have been observed when tumor cells were 
transplanted into different microenvironments: intracranial injection of putative 
CSCs of glioblastoma consistently induced neoplastic growth, while significantly 
reduced rates of tumor formation were observed when the same cells were injected 
subcutaneously.15 In the case of colon CSCs (where orthotopic transplantation 
experiments, i.e. by injection in the intestinal wall, have been described16 but are 
relatively difficult to implement), marked differences in the tumor initiating frequency 
of cells injected in the kidney capsule compared to the subcutaneous technique were 
reported.17, 18 
The variable frequencies of tumor initiating cells estimated in different malignancies 
depending on the experimental set-up have raised doubts on the validity of the CSC 
model.7, 19 However, as emphasized by John Dick and colleagues20, the fundamental 
concept underlying the CSC model is independent of the absolute tumor initiating 
frequency of these cells. Instead, the model proposes that the functional 
heterogeneity within tumors reflects a hierarchical organization with a distinct 
population of cells that can initiate malignant growth in vivo while the remaining cells 
cannot. Nevertheless, it cannot be a priori assumed that all types of malignancies, 
with no exception, comply with the CSC model. 
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In conclusion, notwithstanding its reported limitations, transplantation into 
immunodeficient mice is the only available method to operationally define whether 
human CSCs have the potential to form tumors. At present, the main alternative is 
represented by in vitro cell culture methods that select for the stem cell capacity of 
growing in suspension in an undifferentiated state (spheroids). These non-adherent 
spheres were shown to be enriched in both stem- and progenitor cells and have 
been established from a broad spectrum of tumor types (e.g. neurospheres from 
glioblastomas21, mammospheres from breast cancer22, colospheres from colorectal 
cancer18). Primary sphere-derived cells are able to initiate secondary spheres as 
well as differentiate to give rise to various specialized cell lineages, thereby again 
demonstrating the two fundamental properties of stem cells, i.e. self-renewal and 
differentiation. Although promising, these in vitro suspension cultures of CSCs still 
rely on transplantation in immunodeficient mice to assay their in vivo differentiation 
potential.
Cancer stem cells and dissemination
Only a minority of cancer cells has the ability to detach from the primary tumor 
mass, invade the surrounding tissues and disseminate to distant organ sites to 
form metastases. Metastatic potential depends on multiple factors that determine 
overall tumor growth, angiogenesis and invasion. Among epithelial malignancies 
(carcinomas), the so-called epithelial-to-mesenchymal transitionh (EMT) represents a 
crucial event in invasion and metastasis. In adult tissues, EMT is involved in processes 
such as wound healing, tissue regeneration and organ fibrosis.23 In cancer, EMT is 
thought to endow tumor cells the capacity to detach from the primary tumor mass 
by loosing cell adhesive properties and acquiring motile features, thus enabling 
local invasion, intravasation into blood or lymph vessels, extravasation and the 
recapitulation of the primary tumor at distant sites through the reverse process of 
mesenchymal-epithelial transition (MET).23, 24 
h The term epithelial-mesenchymal transition (EMT) refers to a process where epithelial cells 
undergo loss-of-cell-adhesion features and acquire increased cell mobility.
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In colon cancer, constitutive activation of the Wnt signaling pathwayi is preferentially 
observed at the invasive front of the primary lesion where it earmarks cells undergoing 
EMT and detaching from the primary tumor into the stromal microenvironment.25, 26 
Cells undergoing EMT may also develop resistance to anticancer agents. In fact, EMT 
can be induced by stress conditions such as neoadjuvant chemo- or radiotherapy.27 
These observations have led to the concept of ‘migrating CSCs’ where EMT cells 
have acquired stem cell features that give them the plasticity to adapt to different 
environments and eventually metastasize to distant organ sites.25
Indeed, recent evidence suggests that there may be a direct link between EMT and 
acquisition of CSC properties. Induction of EMT in a mammary epithelial cell line 
resulted in enrichment in cells with CSC characteristics such as tumor-seeding ability 
and the expression of cell-surface markers reminiscent of breast CSCs.12, 28 This so-
called phenotypic plasticityj suggests that a dynamic equilibrium may exist between 
CSCs and non-CSCs within tumors possibly regulated by the microenvironment, 
the CSC niche, similar to normal stem cell niches controlling stem cell number and 
proliferation.29, 30 A more recent study has demonstrated that the stemness of colon 
cancer cells is at least in part regulated by the microenvironment.31
The studies showing that CSCs and non-CSCs are mutually exchangeable have 
been interpreted as the denial of the very CSC model: cancer stemness is not a 
cell autonomous state and in theory each tumor cell can be converted into a CSC 
upon exposure to specific environmental cues. Nevertheless, the possibility of a 
bidirectional exchange between stem-like and more committed cancer cells does 
not in itself undermine the essence of the CSC concept according to which tumors 
encompass distinct cell identities earmarked by specific phenotypic and functional 
characteristics.32 Moreover, the CSCs’ intrinsic capacity to undergo EMT may provide 
an explanation for the variation in frequency of CSCs between different malignancies7 
and perhaps even between patients. Individual and tissue-specific variations in the 
expression of microenvironmental signals are likely to affect relative numbers and 
malignant behavior of CSCs among different tumors and patients. Nevertheless, it 
i The Wnt signaling pathway refers to a sequence of biochemical events capable of transducing 
an extracellular signal to the nucleus by modulating expression of specific target genes. Wnt 
plays an important role in the regulation of different stem cell niches and its constitutive (i.e. 
uncontrolled) activation represents the main cause of colon cancer. 
j The phenotypic plasticity of a cell is the ability to change its phenotype in response to changes 
in the environment.
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should be noted that thus far no direct experimental evidence has been provided 
showing that CSCs indeed underlie the process of dissemination and metastasis.
Therapeutic implications
The identification of CSCs has potentially vast implications: not only for cancer 
research but also (and more importantly) for the clinical management of cancer in 
terms of the development of future targeted therapies. For example, in genome-
wide expression analyses of whole tumor preparation (in which CSCs often represent 
a minor subpopulation), CSCs are poorly represented in the resulting gene signatures 
meant to predict prognosis of the cancer patient. It will be interesting to assess 
whether CSCs signatures will be more accurate predictors of survival and of response 
to treatment. Here, we will focus on the consequences and implications of the CSC 
model for neoadjuvant therapy and surgical intervention.   
Implications for neoadjuvant therapy and surgery 
Together with surgery, neoadjuvant chemo- and/or radiotherapy are widely used 
in the treatment of specific stages of various solid malignancies such as breast 
and colorectal cancer. At present, neoadjuvant treatment targets the proliferative 
potential of the tumors by killing rapidly dividing cells within the bulk of the tumor. 
However, even a therapy that successfully affects the vast majority of tumor cells 
and is considered to be highly efficient based on the initial shrinkage of the primary 
mass, will most likely leave CSCs unaffected which will eventually underlie relapse. 
This hypothesis is plausible in view of several characteristics of CSCs, which make 
them resistant to DNA damage-induced cell death. An intrinsic or acquired resistance 
to cytotoxic agents or radiation is indeed likely to play a role.33 The underlying 
mechanisms include increased DNA damage recognition and repair, impairment 
of tumor apoptotic pathways, and reduced accumulation of chemotherapeutic 
agents through enhanced drug efflux (toxic agents are pumped out by the CSCs).33 
Furthermore, it has been shown that, at least in some tumor types (e.g. leukemia and 
ovarian cancer), CSCs may encompass a slow-cycling subpopulation34-36 (the so-called 
quiescent or dormant CSCs), which may escape conventional chemotherapeutic 
regimens that target actively cycling cells.
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Evidence for preferential resistance of CSCs to neoadjuvant therapy has been 
provided. In glioblastoma the fraction of CD133+ CSC population was found to be 
enriched after radiation.37 Also, compared to their CD133- counterparts, CD133+ 
glioblastoma cells exhibited lower rates of apoptosis in response to chemotherapy.38 
In breast cancer, significantly increased levels of cells expressing the CSC-markers 
have been reported in residual tumor cell populations in patients who had 
received conventional chemotherapy compared to the tumors evaluated prior to 
therapy.39, 40 Also, in pancreatic cancer CD133+ cells showed increased resistance 
to chemotherapeutic agents.41 The cellular and molecular mechanisms underlying 
CSCs’ innate resistance to chemo- and radiotherapy include expression of specific 
interleukins42, 43, lower levels of reactive oxygen species (ROS)44, and ATP-dependent 
drug transporters33. Overall, these data point to the clinical relevance of the CSC 
model by providing experimental evidence for increased resistance of CSCs to 
conventional neoadjuvant therapies directed at bulk populations of tumor cells. 
The CSC model predicts that complete cure can not be achieved unless all CSCs 
are removed, either surgically or in combination with neoadjuvant chemo- or 
radiotherapy. Accordingly, it has been hypothesized that preoperative labeling of 
CSCs can give valuable information on the best surgical approach with regard to 
tumor invasion into adjacent structures and lymph node dissection, but also on 
the presence of potential circulating tumor cells (CTCs).45 In fact, significantly less 
CTCs were detected in portal blood after tumor mobilization by laparoscopic surgery 
compared to open surgery in colorectal cancer patients46, thus further supporting 
the reduced tumor cell dissemination with a no-touch operation technique. 
Therapeutic opportunities
The implications for neoadjuvant and surgical therapy highlight the therapeutic 
promise of CSC-directed treatment strategies. Potential therapies which are selective 
to CSCs and not toxic to normal stem cells hold great promise for the effective and 
potentially curative impact on many human malignancies. CSC-targeted strategies 
(Figure 2) may include (a) direct targeting of CSCs through antibodies directed at CSC-
surface markers, (b) blocking essential self-renewal signaling pathways, (c) reversal 
of CSCs’ innate resistance to chemo- and radiotherapy, and (d) induction of CSC 
terminal differentiation.47, 48 
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Figure 2. Therapeutic strategies for cancer treatment directed at cancer stem cells and bulk 
tumor cells.
Direct targeting of CSCs through their CSC-surface markers seems an obvious yet not 
straightforward solution as most of the CD markers identified to isolate tumor cell 
subpopulations enriched in CSCs are also expressed in normal cells. Therefore, the 
definition of an appropriate ‘therapeutic window’ will represent a major challenge 
for the clinical implementation of this CSC-targeted strategy. Nevertheless, selective 
killing by means of administration of an anti-CD44 and anti-ABCB5 antibodies in 
acute myeloid leukemia (AML)49 and melanoma50, respectively, was sufficient to 
inhibit tumor growth, thereby supplying the initial proof of principle for the potential 
therapeutic applications of this approach. 
Blocking essential self-renewal signaling pathways such as Wnt, Hedgehog and 
Notch (known to be activated in CSCs) also represents a promising therapeutic 
strategy. In colon cancer, small-molecules inhibiting the Wnt- and Notch pathway 
have recently been identified.51 Nevertheless, these pathways play equally important 
roles in the maintenance of normal stem cells, which again points to the potential 
cytotoxic side-effects of such small molecules on normal tissues. Specific targeting 
of signals that regulate CSC resistance to chemo- and/or radiotherapy, may also 
represent a promising approach for adjuvant therapy to enhance the efficacy of 
conventional chemo- and radiotherapy regimes. Inhibition of the enhanced drug 
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efflux characteristic of CSCs has been achieved by antibodies directed against ABC-
transportersk in melanoma.52 In colon cancer, further support for the potential utility 
of CSC chemosensitizing agents was provided: pretreatment of CD133+ colon CSCs 
with an interleukin-4-specific neutralizing antibodyl enhanced apoptosis mediated by 
chemotherapy both in vitro and in vivo.43 
Finally, differentiation therapy might induce CSCs to differentiate into more mature 
tumor cells thus limiting their tumorigenic and invasive potential. For example, 
salinomycin has been described as the first compound that is able to decrease the 
proportion of CSC-phenotypic breast cancer cells and to eradicate selectively the tumor 
by inducing terminal epithelial differentiaton.53 The alleged existence of quiescentm 
CSCs and their established intrinsic resistance to DNA-damaging agents which rely 
on active cell division also opens novel therapeutic avenues. In a mouse model for 
AML, quiescent stem cells can be induced to enter the cell cycle by treatment with 
growth factors (e.g. G-CSF) thus rendering them more susceptible to conventional 
chemotherapy. In combination with cell cycle-dependent chemotherapy, G-CSF 
treatment was indeed shown to significantly enhance induction of apoptosis and 
elimination of human primary AML stem cells in vivo54. 
k ABC-transporters (ATP-binding cassette transporters) are transmembrane proteins that 
utilize the energy of ATP hydrolysis to carry out a broad spectrum of biological processes 
including the transport of various substrates across cell membranes, e.g. metabolic products, 
lipids and drugs.
l Interleukin-4 (IL-4) is a cytokine that stimulates the immune system. It has been previously 
shown that IL-4 plays a central role in resistance to induction of cell death (apoptosis). By 
neutralizing its effect by means of an antibody, apoptosis caused by chemotherapy can be 
increased. In other words, cells are sensitized to chemotherapy.
m Quiescence is the state of a cell when it is not dividing; it refers to the G
0
 phase of a cell in 
the cell cycle. 
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Conclusion
The growing evidence indicating that CSCs drive and maintain various types of human 
malignancies has important implications for the treatment of patients. However, 
over the years the development of CSC-targeted therapies has faced a number of 
potential hurdles, including normal stem cell toxicity and treatment resistance. These 
must be considered carefully in order to maximize the chance that such therapies 
will be successful. Following the more recent findings suggesting the interaction 
between EMT and CSCs and the regulation of the stemness of cancer cells by the 
tumor microenvironment (indicating that the distinction between CSCs and non-CSC-
tumor cells may not be the clear dichotomy as it was proposed originally), cancer 
therapy should ideally include agents targeting both CSCs and non-CSCs (Figure 2). 
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Abstract
Accumulating evidence has suggested that tumors have a hierarchical 
organization where only the cancer stem cells (CSCs) have tumor-initiating 
properties. Several surface antigens have been employed to isolate CSCs from 
various malignancies, though not from esophageal adenocarcinoma (EA). We 
tested whether Barrett’s esophagus (BE) and EA might serve as a model for 
the CSC concept. 
In vivo assays were performed by transplantation of serially diluted bulk EA 
cells into NOD-SCID mice to establish the presence and frequency of tumor-
initiating cells. These were found to be present in approximately 1:64,000 
cells. The transplanted tumors fully recapitulated the primary lesions. 
Subsequently, a panel of previously established CSC markers was employed 
for immunohistochemistry. CD24, CD29 and CD44 showed heterogeneous 
staining in EA. Nuclear ß-catenin accumulation increased during progression 
from metaplasia to dysplasia, and was often observed in the basal compartment 
with CD24 and CD29 staining. However, the overall staining patterns were not 
such to clearly point out specific candidate markers. Accordingly, all markers 
were employed to sort the corresponding subpopulations of cancer cells and 
transplant them at low multiplicities in NOD-SCID mice. No increased tumor-
initiating capacity of sorted EA cells was observed upon transplantation. 
These results indicate that tumor-initiating cells are present in EA, thus 
reflecting a hierarchal organization. However, antibodies directed against 
novel surface antigens are needed to detect subpopulations enriched for CSCs 
in EA by transplantation assays.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
Esophageal adenocarcinoma and cancer stem cells 
39
2
Introduction
Esophageal exposure to refluxed gastric contents (gastro-esophageal reflux disease, 
GERD) represents the major risk factor in the replacement of squamous epithelial 
cells lining the esophagus by an intestinal columnar epithelium, a condition known 
as Barrett’s esophagus (BE)1. The intestinal metaplasia characteristic of BE features 
mucous glands and goblet cells2,3, and is recognized as a premalignant condition4, 
5. It is generally accepted that the development of esophageal adenocarcinoma 
(EA) follows a metaplasia (BE) → dysplasia → carcinoma sequence characterized by 
specific genetic and epigenetic changes6. However, the cell of origin involved in the 
transition from normal squamous epithelium into intestinal metaplasia has not been 
identified yet. Transdifferentiation of esophagus-specific cell types into intestinal-like 
columnar epithelial cells as the result of GERD may explain the observed histological 
changes7, 8. On the other hand, it is also plausible that resident stem cells are involved 
in this process. In this alternative scenario, BE develops when GERD damages the 
superficial layers of the esophageal squamous epithelium, thereby exposing the 
basal epithelial layers (where stem cells are thought to reside9) to tissue-damaging 
agents thus triggering abnormal differentiation programs and metaplastic changes6, 
7. Attempts towards the isolation and characterization of stem cells of the normal 
esophageal epithelium have not been successful thus far, although more recently 
CD34 has been shown to represent a stem cell marker in the mouse esophagus10. 
Patients with BE have a significantly higher risk of developing EA when compared 
to the general population11, 12. The overall estimate of cancer incidence in BE varies 
between 6 and 7 cases per 1,000 person-years (0.6 – 0.7% per year)13, 14. Currently, 
high-grade dysplasia represents the most reliable predictor of progression to 
EA. Surgery (by means of radical esophagectomy) is the best curative option for 
adenocarcinoma of the distal esophagus or gastro-esophageal junction, provided 
that neither tumor infiltration in adjacent organs nor distant metastases are present. 
Nevertheless, even in this selected patient group, five-year survival rarely exceeds 
40%15-17.
In recent years, accumulating experimental evidence has suggested that tumors 
have a hierarchal organization where a minority of cells, the cancer stem cells (CSCs), 
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is characterized by tumor-initiating properties when transplanted into immuno-
incompetent recipient animals18-21. The CSC concept has immediate therapeutic 
consequences: if cancer growth is sustained by CSCs, then curative therapy will 
require targeting this specific subpopulation22, 23. Combinations of cell-surface antigen 
markers are currently being employed for the prospective isolation of these tumor-
initiating cells and their subsequent in vitro and in vivo functional analysis24-26. During 
the past years, specific combinations of these surface antigens, the so-called Cluster 
of Differentiation (CD) markers, have been shown to enrich for CSCs in different 
tumor types, among which colorectal adenocarcinoma27-29, but not in EA of Barrett’s 
origin. 
Because of their etiology and natural history, BE and EA are likely to represent a 
unique model to study the cellular and molecular mechanisms underlying the onset 
and malignant behavior of CSCs. Here, we present an initial set of experiments aimed 
at the identification of tumor-initiating cells in EA as well as the evaluation of the 
expression pattern of CSC markers previously reported in other tumor types during 
the metaplasia → dysplasia → carcinoma sequence.
Material and methods 
In vivo transplantation assays
To establish the presence and frequency of tumor-initiating cells in EA, 
esophagectomy resection specimens from patients with lesions located in the distal 
esophagus with or without infiltrative growth at the gastro-esophageal junction 
were employed. Only tumors of patients in whom no neo-adjuvant chemo- and/or 
radiation therapy was applied were considered appropriate for the transplantation 
experiments. In the period between January 2008 and February 2009, a total number 
of 17 esophagectomy resection specimens were obtained. Tumor samples were 
obtained from the resection specimens immediately after arrival at the Department 
of Pathology, according to the code for adequate secondary use of tissue (code 
of conduct “Proper Secondary Use of Human Tissue”) established by the Dutch 
Federation of Medical Scientific Societies (http://www.federa.org). 
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In general, tumor tissue was minced and dissociated to a single cell suspension 
after a 3 hours digestion with DNAse-I (50 μl/ml, Roche, Basel, Switzerland) and 
collagenase A (3 mg/ml, Sigma-Aldrich, St. Louis, MO, USA) at 37˚C. Samples 
were then passed through a 40 μm cell strainer (BD Biosciences, San Jose, CA, 
USA) and subsequently incubated with antibodies at 4˚C for 30 minutes. Dead cell 
discrimination was performed with Hoechst33258 (1:10,000 Invitrogen, Carlsbad, CA, 
USA). Fluorescence-activated cell sorting (FACS) was performed with a FACSAriaTM cell 
sorter (BD Biosciences). Cells were sorted into RPMI medium supplemented with 5% 
fetal calf serum and penicillin-streptomycin. After sorting, cells were resuspended in 
a 1:1 mixture of this RPMI-based medium and MatrigelTM (BD Biosciences) in a total 
volume of 100μl and injected subcutaneously into NOD-SCID mice not older than 8 
weeks. A maximum of four injection sites for each recipient mouse was applied. The 
relative frequency of tumor-initiating cells in EA was estimated by limiting dilution 
analysis30 (analogous to that employed in the identification of stem cells in other 
tissues). Limiting dilution analysis calculations were done by using the L-Calc™ 
Software (StemCell Technologies) (http://www.stemcell.com/product_catalog/
product_catalog_index.aspx?type=catalog_item&id=618).
First, in order to purify bulk tumor cells from contaminating cells present in the 
surgical specimens, we employed antibodies raised against well-characterized 
endothelial (CD31-APC, dilution 1:50, EMELCA Bioscience, Breda, The Netherlands), 
and hematopoetic (CD45-APC, dilution 1:200, BD Biosciences, and CD235A-APC, 
dilution 1:1000, BD Biosciences) antigens and depleted these so-called lineage-
positive (Lin+) cells by gating the CD31-/CD45-/CD235A- population24. The resulting 
Lin- tumor cells (i.e. enriched for epithelial cells) were injected subcutaneously at 
different multiplicities, from 105 to 103 (‘limiting dilution’), into NOD-SCID mice.
In a second set of transplantation assays, surface antigen markers that have previously 
been reported as (cancer) stem cell markers were employed to sort subpopulations 
of EA cells by FACS (CD2431, CD2931, CD3410, CD4429, CD13327, 28, CD16629, EpCAM29, 
b-catenin32). To this aim, the tumor-derived single cell suspensions were incubated 
with the following antibodies: CD24-PE (dilution 1:10, BD Biosciences), CD29-FITC 
(dilution 1:25, Bioconnect, Huissen, The Netherlands), CD34 (dilution 1:500, EMELCA 
Bioscience), CD44-FITC (dilution 1:1000, BD Biosciences), CD133-PE (dilution 1:100, 
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Miltenyi Biotec, Auburn, CA, USA), CD166-PE (dilution 1:100, R&D Systems, Abingdon, 
UK), and EpCAM-PerCP (dilution 1:100, BD Biosciences). Although most of the above 
Ab’s are directly labelled which bypass the use of isotypic controls, their staining 
specificity was verified against isotypic controls at the same concentration. Also, the 
staining pattern of individual tumors is per se indicative of specific staining for all the 
markers here employed.
Subpopulations of Lin- cells positive for the different cancer stem cell markers were 
then sorted by FACS and injected subcutaneously at a fixed multiplicity (n = 5,000) 
in NOD-SCID mice. The viability of sorted cells was estimated in an independent set 
of experiments to be ~80-90% (data not shown). Injections of 5,000 Lin- cells were 
employed as controls. This multiplicity (5,000) was chosen assuming an enrichment 
factor of at least 10 fold when compared with the bulk Lin- cancer cells. The recipient 
mice were scheduled for an observation period of 6 months following transplantation, 
unless discomfort following tumor growth indicated earlier termination of the 
experiment.
In addition to the above mentioned panel of (cancer) stem cell markers, we also 
attempted the prospective isolation of ALDH1-positive tumor cells from esophageal 
adenocarcinomas (data not shown). As for ALDH1 as a potential CSC marker33, 
preliminary experiments showed that it is technically feasible to sort Aldefluor–
positive and –negative cells, (data not shown). Subsequently, we injected these 
subpopulations from 4 individual tumor samples. However, no tumor growth could 
be observed after 6 months. Eventually, also in view of the lack of ALDH1 IHC analysis 
and of the appropriate positive controls (i.e. injection of 100,000 Lin- cells) for the 
4 tumors FACSorted according to ALDH1 expression, we decided to omit these data 
from the present mansucript.  
Immunohistochemistry (IHC)
A panel of previously established (cancer) stem cell markers (CD24, CD29, CD34, 
CD44, CD133, CD166, EpCAM, b-catenin) was employed for IHC analysis. To this aim, 
we used resection specimens from 20 BE patients who underwent esophagectomy 
for either high-grade dysplasia or EA. The surgical specimens were transported to 
the Department of Pathology, where an experienced gastro-intestinal pathologist 
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(HvD) selected separate tissue samples indicative for Barrett’s metaplasia and EA. 
Barrett’s mucosa was diagnosed by both macro- and microscopy when epithelium 
of the intestinal type was demonstrable in the tubular esophagus34, including 
the presence of goblet cells, characteristic for intestinal metaplasia (mucin-filled 
cytoplasm that stains positively with Alcian blue)35. In this series of 20 formalin-fixed 
paraffin-embedded resection specimens, a total of 15 areas of metaplasia, 12 areas 
of low-grade dysplasia (LGD), 18 areas of high-grade dysplasia (HGD) and 28 areas of 
adenocarcinoma were identified in hematoxylin-eosin (H&E) stained sections. From 
each formalin-fixed, paraffin-embedded tissue block, 14 consecutive 2 μm sections 
were cut. Subsequently, the first 13 of 14 consecutive sections were stained by 
IHC in the specific sequence of CD24, ß-catenin, CD29, ß-catenin, CD34, ß-catenin, 
CD44, ß-catenin, CD133, ß-catenin, CD166, ß-catenin and EpCAM, respectively. The 
last section of the series was employed as a negative control. Multi-tissue sections 
containing pancreas-, liver-, stomach-, colon-, and tonsil-samples were used as 
positive controls to test antibody specificity.
Sections were mounted on aminoacetylsilane-coated slides (Starfrost, Berlin, 
Germany) and IHC was performed using the Envision system (DAKO, Glostrup, 
Denmark). In brief, the sections were de-waxed in xylene and rehydrated through a 
graded ethanol series. Endogenous peroxidase activity was inhibited by incubating 
the sections in methanol with 3% hydrogen peroxide for 20 minutes. For all 
antibodies, microwave pretreatment (700 W) in Tris-EDTA (pH 9) was performed for 
15 minutes, except for CD29, CD44 and EpCAM, for which pretreatment in citrate 
buffer (pH 6) was used. All primary antibodies, i.e. against CD24 (clone CLB-gran-
B-Ly/1-1B5, dilution 1:200, RDI, Concord, MA, USA), CD29 (clone 4B7R, dilution 
1:100, Abcam, Cambridge, UK), CD34 (clone QBEEnd/10, dilution 1:100, Thermo 
Scientific, Fremont, CA, USA), CD133 (clone AC133, dilution 1:100, Miltenyi Biotec), 
CD166 (clone MOG/07, dilution 1:80, Abcam), EpCAM (clone Ber-EP4, dilution 1:00, 
Abcam) and ß-catenin (clone 14, dilution 1:100, BD Biosciences) were incubated on 
the sections for one hour at room temperature, except the CD44H antibody (clone 
IM7, dilution 1:100, BD Biosciences) that was incubated overnight at 4°C. Negative 
controls were performed by omitting the primary antibody. This was followed by the 
secondary incubation step of the Envision system. Diaminobenzidene tetrachloride 
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from the Envison kit, prepared according to the manufacturer’s instructions, was 
employed for visualization. Tissues were counterstained with hematoxylin. Finally, 
the slides were dehydrated through a graded ethanol series, cleared in xylene and 
mounted in Malinol (Chroma-Gesellschaft, Köngen, Germany). 
The specific areas of metaplasia, LGD, HGD and adenocarcinoma identified by the 
pathologist (HvD) in the H&E stained sections, were compared with their counterparts 
in the 14 consecutive sections, stained with the above mentioned antibodies. The 
immunoreactivity patterns were evaluated independently by three investigators 
(BAG, HvD and WNMD). Discrepant results were re-evaluated by all three investigators 
to reach consensus. All 15 sections from each tissue block (i.e. the H&E section and 
the 14 consecutively stained sections) were microscopically evaluated at both high 
and low magnifications and scored according to multiple parameters: percentage 
of positive cells in the defined areas (>25% of cells as ++, 1-25% of cells as +, and 
no cells as 0), their location, a potentially increased staining during progression in 
the metaplasia → dysplasia → carcinoma sequence, and potential overlaps in the 
staining patterns. 
Results
Tumor-initiating cells are present, though rare, in EA
In order to assess whether tumor-initiating cells are present in EA, limiting dilution 
transplantation assays were performed with a consecutive series of surgically resected 
tumors. Lin- (bulk) EA cells from seven patients were transplanted subcutaneously in 
NOD-SCID mice at different multiplicities, ranging from 105 to 103 cells. Out of the 7 
primary tumors employed, four were of moderate and three of poor differentiation 
grade. 
Tumor growth was almost invariably observed when 105 bulk EA cells were injected, 
with the only exception of a poorly differentiated adenocarcinoma (tumor #5 in Table 
1). Transplantation with 104 Lin- cells also resulted in frequent tumor growth though 
not in all cases (4/7) and with lower incidence (1 out of 3-4 injections). No tumor 
growth was observed when 1,000 Lin- cells were injected (Table 1).  
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Table 1. Limiting dilution assay: observed tumor growth after transplantation of 
Lineage-negative bulk esophageal adenocarcinoma cells into NOD-SCID mice.
TUMOR 1 2 3 4 5 6 7
Differentiation grade Moderate Moderate Moderate Poor Poor Moderate Poor
No. injected cells
- 100,000 4/4 3/3 2/4 3/3 0/2 2/2 1/1
- 10,000 1/4 1/3 1/4 0/3 0/4 0/4 1/4
- 1,000 0/4 0/3 0/4 0/3 ND ND 0/4
ND = not done
By performing limiting dilution analysis (L-CalcTM Sotware, StemCell Technologies) it 
was estimated that the frequency of tumor-initiating cells in the Lin- population of EA 
(n=7) was 1 in 64,287 cells (s.e. 18,049). The histology of all the tumors obtained by 
transplantation of bulk EA cells in NOD-SCID mice fully resembled the differentiation 
grade of the primary tumors (Figure 1). 
Figure 1A-D. Histology of tumors derived from the limiting dilution experiment.
A-B. Histology showing a moderately differentiated tumor in both the primary tumor (A) and 
the mouse-tumor (B) derived from injected Lineage-negative cells.
C-D. Histology showing a poorly differentiated tumor in both the primary tumor (C) and the 
mouse-tumor (D) derived from injected Lineage-negative cells.
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Expression analysis of CSC markers in BE and EA by IHC
Subsequently, we performed IHC analysis of resection specimens from 20 unrelated 
BE/EA patients with a panel of previously established (cancer) stem cell markers 
(CD2431, CD2931, CD3410, CD4429, CD13327, 28, CD16629, EpCAM29, b-catenin32). The IHC 
analysis was here meant to explore whether the expression pattern and subcellular 
localization of the above markers may be suggestive of their usefulness as CSCs 
markers in esophageal adenocarcinomas and possibly to select a subset of them 
to perform the further FACSorting and transplantation assayThe overall results of 
the IHC analysis including the percentage of cells positive for specific CSC markers 
in the different histological lesions are summarized in Table 2. In a unique tissue 
block derived from the resection specimen of a single patient, defined areas of all 
progression stages (normal squamous epithelium → metaplasia → LGD → HGD → 
adenocarcinoma) could be identified, which were here employed as representative 
of the staining patterns observed throughout the cohort (Figure 2). 
CD24 and CD29 positive cells were mainly located at the basal compartment of the 
epithelium in metaplastic and dysplastic areas (Figures 2 and 3A-B). 
The CD24 and CD29 staining did not increase with advanced stage, but a patchier 
staining pattern was observed within EA (Figure 4A-B). The endothelial cell marker 
CD34 predominantly labeled blood vessels in the stroma, but not epithelial cells 
(Figure 2). CD44 staining showed positive stromal cells in the metaplastic and 
dysplastic lesions (Figure 2), and a heterogeneous membranous staining pattern in 
tumor cells in more than half of all adenocarcinomas examined (15/28, 54%, Figure 
4C). CD133 IHC did not reveal any staining in the normal squamous epithelium or in 
the pathological specimens (data not shown). CD166 IHC revealed extensive staining 
in almost all epithelial cells, with a homogeneous staining pattern in EA (Figure 2). 
Likewise, EpCAM appeared to be a good indicator for epithelial cells with homogeneous 
staining in metaplastic and dysplastic tissue as well as in adenocarcinoma (Figure 2).
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Table 2. Outcome of immunohistochemical analysis of individual potential (cancer) 
stem cell markers along the metaplasia - dysplasia - carcinoma sequence.
METAPLASIA
N=15
LGD
N=12
HGD
N=18
EA
N=28
1. CD24        ++
                      +
                      0
0/15
9/15
6/15
0/12
9/12
3/12
0/18
13/18
5/18
5/28
15/28
8/28
2. CD29        ++
                      +
                      0
0/15
8/15
7/15
0/12
7/12
5/12
0/18
9/18
9/18
2/28
11/28
15/28
3. CD34       ++
                      +
                      0
0/15
0/15
15/15
0/12
0/12
12/12
0/18
0/18
18/18
0/28
0/28
28/28
4. CD44        ++
                      +
                      0
0/15
0/15
15/15
0/12
0/12
12/12
2/18
2/18
14/18
1/28
14/28
13/28
5. CD133      ++
                      +
                      0
0/15
0/15
15/15
0/12
0/12
12/12
0/18
0/18
18/18
0/28
0/28
28/28
6. CD166      ++
                      +
                      0
15/15
0/15
0/15
12/12
0/12
0/12
15/18
0/18
3/18
25/28
0/28
3/28
7. EpCAM  ++
                      +
                      0
5/15
3/15
7/15
5/12
0/12
7/12
10/18
1/18
7/18
20/28
0/28
8/28
8. β-catenin* ++
                      +
                      0
15/15 (3/15)
0/15
0/15
12/12 (4/12)
0/12
0/12
17/18 (7/18)
0/18
1/18
27/28 (6/28)
0/28
1/28
Notes. The categories indicated as ++, +, and 0 indicate the presence of >25%, 1-25%, or 
no positive cells, respectively. LGD = low-grade dysplasia; HGD = high-grade dysplasia; 
EA = esophageal adenocarcinoma. *number of sections positive for membranous and/or 
cytoplasmic β-catenin staining; the number of sections with nuclear β-catenin is indicated in 
brackets.
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IHC analysis of b-catenin expression and subcellular localization also showed 
preferential staining of cells located in the basal compartment, with a decreasing 
gradient of intensity along the basal-luminal axis (Figure 5A). ß-catenin was mainly 
observed in the cytoplasm of all progression stages, with >25% cells staining positively 
(Figure 3C and 5A-B). An increase in the percentage of cells with nuclear ß-catenin 
accumulation was seen from metaplasia and LGD lesions (3/15, 20.0%; 4/12, 25.0%, 
respectively) to HGD (7/18, 38.9%), but not in EA (6/28, 21.4%). However, groups of 
cells with heterogeneous nuclear ß-catenin staining were detected at the invasive 
front of the majority of the tumors (Figure 5C). Hence, it appeared that nuclear 
accumulation of ß-catenin partially overlapped with the staining pattern observed 
for the cell-surface antigens CD24 and CD29 (Figure 3A-C).
Overall, although the IHC analysis of resection specimens from BE/EA patients 
with previously established (cancer) stem cell markers did not unequivocally point 
to a specific candidate cell surface antigen, it provided some interesting clues on 
the basal compartment (CD24 and CD29) and the invasive front (b-catenin) as 
alleged locations of subpopulation of cancer cells with distinct biological properties. 
Nevertheless, the IHC results were not such to justify the selection of a subset of CD 
markers for the further sorting and transplantation assays. Therefore, we decided to 
employ all of the above (cancer) stem cell markers for the sorting and transplantation 
of subpopulations of EA cells and the evaluation of their putative tumor-initiating 
capacities.
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Figure 2. In one unique tissue block of the present series, defined areas of all stages towards 
malignant progression (normal squamous epithelium → metaplasia → LGD → HGD → EA) 
could be identified and were employed as representatives of the staining patterns for all 
potential CSC markers on IHC.
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Common CSC markers do not enrich for EA initiating cells
The above demonstration of the existence of a minority of tumor-initiating cells in 
EA (frequency of 1 in 64,287 cells) and the heterogeneous expression pattern of 
some CSC markers are of good auspices for the isolation of EA initiating cells. EA 
cell suspensions derived from 13 resection specimens were stained with antibodies 
directed against the same cell-surface antigens tested by IHC, analyzed and sorted 
by FACS, and transplanted in NOD-SCID mice. In this way, we were able to assess 
whether any of the resulting subpopulations encompassed an increased fraction of 
tumor-initiating cells when compared to the bulk tumor cells. The percentages of 
Lin- tumor cells positive for the employed CD markers upon FACS analysis greatly 
varied among individual patients (Table 3). Supplementary Figure 1 illustrates some 
examples of the observed FACS profiles.
Sorted cells were transplanted subcutaneously at a fixed multiplicity (N=5,000). 
For each CD marker, 8-20 transplantations were performed. Also, subpopulations 
of cells positive for a combination of these markers (i.e. CD24/29, CD44/166) were 
transplanted. Following transplantation, the recipient mice were observed for a period 
of 4-6 months. However, no tumor growth could be detected in any of the tumor cell 
subpopulations out of a total of 180 transplantation assays (Supplementary Table 1). 
Table 3. Percentages of Lin- primary esophageal adenocarcinoma cells from 13 
unrelated patients positive for the employed CD (cancer) stem cell markers.
Primary tumor 1 2 3 4 5 6 7 8 9 10 11 12 13
Lin- CD24+ CD29+ 0.9 19.2 6.9 5.0 2.0 24.4 6.5 1.4 NA NA NA 0.8 NA
Lin- CD44+ 69.8 6.9 3.8 39.5 6.9 16.9 12.2 3.8 NA NA NA 0.6 NA
Lin- CD166+ 59.5 33.8 21.8 39.8 50.5 24.1 30.2 1.8 NA NA NA 14.9 NA
Lin- CD44+CD166+ 52.0 5.8 2.6 29.6 5.8 14.0 6.1 0.6 NA NA NA 0.6 NA
Lin- CD133+ 0.1 13.1 18.7 6.6 6.9 10.6 13.3 0.2 NA NA NA 17.9 NA
Lin- EpCAM+ NA NA NA NA NA NA NA NA 33.4 44.8 26.5 20.7 41.7
Lin- CD34+ NA NA NA NA NA NA NA NA 0.3 17.8 11.6 0.3 1.2
NA = not available.
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Discussion
In this study, we tested whether BE and EA might serve as a disease model for the 
cancer stem cell concept. Based on the in vivo limiting dilution experiments, we can 
now state that tumor-initiating cells are present in EA at an average frequency of 1 
in 64,287 cells (s.e. 18,049). The histology of the transplanted tumors resembles that 
of the primary tumors thus confirming the capacity of these tumor-initiating cells of 
recapitulating the heterogeneous composition of these lesions. IHC analysis of several 
(cancer) stem cell markers in BE and EA indicated that, based on their focal staining 
pattern and co-staining with ß-catenin, CD24 and CD29 may represent potentially 
interesting markers for the enrichment of CSCs in EA. The somewhat patchy CD44 
expression pattern is also of interest and may point to a specific subpopulation of 
tumor cells within EA. The negative or homogeneously positive expression observed 
with the markers CD133, CD166 and EpCAM is less likely to be of any significance for 
the isolation of CSCs in EA. 
However, the overall IHC results were not such to clearly point to one or few specific 
cell surface antigens as potential CSC markers in esophageal adenocarcinoma. 
Moreover, it is known that the specificity of the antibodies employed for IHC and 
FACS analysis may vary. Hence, although the negative or homogeneously positive 
expression patterns of markers like CD133 and CD166 may suggest their unlikely role 
as tools to enrich for CSCs in EA, one could be easily misled as the corresponding 
antibody employed for FACSorting recognizes different epitopes and/or isoforms 
of the same protein. Therefore, we proceeded by testing all of the above markers 
for the FACS and transplantation assays. Unfortunately, as shown by the results of 
the in vivo transplantation assay, none of the above cell-surface antigens, previously 
established as CSC markers in a broad spectrum of malignancies, resulted in a 
significant enrichment of EA initiating cells. 
The evolution from the normal squamous esophagus to pre-malignant metaplasia 
(BE) and EA represents a unique model system to study the underlying environmental, 
genetic, and epigenetic events. From this perspective, the availability of biopsies 
from the different stages allows the definition of the temporal order of causative 
molecular events as in the classical case of colorectal cancer. 
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Figure 3A-C. CD24 (A) and CD29 (B) 
positive cells were mainly located at the 
basal compartment of the epithelium 
in metaplastic and dysplastic areas, 
overlapping the staining pattern for nuclear 
β-catenin (C) in metaplastic and dysplastic 
tissues.
Figure 4A-C. CD24 (A), CD29 (B) and CD44 
(C) revealed a heterogeneous staining 
pattern in parenchymal cells in esophageal 
adenocarcinoma.
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Among the different molecular alterations identified in BE and EA, several members 
of the Wnt/b-catenin signal transduction pathways appear to be affected by a 
broad spectrum of different genetic and epigenetic mechanisms36,37, thus pointing 
to a functional role for the constitutive activation of this pathway in esophageal 
metaplasia and neoplasia38. Nuclear b-catenin accumulation is generally regarded 
as the hallmark of constitutive activation of the Wnt pathway and is thought to 
earmark CSCs in several malignancies, among which colorectal cancer32,39. Notably, 
intracellular b-catenin accumulation is observed in the majority of EA, often along 
the invasive front, while less frequently in Barrett’s metaplasia40-42. We confirmed 
these observations by showing an increase in nuclear ß-catenin staining during the 
progression from metaplasia (5/14, 36%) into LGD (5/12, 42%) and HGD (10/16, 
63%). Moreover, b-catenin was often observed in the nucleus of EA cells located 
at the invasive front, and its general pattern of intracellular accumulation appears 
to overlap with the expression of CD24 and CD29, two cell-surface antigens known 
to earmark normal stem cells and CSCs in tissues such as the mammary gland31. 
Figure 5A-C. Nuclear β-catenin staining 
was observed predominantly at the basal 
compartment of metaplastic and dysplastic 
epithelium (A-B) as well as at the invasive 
front of the tumor (C).
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CD24 functions as a cell adhesion molecule that is also involved in regulation of 
proliferation43, 44. CD24 is also known to be expressed in a broad spectrum of human 
cancers where it is thought to contribute to the acceleration of tumor growth, the 
shedding of tumor cells from the primary mass, and their transmigration and invasion 
across endothelial cells, thereby promoting the dissemination of cancer cells43, 44. 
CD29 (more commonly known as ß1-integrin) comprises the largest subgroup of the 
integrin family of transmembrane receptors, which enables cell adhesion as well 
as transduction of signals into cells45, 46. However, although the results indicate an 
overlap between the two staining patterns, co-localization of CD24 and CD29 with 
b-catenin should be validated by double staining of the same histological section. 
Neoplastic cells tend to lose the integrins that secure their adhesion to the basement 
membrane, and maintain or over-express integrins that contribute to survival, 
proliferation and migration during tumor invasion and dissemination46. Notably, a 
recent study reported that the CD24-mediated increase in cell migration depends 
on the ß1-integrin subunit47. Also, as mentioned before, CD24+CD29hi epithelial 
cells have been shown to represent the stem cells of the mouse mammary gland 
capable of reconstituting a complete and functional gland in vivo31. Besides CD24 
and CD29, CD44 appeared to be an interesting marker based on the IHC results, 
as its expression pointed to a subpopulation of tumor cells within EA. The CD44 
transmembrane glycoproteins mediate cell-matrix adhesion and cell migration. Up-
regulation of specific CD44 isoforms has been associated with poor prognosis in 
Barrett’s adenocarcinoma48, 49. Furthermore, it has been shown that CD44 is a robust 
CSC marker in colorectal cancer29. 
Despite the above-mentioned IHC results, we were not able to demonstrate that 
surface-antigens previously established as CSC markers in other malignancies enrich 
for tumor-initiating cells in EA. However, several points may be considered with regard 
to the applied methods in the present study. To date, CSCs are only operationally 
defined by the transplantation assay in immuno-deficient mice. Subpopulations of 
tumor cells enriched for CSCs are thought to result in tumor formation even when 
injected at low mulitiplicities, in contrast with bulk cancer cells that give rise to 
tumors when injected at higher numbers only. Previous experimental evidence for 
the existence of CSCs has been provided by incorporating a selection step prior to 
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injection into mice. In contrast to the direct transplantation method employed in 
the present study (primary tumor cells injected directly into the recipient mice), 
enrichment for CSCs was facilitated by means of xenografting or culturing suspension 
spheres before transplantation experiments were carried out29, 50, 51. Furthermore, 
transplantation into NOD-SCID mice has shown to underestimate the frequency of 
human cancer cells with tumorigenic potential in some malignancies52. Modified 
transplantation conditions, e.g. by employing more intensely immunocompromised 
mice (for example the NOD-SCID IL2Rgnull mice that lack the interleukin-2 gamma 
receptor and therefore have a decreased natural killer cell activity) may allow for 
more efficient engrafting of CSCs. Also, instead of subcutaneous grafting, one might 
also consider orthotopic transplantations (i.e. in the esophageal epithelial lining of 
the recipient animals), though these are technically challenging and yet unreported 
assays21. 
In conclusion, our results indicate the presence of a subpopulation of EA cells with 
tumor-initiating capacities. However, FACS sorting of EA cells by surface antigen 
markers that have previously been established to enrich for CSCs in other types 
of epithelial malignancies (e.g. colorectal cancer), did not increase the relative 
frequency of tumor-initiating cells. Future studies should focus on the search for novel 
surface antigens and on the modification of the experimental set-up, for example by 
employing NOD-SCID IL2Rgnull mice instead of the conventional NOD-SCID mice, and 
by pre-selection of the tumor cell subpopulations in vitro (establishment of sphere 
cultures i.e. esospheres) or in vivo (use of xenografts rather than primary resection 
specimens). Notwithstanding the above-mentioned technical obstacles, the natural 
history and etiology of BE and EA still represent an ideal setting for the study of how 
modification of the cellular environment may lead to reprogrammed resident stem 
cells which may result in the establishment of CSCs underlying tumor growth and 
invasive behaviour53.     
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Supplementary Table 1. Tumor growth of subpopulations of Lineage-negative cells 
transplanted in recipient NOD-SCID mice at a multiplicity of 5,000 cells.
Primary tumor 1 2 3 4 5 6 7 8 9 10 11 12 13
Lin- CD24+ CD29+ 0/4 0/4 0/4 0/4 0/4
Lin- CD24+ CD29- 0/4 0/4 0/4
Lin- CD24- CD29+ 0/4 0/4 0/4
Lin- CD24- CD29- 0/4 0/4 0/4
Lin- CD44+ 0/4 0/4 0/4
Lin- CD166+ 0/4 0/4 0/4
Lin- CD44+CD166+ 0/4 0/4 0/4 0/4
Lin- CD44+CD166- 0/4
Lin- CD44-CD166+ 0/4
Lin- CD44- CD166- 0/4
Lin- CD133+ 0/2 0/2 0/4 0/4
Lin- CD133- 0/2 0/2 0/4 0/4
Lin- EpCAM+ 0/4 0/4 0/4 0/4 0/4
Lin- EpCAM- 0/4 0/4 0/4 0/4 0/4
Lin- CD34+ 0/4 0/4
Lin- CD34- 0/4 0/4
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Supplementary Figure 1. FACS profiles representative of the staining of the different cell-
surface markers employed in the present study. (A) Staining for the lineage markers in the 
APC channel. Left upper panel: isotypic control antibodies. Right upper panel: cell viability 
(=78%) after Lin- sorting; (B) Right panel: double staining of CD24 (PE channel) and CD29 (FITC 
channel). Lower inset: isotypic control antibodies. Upper inset: viability (=87%) after sorting 
of Lin-CD24+CD29+ tumor cells. Left panel: staining with the single CD markers indicative of the 
quality of the compensations applied throughout the present work; (C) Staining of CD44 (FITC 
channel) and CD166 (PE channel) with relative isotypic controls (inset); (D-F) staining of CD133 
(PE channel), EpCAM (PerCP-Cy5 channel), and CD34 (PE channel) along with their respective 
isotypic controls (insets).
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Abstract
The most important risk factor for the development of Barrett’s esophagus 
is reflux of both gastric and duodenal contents into the esophagus. Why 
Barrett’s metaplasia develops only in a minority of patients suffering from 
gastroesophageal reflux disease remains unknown. It is also unclear what the 
exact mechanism is behind the transition of normal squamous epithelium 
into specialized columnar epithelium. It is likely that stem cells are involved 
in this metaplastic change, as they are the only permanent residents of the 
epithelium. Several tumorigenic steps have been described that lead to the 
underlying genetic instability which is indispensable in the progression from 
columnar metaplasia to esophageal adenocarcinoma. This review outlines 
the process of pathogenesis of Barrett’s metaplasia and its progression to 
esophageal adenocarcinoma. 
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1. Introduction
Over the past 50 years more insight has been gained into the pathophysiology and 
molecular pathways associated with the development of Barrett’s esophagus and 
esophageal adenocarcinoma. Gastroesophageal reflux disease (GERD) has now been 
recognized as the most important risk factor for the onset of Barrett’s metaplasia 
and esophageal adenocarcinoma. Environmental, dietary and genetic factors are 
also likely to play an important role. However, the exact mechanism underlying the 
transition from normal squamous epithelium towards metaplastic epithelium has 
not been elucidated yet. The identification of stem cells in the normal squamous 
esophageal epithelium has lead to speculations about the contribution of these cells 
in the metaplastic process, as these cells are the only permanent residents of the 
epithelium. Recently, some studies have been published that have shed new light on 
the molecular and cellular basis of Barrett’s esophagus. 
This review gives an overview of the pathogenesis of Barrett’s metaplasia and 
its progression towards esophageal adenocarcinoma. The risk factors for the 
development of Barrett’s esophagus are reviewed as well as the different theories 
concerning the cell of origin of Barrett’s metaplasia. Finally, a summary is given 
of the tumorigenic steps that are involved in the development of esophageal 
adenocarcinoma.
2. Normal esophageal epithelium
The luminal surface of the normal esophagus is lined by stratified squamous 
epithelium of the non-keratinizing type.1, 2 This epithelium can histologically be 
divided into two zones: (1) a luminal “differentiated zone” consisting of progressively 
flattened, terminally differentiated keratinocytes, and (2) a basal “generative” zone. 
Within the latter, a basal layer (single layer of cells next to the basal membrane) and 
several epibasal layers (variable number of cell layers above the basal layer) can be 
distinguished (Figure 1). At regular intervals along the epithelium the lamina propria 
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invaginates and forms papillary structures within the epithelium. Subsequently, in 
the basal layer two components can be distinguished: the interpapillary basal layer 
(IBL) covering the interpapillary zone and a papillary basal layer (PBL) overlying the 
papillae (Figure 1).2 Shedding of epithelial cells occurs when cells have migrated from 
the basal zone towards the esophageal lumen.3
Figure 1. Schematic representation of the organization of the human esophageal epithelium. 
The interpapillary basal layer (IBL) cells constitute the stem cell compartment (red). Transit 
amplifying cells are proposed to reside in the papillary basal layer (PBL in green) and 
epibasal layers (grey). Suprabasal cells that can no longer divide and are undergoing terminal 
differentiation are shown in yellow. Arrows indicate the direction of cell movement. Re-printed 
from Seery and Watt (2000)5 with permission.
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To maintain epithelial integrity, the rapidly proliferating esophageal mucosa is 
repopulated by a limited number of stem cells present in the generative basal zone. 
These stem cells divide, replace the stem cell compartment itself and generate transit 
amplifying cells (differentiating daughter cells that enter the epibasal layer).4 It has 
been observed that the process of low proliferation and asymmetric cell division 
(giving rise to one stem cell and one transit amplifying cell) specifically characterizes 
the IBL.5 
It is hypothesized that another stem cell population might also account for 
reconstitution of the surface epithelium. This population is thought to reside in the 
tubuloalveolar glands that are present in the submucosal layer of the esophageal 
epithelium.2 Although there is no direct evidence for the existence of these stem 
cells, an analogy can be drawn with the epidermis in which stem cells are located not 
only in the interfollicular epithelium, but also in the bulge region of the hair follicle.6, 7 
3. Pathogenesis of Barrett’s metaplasia
3.1 Development of Barrett’s esophagus:  congenital versus acquired
Columnar epithelium in the intrathoracic part of the gastrointestinal tract in 
combination with an ulcer and esophagitis was first described in 1950 by Norman 
Barrett, a British surgeon.8 However, he misinterpreted the condition as a tubular 
intrathoracic stomach. Also, he was convinced that this was due to a congenitally 
short esophagus.8 Johns hypothesized that this condition might be due to a premature 
cessation of the physiologic replacement of the columnar ciliated epithelium (which 
lines the esophagus during embryogenesis) by stratified squamous epithelium, 
starting around 22 weeks of gestation.8, 9 In his opinion this was a congenital disorder. 
However, arguments against this congenital theory include the fact that the squamous 
replacement of the fetal columnar epithelium begins in the mid esophagus and 
progresses towards each end.9 The cervical region appears to be the last to lose its 
embryonic lining, which is contradictory to the fact that the columnar epithelium in 
a Barrett’s esophagus is always found in the lower esophagus.10 In 1953, Allison and 
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Johnstone demonstrated that the columnar epithelium was located proximal to the 
lower esophageal sphincter, and thus it was recognized definitively as an abnormality 
of the esophageal mucosa.11 Furthermore, the association between columnar 
lined epithelium and GERD was recognized and led to the concept of an acquired 
condition. Moersch et al. and Hayward were the first to suggest that the columnar 
lining might be an acquired condition due to reflux esophagitis that destroys the 
squamous epithelium.12, 13 This concept was broadly accepted when Bremner et al. 
showed columnar cell regeneration in the distal esophagus in an experimental model 
of chronic gastroesophageal reflux.14 
3.2 Definition of Barrett’s metaplasia
Three histological types of columnar epithelium in the esophagus have been 
described: a gastric fundic type composed of chief and parietal cells; a junctional 
type composed of mucous glands without parietal cells; and a specialized type with 
intestinal characteristics including mucous glands and goblet cells.15 These three types 
are nowadays referred to as oxyntocardiac mucosa, cardiac mucosa and intestinal 
metaplasia, respectively.16 It is only intestinal metaplasia that has been recognized as 
a premalignant condition, which is included in the definition of a Barrett’s esophagus: 
a condition in which the normal squamous epithelium of the distal esophagus is 
replaced by specialized columnar epithelium, which is characterized by the presence 
of intestinal metaplasia.17, 18 Metaplasia refers to the conversion of one cell type to 
another during postnatal life and might be the effect of conversion of tissue-specific 
stem cells.19 Goblet cells are characteristic for intestinal metaplasia, which are barrel-
shaped and have a distended, mucin-filled cytoplasm that stains positively with 
Alcian blue.20, 21 
3.3 Gastroesophageal reflux disease 
There are many risk factors associated with the development of a Barrett’s esophagus. 
GERD is considered to be the key risk factor.22, 23 Chronic GERD is characterized by 
various conditions, including nonerosive and erosive esophagitis, ulceration and 
strictures of the esophagus. It has been reported that approximately 10 % of patients 
with GERD-symptoms develop a Barrett’s esophagus.24-26 Furthermore, increased 
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age27, 28, male sex29, 30 and Caucasian race31 are general risk factors for Barrett’s 
esophagus as described in several epidemiologic studies. 
3.3.1 Pathophysiology 
Esophageal exposure to refluxed gastric contents is considered to be the major 
factor in the development of reflux esophagitis and Barrett’s esophagus. Animal 
models have demonstrated that gastric acids are involved in injuring the esophageal 
mucosa.14, 32 In humans, patients with a Barrett’s esophagus typically have greater 
esophageal acid exposure based on 24-hour pH monitoring when compared to 
patients with esophagitis or normal subjects.33-36 A direct relationship between the 
severity of esophageal mucosal injury and the degree and frequency of refluxed acid 
exposure has been reported.33 Furthermore, it has been found that patients with 
Barrett’s esophagus have a significantly longer exposure time to a pH lower than 4 
than patients with esophagitis.37 Interestingly, there is a clear correlation between 
length of the columnar lined esophagus and the severity of reflux.38 However, 
one study showed that in a group of patients with a Barrett’s esophagus that was 
followed-up for more than 7 years, the length of the Barrett’s segment did not 
change.27 It has been hypothesized that the transformation of squamous epithelium 
into columnar metaplasia does not occur after intestinal metaplasia has developed.39 
In other words, the occurrence of intestinal metaplasia in cardiac mucosa might act 
as a break for further columnar transformation of squamous epithelium by reflux. 
Nevertheless, this hypothesis is still unproven, and further research is needed in this 
field.
Acid injury involves the ability of H+ ions to enter the cytoplasm of the esophageal 
epithelial cell with subsequent cell death. In the normal situation, the apical membrane 
of the epithelial cells is not permeable to acid.40 When luminal acidity is sufficiently 
high, intercellular junctions are damaged and widening of the intercellular spaces 
is observed.41, 42 Subsequently, H+ ions are able to penetrate into the cell through 
the basolateral membrane. The intracellular acids lead to cell death and, finally, to 
ulceration once the necrosis affects a large area. 
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Pepsin is a digestive enzyme, secreted as pepsinogen and activated into pepsin by 
gastric acid. Pepsin is considered to be harmful as it may cause erosive esophagitis 
in an acidic environment by increasing the cell permeability to H+ ions.3, 43 However, 
the exact role of pepsin in damaging the esophageal mucosa has not been explored 
extensively thus far.
Besides the effect of gastric acids and pepsin, also excessive reflux of duodenal 
contents into the esophagus contributes to the development of Barrett’s metaplasia. 
Bile reflux or alkaline reflux are terms that are often used to describe the reflux 
of duodenal contents, which consists of conjugated and unconjugated bile salts, 
lysolecithin, and pancreatic enzymes such as trypsin. The term ‘alkaline reflux’ 
suggest a pH > 7, although it has been reported that the majority of esophageal 
bilirubin exposure occurs when the pH is between 4 and 7.44 Therefore, the term 
duodenogastroesophageal reflux (DGER) may be more appropriate, referring to the 
retrograde reflux of duodenal contents (bile and pancreatic fluid) into the stomach as 
well as the esophagus. It is believed that both pancreatic enzymes and bile salts are 
able to induce severe esophagitis.45, 46
Trypsin is a pancreatic enzyme that is responsible for lysis of proteins. It is thought to 
affect intercellular substances causing shedding of epithelial cells.47 Trypsin can cause 
substantial injury to the esophageal mucosa at alkaline pH. The role of lysolectihin, 
another component of duodenal juice, is less understood. 
Bile salts are conjugated with either taurine or glycine when secreted by the liver. 
The conjugation process makes bile acids more soluble in an acidic environment 
(range pH 2-7) by lowering the Pk
a 
dissociation constant48, 49; an environment in which 
synergistic damaging effects have been described from gastric acids and conjugated 
bile salts.50, 51 However, acidification of bile salts to a pH of less than 2 leads to 
irreversible precipitation and inactivation of the bile salts. At neutral or alkaline pH, 
conjugated bile salts cause only minimal injury. However, this is in contrast with 
trypsin and unconjugated bile salts, which have the greatest potential to damage the 
esophageal mucosa under alkaline circumstances.52 
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It has been suggested that in a moderately acidic gastric environment (range 
pH 2-7), as can occur with the use of acid-suppression medication, bile salts are 
partially soluble and are potentially harmful to mucosal cells.53 For conjugated bile 
salts to remain completely harmless in a patient with GERD taking acid-suppression 
medication, a gastric pH of at least 7 must be aimed for during day and night.53 Hence, 
incomplete acid suppression may allow esophageal mucosal damage to occur while 
the patient is asymptomatic.44 
Several studies using combined pH and bile-reflux monitoring in non-operated 
GERD patients, suggest increasing amounts of both acid reflux and DGER with 
increasing severity of esophageal lesions.44, 50, 54-57 Two consecutive studies showed 
that the highest bilirubin concentration and percentage of time with pH < 4, were 
seen in patients with Barrett’s esophagus, followed by patients with esophagitis and 
controls.37, 50 The results of these studies are supportive of a synergistic activity of acid 
and bile reflux. Moreover, simultaneous esophageal exposure to both acid and DGER 
was the most prevalent reflux pattern (95%) in patients with a Barrett’s esophagus.37 
Reports on esophageal aspirates have shown conflicting results with regard to the 
role of DGER: some studies could detect an increased amount of bile acids in patients 
with Barrett’s esophagus, whereas other studies could not confirm this.58 However, 
aspiration techniques have been criticized because of the short aspiration periods 
and intrinsic limitations of these techniques.50 The overall results of animal studies, 
esophageal monitoring and aspiration studies58, 59 suggest a synergistic role for gastric 
and bile acids in the etiology of a Barrett’s esophagus. 
3.3.2 Role of inflammation and oxidative stress
Increased exposure of the normal esophageal mucosa to (duodeno)gastroesophageal 
reflux results in mucosal damage and tissue inflammation. The mucosal inflammatory 
response is characterized by specific cytokine and chemokine profiles. The nuclear 
factor-kappa B (NF-kB) pathway is thought to play a pivotal role in this response: NF-
kB comprises a family of transcription factors that regulates the host inflammatory 
and immune responses by increasing the expression of many genes that are involved 
in the inflammatory reaction.60 Subsequently, increased levels of cytokines including 
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TNFa, interleukin (IL)-1b, IL-6 and IL-8, can also directly activate the NF-kB pathway, 
thus establishing a positive autoregulatory loop that can amplify the inflammatory 
response and increase the duration of chronic inflammation.60 Inappropriate 
activation of NF-kB has been linked to a variety of inflammatory and neoplastic 
conditions.60, 61 
The cytokines that are released in response to GERD may thus contribute to the 
activation of the NF-kB pathway in these patients. Moreover, NF-kB was found to be 
up regulated in Barrett’s epithelium.62, 63 
Gastric acid and bile salts can activate the arachidonic acid pathway, which controls 
inflammation. Cyclooxygenase-2 (COX-2) is a key enzyme of this pathway, and 
catalyzes the conversion of arachidonic acids into prostaglandins. COX-2 is usually 
not detectable in normal tissues, but can be induced in processes like inflammation 
and carcinogenesis.64 Also, it has been shown that activation of NF-kB can lead to 
an increase in COX-2.65 An in-vitro study showed that COX-2 is functionally active 
in Barrett’s esophagus: treatment with a COX-2 inhibitor diminished cell growth, 
whereas proliferation could be restored by treatment with prostaglandin.66 A gradually 
increased COX-2 expression has been reported from normal squamous epithelium 
towards Barrett’s metaplasia and esophageal adenocarcinoma.67-69 Moreover, an 
increased COX-2 expression seems to be related with a reduced survival in patients 
with esophageal adenocarcinoma.70, 71 
Chronic inflammation can also induce the production of reactive oxygen species: 
highly reactive free radicals that are generated as products of oxygen degradation 
during injury. These free radicals have an important role in the inflammation 
process. They may damage DNA by causing mutations, induce the production 
of proinflammatory cytokines, and produce growth factors for epithelial cells.72 
Under normal conditions cells are protected from reactive radicals by antioxidant 
defense systems. When oxidative stress (an imbalance between oxidant production 
and the antioxidant capacity of the cell) arises, these defense systems promote 
the expression of antioxidants.73 In patients with reflux esophagitis and Barrett’s 
esophagus, it has been demonstrated that mucosal damage is associated with 
increased oxidative stress, characterized by an enhanced free radical proportion and 
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decreased antioxidant activity.74, 75 Also, one study suggested that the lower levels of 
the antioxidant vitamin C found in patients with a Barrett’s esophagus, supporting the 
hypothesis of oxidative stress being of importance in the pathogenesis of metaplastic 
epithelium.76
3.3.3 GERD-related factors
Since not all patients with GERD develop a Barrett’s esophagus, this implicates 
that additional risk factors play an important role. As we will discuss below, genetic 
predisposition, presence of a hiatal hernia, a low esophageal sphincter pressure, 
obesity and dietary patterns have been described to contribute to this risk. It should 
be kept in mind that most of these factors are related to the severity of GERD and 
still cannot fully explain why only the minority of patients with GERD will develop 
Barrett’s esophagus. Indirect evidence for a possible genetic susceptibility comes 
from a study that has reported an increased prevalence of GERD among family 
members of patients with Barrett’s esophagus or esophageal adenocarcinoma.77 It 
is hypothesized that an unknown susceptibility gene is inherited in an autosomal 
dominant fashion with incomplete penetrance, as not all individuals in these families 
develop Barrett’s esophagus or esophageal adenocarcinoma.78 It has been suggested 
that a tumor suppressor gene is involved.79 In this model, germline mutations in the 
gene predispose to neoplasia, and once the second allele is lost or mutated (i.e. a 
‘second hit’ caused by environmental factors like chronic GERD), cancer may develop. 
Furthermore, polymorphisms (specific variant alleles) of different genes have been 
described that may be associated with an altered esophageal cancer risk.80 For 
example, polymorphisms in genes involved in carcinogen metabolism, DNA repair 
and cell cycle control have been correlated with the presence of Barrett’s esophagus 
and esophageal adenocarcinoma.80 
Interference with the physiologic function of the esophago-gastric junction can 
occur in two conditions: dysfunction of the lower esophageal sphincter (LES) and the 
presence of a hiatal hernia.81 
A defective LES causes an increased acid exposure in the distal esophagus and can 
be found in over 95% of patients with a Barrett’s esophagus.82 In the presence of 
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an incompetent LES, ineffective clearance function due to motility disorders of the 
esophageal body further prolongs the time the esophagus is exposed to gastric 
contents.83 
A hiatal hernia may contribute to GERD by a variety of mechanisms.84 First, clearance 
of acid from the esophagus is impaired; gastric acid may be trapped in the hernial 
sac and can subsequently be refluxed in the esophagus during a swallow-induced 
relaxation.85 Secondly, esophageal emptying can be impaired when an irreducible 
large hiatal hernia is present.86 Finally, a large hiatal hernia causes a widening of the 
esophageal hiatus that may impair the ability of the crural diaphragm to function as 
an external sphincter.87 It has been reported that the presence of a hiatal hernia is a 
risk factor in the development of a Barrett’s esophagus88 and metaplastic epithelium 
has been observed more often in patients with a hiatal hernia than in those without.89 
Obesity could increase the risk for the development of a hiatal hernia and provoke 
reflux through an elevated intra-abdominal pressure. Increased body mass index 
(BMI) is known to be a risk factor for GERD90, but it remains unclear whether the 
increased risk for Barrett’s esophagus associated with BMI is mediated by GERD 
directly or whether there is a higher risk regardless of reflux. A recently published 
meta-analysis provided evidence that increasing BMI does not present an increased 
risk of Barrett’s esophagus above what would be expected from GERD alone.91 
However, it was commented that the BMI does not take into account the distribution 
of fat within the body.92 Markers of central obesity (visceral fat) like the waist-hip ratio 
could be more reliable in the determination of a possible independent relationship 
between obesity and the development of a Barrett’s esophagus.93
Diet is a modifiable risk factor that may influence cancer risk through several 
mechanisms. Studies of fruit and vegetable intake are consistent with a protective 
role for anti-oxidants against the development of a Barrett’s esophagus. A case-
control study revealed that diets rich in fruits, vegetables and fish were inversely 
associated with Barrett’s esophagus, whereas this risk in persons following Western 
dietary patterns (high in fast food and meat) may be adversely associated.94 But again, 
it cannot be excluded that the association between diet and Barrett’s esophagus is 
mediated by GERD. 
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Dietary nitrate is another component that may promote the development of 
Barrett’s esophagus as a consequence of GERD. Nitrate is secreted by the salivary 
glands (that derive nitrate from the entero-salivary recirculation of dietary nitrate), 
and is converted into nitrite by oral bacteria. When swallowed saliva enters the acidic 
gastric environment, the nitrite is converted into nitrous acid and nitrosating species, 
which can form potentially carcinogenic compounds (see Figure 2). However, this 
process is inhibited by the vitamin ascorbic acid, which is actively secreted in gastric 
juice95, thereby reducing these compounds to nitric oxide. Although this action 
of ascorbic acid inhibits the luminal generation of the potentially carcinogenic 
nitrosating species, it has been shown that nitric oxide can also rapidly diffuse into 
the adjacent epithelium, resulting in nitrosative stress in the epithelial cells (Figure 
2).96 It has been reported that in the case of severe GERD this process occurs in the 
esophageal lumen rather than the cardia, as saliva encounters gastric acids at a more 
proximal location.97 However, the clinical significance of this nitrosative chemistry in 
the distal esophagus during acid reflux remains unclear. It has been suggested that 
high concentrations of nitric oxide causes oxidative stress, which may contribute to 
carcinogenesis.98 Moreover, the same authors hypothesized that the increase in the 
incidence of adenocarcinoma of the distal esophagus and gastric cardia might be 
related to the increased dietary content of nitrates.99
Helicobacter pylori infection causes a chronic gastritis that is associated with the 
development of intestinal metaplasia and cancer.100 H. pylori does not infect the 
esophagus, and its presence is not associated with an increased risk of Barrett’s 
esophagus. In fact, some data suggest that gastric H. pylori infection may protect 
the esophagus from the effects of acid reflux by decreasing gastric acidity due 
to gastric atrophy.101, 102 In fact, H. pylori infection might be associated with an 
increased risk of esophageal adenocarcinoma in patients in whom it causes high 
acid secretion secondary to an antrum-predominant, non-atrophic gastritis, but it 
might be associated with a reduced risk when the infection induces gastric atrophy.102 
Therefore, the pattern of gastric colonization induced by H. pylori infection may be 
the determinant of the effects of the infection on reflux disease.
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Figure 2. Chemical reaction occurring at the gastroesophageal junction when nitrite in saliva 
encounters acidic gastric juice. Adapted from Iijima et al (2003)96.
3.4 Cell of origin of Barrett’s metaplasia
It has now been generally accepted that Barrett’s esophagus is considered to be an 
acquired condition as a consequence of GERD. Although the process of GERD and 
its contributing risk factors are well described, the exact mechanism underlying the 
transition from normal squamous epithelium into metaplastic columnar epithelium 
has not been identified yet. However, there are several theories with regard to the 
cell of origin that gives rise to the metaplastic change of the epithelium.
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3.4.1 Upward migration of gastric epithelium
Initially, upward cell migration from the gastric epithelium into the distal esophagus 
to reconstitute the reflux-damaged squamous epithelium was favored.11, 14 However, 
it was demonstrated in animal studies that development of a columnar esophagus is 
not hindered when there is a mucosal defect separating the distal esophagus from 
the transitional zone at the gastro-esophageal junction.32, 103 
Furthermore, Barrett’s metaplasia may include a variety of epithelial cells (including 
goblet and neuroendocrine cells) that are not found in the proximal stomach. 
Therefore, it was hypothesized that the cell giving rise to the columnar mucosa is 
intrinsic to the esophagus itself. 
3.4.2 Transdifferentiation
Another possibility is the direct conversion of differentiated cells into another cell 
type in the absence of cell proliferation, a process called ´transdifferentiation´. It is 
based on the normal developmental process whereby the esophagus undergoes a 
columnar to squamous cell transition at 18 weeks of gestation.104 Furthermore, it has 
been shown that during the development of the mouse esophagus, squamous cells 
arise directly from columnar cells independently of cell division and apoptosis.105 
It is assumed that the reverse transdifferentation (from squamous to columnar 
epithelium) could account for the generation of Barrett´s metaplasia in the context 
of GERD. However, this extrapolation of data may not be valid, as the embryological 
maturation of the esophagus may be quite different from the pathological 
development of metaplastic epithelium. 
3.4.3 Transitional zone theory
The transitional zone theory states that cells at the gastro-esophageal junction 
undergo cellular migration and colonize the gastric cardia or distal esophagus in 
response to damaging luminal agents during reflux. This theory was based on the 
identification of a cell with features of both squamous and columnar epithelium 
that had been identified with scanning electron microscopy at the transitional zone 
between the normal squamous esophageal epithelium and the columnar epithelium 
of Barrett’s esophagus.106, 107 These newly colonized cells can express either a columnar 
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or a squamous phenotype depending on their location (esophagus or cardia)108 and 
can maintain a growth advantage due their resistance to the luminal components. 
Furthermore, cells have been identified at the squamo-columnar junction that 
express both squamous and columnar cytokeratin markers.109 Similarities exist 
between the structure of the GEJ and transitional zones in other areas of the body 
such as the cervix uteri, which shows cells of high plasticity in the transitional zone.110 
3.4.4 De-novo metaplasia
More than twenty years ago, it has been hypothesized already that GERD induces 
esophagitis with destruction of squamous epithelium and ulceration, and that the 
ulcer is reepithelialized by multipotential undifferentiated stem cells.111 The prevailing 
hypothesis today is that Barrett’s esophagus develops when GERD damages the 
superficial layers of the esophageal squamous epithelium, thereby exposing stem 
cells in the basal layers of the epithelium to toxic agents that stimulate an abnormal 
differentiation.112 As a result of chronic epithelial damage possibly induced by 
bile reflux and inflammatory conditions, the stem cells undergo a phenotypic or 
metaplastic change that will lead to Barrett´s stem cells eventually. It has been 
reported that a similar change can be observed during the process of mucinosis in the 
squamous mucosa of the vagina, which can be seen in atrophic vaginal epithelium in 
post-menopausal women.113, 114 At this location there is little known about the exact 
cause and the clinical significance of these metaplastic cells.    
3.4.5 Duct cell metaplasia
Columnar cells covering a Barrett’s esophagus may also originate from ductal cells 
of esophageal submucosal glands.32, 115 It has been suggested that stem cells exist 
in the glandular neck region of esophageal submucosal gland ducts similar to those 
found within the bulge region of the hair follicle.116 Therefore, it is believed that 
after ulceration or damage, stem cells may grow out to form a new gland, giving rise 
to a duct by which the glandular cells are carried to the surface. The basis for this 
mechanism is the ulcer associated cell lineage: the development of a new cell lineage 
from mucosal stem cells that occurs adjacent to ulceration in the gastrointestinal 
tract.117 Peptides related to the maintenance of mucosal integrity (i.e. the two trefoil 
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peptides pS2 and human spasmolytic polypeptide that contain three-fold shaped 
(‘trefoil’) cysteine-rich domains) are associated with this process and their expression 
was also reported in the metaplastic epithelium of Barrett’s esophagus.118 However, 
in rats in which no glandular structures are located in the esophageal epithelium, 
reflux can still trigger a similar transition into a Barrett’s like metaplastic epithelium.119
3.4.6 Bone marrow stem cells
Apart from tissue-specific stem cells, it is now known that bone-marrow derived stem 
cells that circulate in the blood have such a degree of plasticity that they can also 
give rise to diverse epithelial cells.120 Recently, a study reported on the contribution 
of bone marrow stem cells to the development of Barrett’s esophagus in an animal 
model. Female rats were given a high dose of irradiation, followed by reconstitution 
of their bone marrow and immune systems through bone marrow transplants of 
male rats. Furthermore, both severe esophagitis and intestinal metaplasia were 
induced by esophagojejunostomy. The study revealed that after 8 weeks the male 
adult progenitor cells of bone marrow origin could be detected in the esophageal 
epithelial cells, thereby contributing to the esophageal regeneration and metaplasia 
in this model of Barrett’s esophagus.121 However, the authors have already pointed 
out that the possibility of fusion of the donor’s bone marrow cells with the host’s 
epithelial cells instead of the transdifferentiation into esophageal epithelial cells 
cannot be excluded.121 
Overall, it can be concluded that the exact origin of the cells involved in the transition 
from a normal squamous epithelium into a metaplastic Barrett’s epithelium has not 
been identified yet. However, it is most plausible that stem cells are involved in this 
process, as they are the only permanent residents of the epithelium. 
3.5 Transformation into a columnar epithelium
To date only few studies have reported on the transformation of normal squamous 
esophageal cells into columnar epithelial cells from a molecular point of view. 
A recent study investigated the role of the bone morphogenetic protein (BMP) 
pathway in the metaplastic transformation process both in vivo and ex vivo.122 
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The study was based on the finding of the same group that the BMP-4 gene was 
abundantly expressed in Barrett’s esophagus and esophagitis as a result of GERD.123 
BMP-4 is a protein belonging to the transforming growth factor (TGF)-b family that is 
involved in controlling cellular differentiation, migration and proliferation. In general, 
BMPs are induced during inflammation and injury. The BMP-pathway proved to be 
over-activated in esophagitis and Barrett’s esophagus when compared to controls. 
Moreover, in ex vivo experiments it was shown that the differentiation of normal 
squamous cells toward a columnar cell type was induced by BMP-4, which was 
particularly illustrated by changes in cytokeratin expression patterns. Therefore, it 
was suggested that the BMP-pathway could play a role in the transdifferentiation of 
normal squamous esophageal cells into columnar cells.122
Another study investigated the role of retinoic acid in the transition between 
squamous and columnar cell types.124 Retinoic acid (RA) is a powerful inducer 
of differentiation during embryogenesis and activates a number of cell-signaling 
pathways that are involved in determining the fate of embryonic cells.125, 126 Indeed, 
one of the target genes of RA is the homeobox gene Cdx2 (encoding for a so-called 
homeodomain transcription factor that is specifically involved in the regulation of 
patterns of development, the morphogenesis), which is likely to induce a change in 
cell differentiation status.127 In the esophagus, Cdx2 expression is observed in the 
areas of specialized intestinal metaplasia and this expression seems to be enhanced 
after exposure to various bile acids.127-131 Interestingly, one of the components of the 
bile refluxate (lithocholic acid) has been demonstrated to influence the efficiency of 
retinoic acid.132 In this study it was shown that ex vivo exposure of squamous biopsy 
specimens to both retinoic acid and lithocholic acid caused columnar differentiation. 
Conversely, an ex vivo Barrett’s esophagus biopsy specimen could be transformed 
into a squamous-appearing epithelium through the inhibition of retinoic acid.124 
These observations implicate a retinoic acid-induced transformation to metaplastic 
epithelium. However, follow-up is needed by in vivo experiments. 
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3.6 Clonal expansion
Barrett’s esophagus has been described as a clonal proliferative disorder: clonal 
fields of abnormal cells populate the metaplastic epithelium, with each field having 
potential clonal alterations in DNA content (ploidy), mutations or deletions.133 After 
the initiation of a metaplastic stem cell, a stage of clonal expansion takes place, which 
may lead to rapid colonization of the adjacent mucosa.134 Under conditions such as 
ongoing GERD, it is thought that this stem cell divides to produce two metaplastic 
stem cells instead of one stem cell and one differentiating transit amplifying cell.134 
Gland bifurcation is thought to be the consequence of this mechanism135 (see Figure 
3). These bifurcating glands will divide again thereby producing a large group of 
epithelial cells with a common genotype (clonal expansion). This process has also 
been shown to occur in the colon, thereby offering support to this theory.136
Figure 3A-B. Role of stem cell number in controlling glandular phenotype. Adapted from 
Jankowski et al (2000)200.
3A. Stem cell division results in one transit cell and one stem cell, which causes gland 
homeostasis.
3B. Stem cell division results in two stem cells, which causes gland bifurcation.
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4. Progression to esophageal adenocarcinoma
Patients with a Barrett’s esophagus have a higher risk of developing esophageal 
adenocarcinoma when compared to the general population.25, 137 Two meta-analyses 
showed that the overall estimate of cancer incidence in Barrett’s esophagus 
varies between 6 and 7 cases per 1,000 person-years (0.6 – 0.7% per year).138, 139 
Another recently published systemic review focused on the incidence of esophageal 
adenocarcinoma in patients with histologically proven high-grade dysplasia who 
were undergoing surveillance. An average incidence rate of 6.6 per 100 patient years 
(range 2.3 – 10.3) was found.140 However, one study showed an inverse relationship 
between study size and reported cancer risk in the setting of Barrett’s esophagus, 
with small studies reporting much higher risks of cancer than larger studies.141 This 
finding suggests publication bias, which may have lead to an overestimated cancer 
risk in patients with Barrett’s esophagus in the literature.
It is generally accepted that the development of esophageal adenocarcinoma follows 
a metaplasia – dysplasia – carcinoma sequence, which is characterized by a number 
of genetic and epigenetic changes.112 Currently, the histologic finding of high-
grade dysplasia remains the most reliable predictor of progression to esophageal 
adenocarcinoma. Also, genetic changes linked to this progression may be used as 
biomarkers.142, 143 
4.1 Hallmarks of cancer progression
In the development of an invasive carcinoma, six essential steps have been described: 
self-sufficiency in growth, insensitivity to anti-growth signals, evading apoptosis, 
limitless replicative potential, sustained angiogenesis, and ability for invasion and 
dissemination.144 In Barrett’s carcinogenesis there is clear documentation for all of 
these biological characteristics, which has been summarized previously.145-147 Here, 
an overview is given of the most important molecular changes during the progression 
from metaplasia to dysplasia and, ultimately, invasive carcinoma.
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4.1.1 Self-sufficiency in growth
The cell cylce is divided into G1 (first gap), S (DNA synthesis), G2 (second gap), and M 
(mitosis) phase. In G1, cells reach a key restriction point at which they either enter 
the S phase and complete the cell cycle, or exit the cycle and become quiescent 
(G0).148 Growth signals are required for cells to leave the G0 phase and progress 
through the restriction point. Growth-signaling molecules bind to receptors on the 
cell surface, thereby activating intracellular pathways involving activation of growth 
regulatory molecules, including cyclins D1 and E. Cyclin D1 is a key regulator of cell-
cycle progression, particularly at the transition from G1- to S-phase.149 Expression of 
cyclins D1 and E has increased in neoplastic cells in Barrett’s esophagus.150-153 
Several growth factors have been associated with the metaplasia – dysplasia – 
carcinoma sequence in esophageal adenocarcinoma. The epidermal growth factor 
(EGF) as well as transforming growth factor-a (TGF-a) bind to the EGF receptor to 
stimulate cell proliferation.154 Overexpression of the EGF receptor has been reported 
to correlate with tumor progression and a poor differentiation grade.155-158  
Besides the EGF receptor, it has been shown that the hepatocyte growth factor (HGF) 
receptor (also known as Met) is overexpressed in both dysplastic epithelium and 
esophageal adenocarcinoma.159 Activation of Met causes decreased apoptosis and 
enhanced proliferation, angiogenesis and invasion.159, 160 Another study has identified 
Met expression as an independent prognostic risk factor in patients with esophageal 
adenocarcinoma: patients with high Met expression had a reduced survival and 
were more likely to develop distant metastases and local recurrences compared 
to patients with low Met expression.161 Interestingly, inhibition of COX-2 has been 
shown to downregulate Met expression both in vitro and in vivo.159, 162 
4.1.2 Insensitivity to anti-growth signals
In normal tissue, multiple antiproliferative signals operate to maintain cellular 
quiescence and tissue homeostasis. These growth-inhibitory signals are received 
by cell surface receptors linked to intracellular signaling pathways. Proliferation can 
be blocked by two distinct mechanisms: cells may be forced out of the active cell 
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cycle into the G0 phase or cells may be pushed towards a permanent growth arrest 
characterized by differentiation. The Retinoblastoma (Rb)-pathway plays an important 
role in this process. Changes in genes that normally block Rb-phosphorylation (i.e. 
p16 and p53) have been identified. Loss of heterozygosity (LOH), mutations or 
promoter hypermethylation of the p16 gene have been reported in up to 80% of 
patients with a Barrett’s esophagus.163 Furthermore, p16 alterations are recognized 
as early molecular lesions associated with clonal proliferation within metaplastic 
epithelium.164 
The adenomatous polyposis coli (APC) gene is a tumor suppressor gene that blocks 
cell proliferation by binding cellular signal proteins and by inducing differentiation. 
The prevalence of mutations in the APC gene is low in esophageal adenocarcinoma 
compared with colon cancer165; on the other hand, LOH on chromosome 5q (where 
the APC gene is located) frequently occurs.166, 167  
Cell cycle progression of normal epithelial cells is inhibited by transforming 
growth factor-b (acting as a negative growth factor) whereas malignant epithelial 
cells are often insensitive to the growth inhibitory effects of TGF-b. Indeed, TGF-b 
responsiveness is reduced during all stages of the metaplasia – dysplasia – carcinoma 
sequence, resulting in an impaired TGF-b signaling. Loss of expression of the functional 
receptor for TGF-b is associated with adenocarcinoma of the esophagus.168, 169 During 
subsequent tumor progression, TGF-b can be overexpressed, and may contribute to 
tumor invasion and systemic tumor spread. In esophageal adenocarcinoma TGF-b 
overexpression is associated with advanced tumor stage.170
4.1.3 Evading apoptosis
The ability of tumor cell populations to expand in number is determined not only 
by the rate of cell proliferation, but also by the rate of cell apoptosis (programmed 
cell death). Apoptosis can be regulated through several pathways that are activated 
by DNA damage. The protein p53 activates one of these pathways: DNA damage 
results in accumulation of p53 which stops the progression of the cell cycle until the 
genetic damage has been repaired or apoptosis has been induced.171-173 Mutations, 
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LOH and deletions of the p53 gene have been reported in the majority of patients 
with esophageal adenocarcinomas.174-176 Moreover, p53 mutations were associated 
with poor tumor differentiation grade, reduced disease-free survival and reduced 
overall survival.177-180      
4.1.4 Limitless replicative potential
In normal cells the replicative potential is limited by the length of telomeres (ends 
of chromosomes). During each cell cycle a loss of 50-100 base-pair telomeric DNA of 
each chromosome is noted. After a certain number of divisions, the telomeres are 
too short to protect chromosomes from degradation, and the cell is triggered to exit 
from G1 into a permanent growth-arrested G0-state. To reach a state of unlimited 
replication, tumor cells must stabilize the length of their telomeres. In 85-95% of 
human cancers, stabilization of telomeres is achieved by reactivation of telomerase 
(which can impede telomere degradation).181 Increasing levels of telomerase are 
observed along the metaplasia – dyplasia – carcinoma sequence.182 Furthermore, it 
has been presumed that telomere dysfunction contributes to genomic instability in 
human cancer.183 
4.1.5 Sustained angiogenesis
Angiogenesis is required to maintain tumor growth as oxygen and nutrients supplied 
by the vasculature are crucial for the development and progression of a malignant 
tumor. Tumor angiogenesis is a multi-step process. The initial step requires the release 
of angiogenic factors that stimulate endothelial cell proliferation and migration. The 
most potent angiogenic molecules belong to the vascular endothelial growth factor 
(VEGF) family, and are secreted by almost all solid cancers. Several groups have 
reported that, compared with the normal squamous epithelium of the esophagus, 
a higher level of expression of VEGF-A can already be observed in non-neoplastic 
Barrett’s epithelium, with a further increase in high-grade intra-epithelial neoplasia 
and superficial cancer.184-186 The switch towards an angiogenic state appears to be an 
early event in the progression towards esophageal adenocarcinoma. However, no 
prognostic role of increased expression of VEGF in patients with invasive esophageal 
cancer has been established yet.
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4.1.6 Tissue invasion and dissemination 
Abnormalities in cell-cell adhesion molecules play an important role in the process 
of invasion and dissemination of tumor cells. The principle functions of these 
molecules are to hold cells together and mediate cell-cell interactions. For example, 
E-cadherin on the surface of all epithelial cells, is linked to the actin cytoskeleton 
through interactions with catenins in the cytoplasm (especially b-catenin), and is able 
to form bridges with other cells. In epithelial cancers, a disrupted cell-cell adhesion 
might lead to metastases.187, 188 A significant reduction of E-cadherin expression 
has been shown as the Barrett’s metaplasia – dysplasia – carcinoma sequence 
progresses.189 Furthermore, it has been reported that a reduced expression of both 
E-cadherin and b-catenin correlates with decreased patient survival in esophageal 
adenocarcinoma.190, 191
Loss in epithelial cell-cell contact is thought to play a pivotal role in the process by 
which epithelial cells acquire motile properties that are required for invasion. This 
process is called the epithelial to mesenchymal transition (EMT).192 During EMT, 
epithelial cell-cell contact is decreased by the down-regulation of cytoskeletal 
components and the cell morphology becomes more fibroblast-like with up-
regulation of mesenchymal markers.193 It has been shown that EMT promotes cellular 
motility and invasion in a range of tumor cells in vitro. TGF-b is an important inducer 
of EMT,193 and one immunohistochemical study confirmed its role in EMT in patients 
with esophageal adenocarcinoma.194 However, more evidence is needed to support 
these limited data. 
4.2 Genetic instability
The tendency towards these six tumorigenic steps to occur is increased by a 
general underlying phenomenon of genetic instability. Exposure to (duodeno-)
gastroesophageal reflux has been shown to cause non-specific DNA damage,195 and 
the most prominent gene abnormality that promotes mutagenesis in response to 
DNA damage is the loss of the p53 tumor suppressor protein. Epigenetic changes (i.e. 
hypo- or hypermethylation of DNA) may also result in genetic instability, which has 
been reported in the development of esophageal adenocarcinoma.196 Aneuploidy 
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(abnormal nuclear DNA content) does not correlate with any single mutation, but 
reflects widespread DNA changes due to genomic instability.146 Several studies 
showed that aneuploidy in Barrett’s epithelium is associated with risk for progression 
to malignancy, and that the prevalence of aneuploidy increases with the degree of 
dysplasia.197-199
5. Summary
Barrett’s esophagus is an acquired condition in which the normal squamous 
epithelium of the esophagus has been replaced by specialized (intestinal-type) 
columnar epithelium. Reflux of both duodenal and gastric contents is thought 
to be the causative factor. Several factors have been described that promote 
duodenogastroesophageal reflux, including dysfunction of the lower esophageal 
sphincter, the presence of hiatal hernia, obesity, dietary patterns and Helicobacter 
pylori infection. The refluxate induces several changes in the esophageal epithelium 
at the cellular and molecular level. Why only a minority of patients suffering from 
GERD develops Barrett’s epithelium remains unknown. Despite recent progress in 
our understanding of some pathophysiologic observations in Barrett’s esophagus, 
we have not been successful in identifying the key steps in cellular transformation. 
It is most plausible that stem cells are involved in this process, as they are the only 
permanent residents of the epithelium. Obviously, further research in this field is 
required that should focus on revealing the stem cells involved in the development 
of Barrett’s esophagus, in order to achieve better understanding of this complex 
process.
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Abstract
Introduction: Recently, a mouse model for Barrett’s esophagus based on 
a zinc-deficient diet supplemented with deoxycholic bile acids has been 
published. The aim of this study was to attempt to reproduce these data and 
extend them by employing genetically modified mice and intraperitoneal iron 
supplementation.
Methods: The study design encompassed 6 experimental groups (wild type, 
Apc-mutant and Smad4-mutant mice, with or without iron injections), with all 
animals fed with the zinc-deficient diet supplemented with deoxycholic bile 
acids. All treatments were started at 3-5 weeks of age (the majority (78%) at 
5 weeks). Animals were scheduled for euthanasia at two distinct time points, 
namely at 3 and 6 months of age.
Results: All mice showed signs of considerable distress already 4 weeks after 
the start of the modified diets, and had to be euthanized before the first 
evaluation time point (mean age 9.3 weeks, range 5-15 weeks). No differences 
were observed between wild type and genetically modified mice, or between 
animals with or without iron supplementation. On histological examination, 
we could not detect any lesions (Barrett’s esophagus-like or tumors) other 
than esophagitis.
Conclusion: In the currently presented experimental settings, we were not 
able to reproduce the mouse model according to which Barrett’s like lesions 
could be detected in animals fed with the zinc-deficient diet supplemented 
with deoxycholic bile acids.
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Short report
Introduction
Gastroesophageal reflux disease is thought to trigger the development of Barrett’s 
esophagus (BE), a condition where specialized intestinal cells replace the normal 
squamous epithelium of the distal esophagus. These metaplastic changes progress 
to dysplasia and esophageal adenocarcinoma (EA) with an annual conversion rate 
of approximately 0.5-1%. The molecular and cellular mechanisms underlying this 
metaplasia → dysplasia → carcinoma sequence are as yet poorly understood, 
partly due to the lack of a convenient and clinically relevant animal model. To 
date, the only in vivo model for BE is based on surgical manipulation of the rat’s 
upper gastrointestinal (GI) tract, namely esophago(gastro)duodenal anastomosis 
leading to chronic reflux of both gastric and duodenal contents into the distal 
esophagus.1 Although lesions resembling BE and/or EA do occasionally develop, a 
number of limitations make this model rather unpractical for research purposes, 
e.g. considerable animal suffering and death, low incidence of BE/EA lesions among 
surviving animals, uncertainty about the true nature of the lesions, and the limited 
possibilities of genetic manipulation in the rat. More recently, a new mouse model of 
esophagitis and BE has been described by feeding C57Bl6/J inbred mice with a zinc-
deficient diet supplemented with deoxycholic bile acids.2 All animals fed with the 
modified diet developed esophagitis and 63% presented with a Barrett’s-like lesion 
after 88 to 152 days. However, no malignant EA-like lesions were observed.2
In an attempt to reproduce and expand on the results by Guy et al. 2, we fed the 
zinc-deficient diet supplemented with deoxycholic bile acids to wild type as well as 
Apc- (Apc1638N/+)3 and Smad4- (Smad4E6sad/+)4 mutant mice (on the inbred C57Bl6/J 
genetic background), the latter in view of their intrinsic predisposition to GI tract 
tumors. Furthermore, we tested the effects of intraperitoneal iron supplementation, 
previously shown to enhance tumor formation in the surgery-based model.5 We 
hypothesized that the combination of these risk factors (zinc-deficient diet with 
supplemented bile acids, germline Apc and Smad4 mutations, and iron supplement) 
would lay the basis for the generation of a novel non-invasive mouse model for BE-
related EA. 
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Material and Methods
The study design encompassed 6 experimental groups (wild type, Apc-mutant and 
Smad4-mutant mice, with or without iron injections; see Table 1), with all animals 
fed with the zinc-deficient diet supplemented with deoxycholic bile acids.2 The wild 
type mice without iron injections served as a control group for the study by Guy et 
al.2 All treatments were started at 3-5 weeks of age. The majority of the animals 
(78%) received the zinc-deficient diet at 5 weeks of age after having been fed a 
standard mouse diet (zinc content 86.59 mg/kg, Special Diet Services, Essex, United 
Kingdom) from weaning. The remaining mice started were fed the zinc-deficient diet 
immediately from weaning. Animals were scheduled for euthanasia at two distinct 
time points, namely at 3 and 6 months of age. 
Table 1. Study design: a total of 72 C57Bl6/J mice were allocated to 6 experimental 
groups according to the scheme here depicted. Note: to limit experimental variability, 
both the modified diet and the 0.2% deoxycholic acid supplements (Sigma D6750) 
were obtained from the same manufacturer (Harlan Teklad, Madison, WI, USA) as 
described in the original study.2 Treatments were started at weaning and continued 
until the first signs of discomfort were observed.
zinc-deficient diet + bile acids2 zinc-deficient diet + bile acids2, 
supplemented by Fe2+  IP injections
wild type C57BL6/J 12 12
Apc1638N/+ C57BL6/J 12 12
Smad4E6sad/+  C57BL6/J 12 12
Results
All mice, regardless of the experimental group, showed signs of discomfort already 
4 weeks after the start of the modified diets, with diarrhea and gradual weight loss. 
In view of the considerable distress, all animals had to be euthanized before the 
first evaluation time point scheduled at 3 months (mean age 9.3 weeks, range 5-15 
weeks). No differences were observed between wild type and genetically modified 
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mice, or between animals with or without iron supplementation. Upon macroscopic 
examination, the intestines of all mice appeared severely inflamed (the colon being 
predominantly affected), and a distended coecum was found in the majority of the 
mice. On histological examination by H&E and Alcian Blue staining, we could not 
detect any lesions (BE-like or tumors) other than esophagitis (Figure 1).
To exclude that the observed lack of reproducibility resulted from an incorrect 
formulation of the zinc-deficient diet supplemented with deoxycholic bile acids, an 
independent batch was ordered from the same manufacturer and fed to wild type 
C57BL6/J mice (N=42). As for the larger study, similar results in terms of early signs 
of discomfort, esophagitis (Figure 1), and absence of BE-like lesions were observed.
Figure 1. Example of esophagitis as observed in wild type C57BL6/J mice fed with the zinc-
deficient diet supplemented with bile acids, as described by Guy et al.2 General hyperplasia of 
the squamous epithelium, including acanthosis, keratosis and degenerative vacuolization can 
be observed.
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Discussion
In this study we attempted but were not able to reproduce the results by Guy et al. 
according to which Barrett’s like lesions could be detected after 88 to 152 days in 69% 
of the animals fed with the zinc-deficient diet supplemented with deoxycholic bile 
acids.2 Several explanations can be envisaged for our results. First, the effect of zinc-
deficiency on immunity and the possible presence of pathogens (e.g. Helicobacter) 
in the mouse facility. However, the above-described experiments were performed 
within a pathogen-free unit where no Helicobacter has been detected during the 
time our study was carried out. 
Second, the early morbidity in the present study may be explained by the different 
time points at which administration of the modified diet was started: whereas in 
the study by Guy et al. all mice were kept on a regular dietary regime for 2 weeks 
after weaning before being fed the experimental diet (i.e. at 5 weeks of age), in our 
study the age of the animals upon start of the treatment was 3 to 5 weeks. However, 
only a minority of these animals were fed the diet immediately after weaning (i.e. 
at 3 weeks of age) whereas the vast majority (78%), in compliance with the Guy 
et al. study, were first administered a conventional chow for 2 weeks after which 
the zinc-deficient diet was provided. Notably, the zinc level present in regular chow 
employed in the Guy study was significantly higher than present in mouse milk.6 As 
zinc levels build up in the tissues (when provided in the diet), it is plausible to assume 
that the mice started the zinc-deficient regime with a considerable zinc reserve. 
The zinc content of the regular chow administered in our study prior to the start 
of the experimental diet was 86.59 mg/kg, which is very similar to the zinc content 
(89.3 mg/kg) of standard mouse diet fed prior to administration of the zinc-deficient 
regime in the Guy et al. study.2  
A third putative explanation for the contrasting results resides in the regular bedding 
of the mice cages the zinc content of which may represent a confounding factor. 
Bedding may indeed contain zinc, although it is not known how much it can affect 
zinc intake in rodents. According to the testing results of the bedding in our mouse 
facilities (Agrolab, Kiel, Germany), no zinc has been detected in the reports sent out 
during the period of time in which our experiments were carried out. No details have 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
Mouse model of Barrett’s esophagus 
99
4
been provided with regard to this issue in the primary report of Guy et al. Hence, it 
is possible that the presence of zinc in the cage bedding employed in the Guy et al. 
study is responsible for a protective effect to the early morbidity observed in our 
experimental setup.
Overall, although our results did not confirm the original report by Guy and 
collaborators2 and failed to induce Barrett’s-like lesions, the presence of inflammatory 
lesions (esophagitis) is of good auspices and it is still plausible to think that a different 
formulation or administration schedule of the diet, or the use of a different type of 
cage bedding will result in the modeling of the effects of gastroesophageal reflux 
on Barrett’s metaplasia and esophageal adenocarcinoma. If confirmed, the diet 
approach will also be useful in addressing the role played by mutation in specific 
genes as here attempted with the Apc and Smad4 tumor suppressor genes. 
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Abstract
Introduction: In patients with resectable adenocarcinoma of the 
gastroesophageal junction (GEJ) preoperative staging will determine the 
therapeutic strategy with regard to type of surgical procedure and use of 
neoadjuvant therapy. Tumor location and lymph node status play a pivotal role 
in this tailored strategy. The aim of this study was to prospectively evaluate 
the accuracy of preoperative assessment of tumor location according to the 
Siewert classification and lymph node status per station with endoscopy/
endoscopic ultrasound (EUS) and CT.
Methods: In 50 esophagectomy patients with adenocarcinoma of the 
GEJ without application neo-adjuvant therapy, tumor location according 
to Siewert and N-stage per nodal station (paratracheal, aortopulmonary 
window, subcarinal, paraesophageal, lesser curvature, celiac trunk nodes) as 
determined preoperatively by endoscopy/EUS and CT were compared with 
the histopathologic findings in the resection specimen. 
Results: Overall accuracy in predicting tumor location according to the Siewert 
classification was 70% for endoscopy/EUS and 72% for CT. Preoperative data 
could not be fully compared with the pathologic assessment in 11 patients 
(22%), as large tumors obscured the landmark of the gastric folds. The overall 
accuracy for predicting the N-stage in 250 lymph node stations was 66% for 
EUS and 68% for CT. The accuracy was good for those stations located high in 
the thorax, but poor for celiac trunk nodes.
Conclusion: Given the frequent discrepancy between the endoscopic and 
pathologic location of the GEJ and the common problem of advanced tumors 
obscuring the landmarks used in the assessment of the Siewert classification, 
its usefulness in the assessment of tumor location is limited. The overall 
accuracy for EUS and CT in predicting the N-stage per station was moderate. 
When the therapeutic approach depends on the status of a specific lymph 
node station, a more objective and reliable assessment of lymph nodal 
involvement (e.g. EUS-FNA) should be considered. 
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Introduction
In patients with resectable esophageal adenocarcinoma, surgical therapy is the 
treatment of choice. A complete removal of the primary tumor and its lymphatic 
drainage is the primary goal of any surgical approach. An individualized therapeutic 
strategy is thought to improve overall survival in patients with esophageal cancer.1-3 
Decisions on the surgical approach and possible application of neoadjuvant therapy 
play an important role in this tailored strategy, which relies largely on the location of 
the primary tumor and positive lymph nodes. Hence, accurate preoperative staging 
is a prerequisite for choosing the most optimal therapeutic strategy. 
The ‘Siewert classification’ was introduced in 1997 for the classification of 
adenocarcinomas arising in the area of the gastroesophageal junction (GEJ).4 This 
classification is based on the specific topographic characteristics, i.e. the location 
of the tumor center up to 5 cm above, at, or up to 5 cm below the gastric cardia 
(defined by the proximal end of the gastric folds). It is thought that three distinct 
tumor entities arise in this area (Figure 1): type I - adenocarcinomas of the distal 
esophagus with the center of the tumor more than one centimeter above the GEJ; 
these tumors generally arise from an area of intestinal metaplasia in the esophagus; 
type II - adenocarcinomas of the gastric cardia, arising from cardiac epithelium or a 
short segment of intestinal metaplasia, with the tumor center located within 1 cm 
proximally and 2 cm distally to the GEJ (‘true’ carcinomas of the cardia); type III - 
subcardial gastric carcinomas, with the tumor center more than 2 cm distal to the 
GEJ infiltrating the junction and the distal esophagus.
Lymph node status (N-stage) is divided into two categories according to the TNM-
classification: N0 (no suspicious locoregional lymph nodes) and N1 (one or more 
locoregional suspicious lymph nodes).5 Endoscopic ultrasonography (EUS) has been 
shown to be superior in the assessment of locoregional lymph node status in patients 
with esophageal cancer6-9: the reported diagnostic accuracy of EUS varies between 
65% and 86%.10-16 No subdivision or detailed assessment per nodal station is usually 
provided as N1-status is rarely considered a contra-indication for surgery. Recently, 
a revised classification has been proposed, in which the prognostic significance of 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R11
R12
R13
R14
R15
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
106
the location of the lymph nodes (in relation to the diaphragm) has already been 
emphasized.17
Figure 1. Classification of adenocarcinomas of the esophagogastric junction according 
to Siewert: this classification is based on the topographic anatomic characteristics and the 
location of the tumor center up to 5 cm above (type I), at (type II), or up to 5 cm below (type 
III) the gastric cardia (as defined by the proximal end of the gastric folds). Reprinted with 
permission from Fein et al, Surgery, 1998.44
For an individualized surgical treatment, the type of operation as well as the 
application of neoadjuvant therapy largely depend on the location of the tumor and 
its related pattern of dissemination.1 The surgical strategy will be influenced by the 
preoperative assessment of tumor location according to the Siewert classification 
(esophagectomy versus gastrectomy) and nodal status (transthoracic versus 
transhiatal esophagectomy). Furthermore, a reliable classification with regard to 
tumor location is indispensable in case neoadjuvant therapy is considered, since 
patients with a cardia carcinoma benefit from (neo)adjuvant chemotherapy according 
to the MAGIC-scheme18, whereas patients with esophageal cancer might benefit 
from neoadjuvant chemoradiation.19 Accurate information on the location of positive 
lymph nodes is also required to determine the extent of the radiotherapeutic field 
(distance between tumor and involved lymph nodes) which can turn the scale whether 
neoadjuvant chemoradiation is feasible in the first place. Moreover, in patients with 
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gross involvement of celiac trunk lymph nodes, induction chemotherapy or palliation 
are the treatment options of choice rather than primary surgery.20
Hence, an accurate preoperative assessment of the location of the primary tumor 
and positive lymph nodes is required for making therapeutic decisions for the 
individual patient. Nowadays upper gastrointestinal endoscopy combined with EUS 
is considered the gold standard for these preoperative assessments. However, in the 
literature little evidence is available about the accuracy of EUS and CT for determining 
the location of the primary tumor and potential positive lymph nodes. The aim of 
the present study was to investigate prospectively the accuracy of endoscopy/EUS 
and CT in determining tumor location according to the Siewert classification and 
lymph node status per station by comparing the preoperative assessment with the 
histopathologic findings in the resection specimen (gold standard). 
Patients and methods
Patients
Between April 2008 and December 2009, 104 patients underwent esophagectomy 
for cancer of the esophagus or GEJ in the Erasmus MC. Patients with esophageal 
cancer received neoadjuvant chemoradiotherapy in the setting of a randomized 
controlled trial (N=20).19 (Neo)adjuvant chemotherapy was given to patients with 
a tumor located in the cardia.18 Induction chemo- and/or radiotherapy was given in 
patients with either a cT4-tumor without distant metastases or in patients with gross 
involvement of celiac trunk lymph nodes (M1a), who were not considered eligible for 
primary surgical therapy (N=10). To avoid possible stage migration following chemo- 
and/or radiotherapy, patients receiving neoadjuvant therapy were excluded from 
this analysis. In five patients no surgical resection was performed as the tumor was 
irresectable intraoperatively. As the Siewert classification arranges adenocarcinomas 
in the vicinity of the GEJ, patients with a squamous cell carcinoma of the esophagus 
(N=4) were excluded from this analysis. In total, data of 50 patients were available in 
the present study. In 26 patients a transthoracic esophagectomy (TTE) with extended 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R11
R12
R13
R14
R15
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
108
lymphadenectomy was performed, whereas 24 patients underwent a transhiatal 
esophagectomy (THE) with locoregional lymphadenectomy only. The applied surgical 
techniques have been described previously.21, 22 
Methods
All patients underwent the standard work-up including upper gastrointestinal 
endoscopy combined with EUS, CT of chest and abdomen and external ultrasound of 
the neck. Endoscopic procedures were performed by experienced gastroenterologists 
with a Q-endoscope (GIF-Q180; Olympus Europeholding, Hamburg, Germany) and an 
electronic radial echoendoscope (GF-UE160-AL5; Olympus Europeholding, Hamburg, 
Germany). Stenotic tumors were not dilated. The mechanical blind probe (MH-908) 
has not been available in our unit. The CT protocol consisted of a standardized timing 
of contrast in both arterial and venous phases, maximized esophageal and gastric 
distension by adding oral carbon dioxide-granules, and adjustment of the thickness 
of the (reconstruction) sections to a maximum of 5 mm.23, 24 
Data were prospectively collected of all patients in whom a malignant tumor of the 
esophagus or GEJ was suspected and who underwent the routine staging procedures. 
The Medical Ethics Committee of the Erasmus MC approved the study; there was no 
need for patients’ informed consent. Data-analysis was carried out with SPSS version 
15.0 (SPSS, Chicago, IL, USA). 
A. Accuracy of assessing tumor location according to the Siewert classification
Registration of data with regard to the exact tumor location on upper gastrointestinal 
endoscopy combined with EUS, and CT was completed by the endoscopist and 
radiologist, respectively. On endoscopy and EUS the upper and lower limit of the 
tumor as well as the position of the Z-line (squamocolumnar junction), GEJ (proximal 
end of the gastric folds) and diaphragm were determined (distance as measured 
from the incisors). The endoscopist scored patient’s tumor type according to the 
Siewert classification by assessing the length and location of the tumor in relation to 
the proximal end of the gastric folds on conventional endoscopy. In case the tumor 
covered this landmark (thus prohibiting a proper assessment of its location), patient’s 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
Assessment of tumor location and lymph nodal status 
109
5
tumor type was assessed in relation to the diaphragm on EUS. The radiologist 
examined the length of the tumor and the position of the GEJ (above or below the 
diaphragm). Subsequently, the tumor was radiologically classified as a Siewert type I, 
II or III. The surgical resection specimen was analyzed by a dedicated gastrointestinal 
pathologist to determine patient’s tumor type according to the Siewert classification 
by assessing the length and location of the tumor in relation to the proximal end 
of the gastric folds. Finally, a comparison was made between the endoscopic and 
radiologic classifications as established preoperatively (by endoscopy/EUS and CT) 
and the histopathologic classification as assessed postoperatively by the pathologist 
in the resection specimen. The latter was considered the gold standard. 
B. Accuracy of assessing N-stage per lymph node station
Data were collected with regard to tumor stage (cTNM-stage) as predicted by EUS 
and CT. The most commonly involved lymph node stations (intrathoracic: upper 
paratracheal - station 2, lower paratracheal including the azygos vein nodes - station 
4, aortopulmonary window - station 5, subcarinal - station 7, paraesophageal - 
station 8; intraabdominal: lesser curvature (including paracardiac nodes), celiac 
trunk) were evaluated separately.25-27 In the vicinity of the celiac trunk the splenic 
and hepatic arteries were identified. Lymph nodes within a radius of 2 centimetres 
of its branching were classified as celiac trunk nodes. On EUS a lymph node was 
considered malignant based on morphological criteria as previously described.28, 
29 In case fine needle aspiration (FNA) was performed of lymph nodes, the initial 
endoscopic classification was not changed when the cytology results were disclosed. 
The radiologist identified suspected lymph nodes according to size (>6 mm for 
paraesophageal nodes and >10mm for all other lymph node stations) and the 
ratio between the longitudinal and transverse dimensions (L/T ratio<1.5) of the 
nodes.24 During a transthoracic resection with an extended lymphadenectomy the 
surgeons sampled separately the intrathoracic lymph node stations (paratracheal, 
aortopulmonary window, subcarinal nodes) as well as the celiac trunk nodes. An 
experienced gastrointestinal pathologist identified the paraesophageal and the 
lesser curvature lymph nodes in the surgical resection specimen and analyzed these 
nodes separately. In case a transhiatal procedure was performed, only three lymph 
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node stations were assessed (paraesophageal, lesser curvature, celiac trunk nodes). 
The pathologist did not search for micrometastases or isolated tumor cells. Finally, 
a comparison was made between the preoperative N-stage per lymph node station 
(as evaluated by EUS and CT) and the histopathologic N-stage (as assessed by the 
pathologist in the surgical resection specimens). The latter was considered the gold 
standard.
Results
Clinicopathological characteristics of the current study population are shown in Table 
1. The endoscopic preoperative evaluation was incomplete in 3 patients as the tumor 
could not be passed by a conventional or pediatric endoscope; in 7 patients the 
tumor was too stenotic on EUS to allow complete passage. In 6 patients radiological 
staging was incomplete since the tumor was not visible on the CT-scan. Four of these 
6 patients were diagnosed with an early tumor stage (pT1). The median time period 
between the preoperative investigations and surgery was 6.0 weeks (± 2.4, range 
3.0 – 12.0 weeks).
A. Accuracy of assessing tumor location according to the Siewert classification
In 11 patients (22%) the pathologist was not able to assign the exact location of the 
tumor to one of the 3 tumor types according to the Siewert classification. In 8 of 
these 11 patients the tumor had grown circumferentially in the distal esophagus and 
invaded the proximal part of the stomach, thereby covering the proximal end of the 
gastric folds and thus impeding a proper classification. These tumors were classified 
as Siewert type I/II. In another 3 patients the landmark of the gastric folds was 
visible, but the tumor invaded exactly one centimetre from the GEJ proximally into 
the esophagus and 4-5 cm distally into the stomach, without a clear tumor center at 
either side of the spectrum. Therefore, these three tumors were classified as Siewert 
type II/III.
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Table 1. Clinicopathological characteristics of 50 patients in our study population 
who underwent esophagectomy for adenocarcinoma of the distal esophagus or 
gastroesophageal junction.
Age* 65 years (48-81)
Gender
- male
- female
39 (78%)
11 (22%)
Type of operation
- transthoracic esophagectomy
- transhiatal esophagectomy
26 (52%)
24 (48%)
Barrett’s metaplasia
- yes
- no
20 (40%)
30 (60%)
Tumor infiltration depth (pT)
- pT1
- pT2
- pT3
4 (8%)
  9 (18%)
37 (74%)
Lymph nodal status (pN)
- pN0
- pN1
14 (28%)
36 (72%)
Differentiation grade 
- G1 (good)
- G2 (moderate)
- G3 (poor)
4 (8%)
23 (46%)
23 (46%)
Radicality of resection 
- R0
- R1a
- R1b 
36 (72%)
  9 (18%)
  5 (10%)
Total number of harvested nodes* 25 (8-58)
Number of positive lymph nodes*   3 (0-34)
Lymph node ratio* 0.10 (0.00-1.00)
* Value presented as median (range in brackets)
R0 = resection margin microscopically tumor-free, > 1mm
R1a = resection margin microscopically tumor-free, but < 1mm 
R1b = resection margin microscopically not tumor-free
Lymph node ratio  = number of positive lymph nodes/total number of harvested nodes
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The results of the preoperative assessment of tumor location by endoscopy/EUS 
are shown in Table 2A. Endoscopic accuracy was high when the tumor was (mainly) 
located in the distal esophagus (accuracy 100% in type I tumors). However, the 
accuracy of the type II tumors was 33% only; the majority of the type II lesions 
was preoperatively classified as a type I. In those patients in whom the tumor was 
allocated as a type I/II by the pathologist, the endoscopist had classified 6 out of 8 
tumors either as a type I or a type II tumor. Finally, the overall accuracy of endoscopy 
in combination with EUS in determining the location of the tumor according to 
the Siewert classification was 70% (35/50) if allowing a type I or type II tumor on 
endoscopy to predict a type I/II tumor and a type II or type III tumor to predict a type 
II/III tumor. 
 
The results of the preoperative assessment of tumor location by CT are shown in 
Table 2B. The radiologist was able to correctly classify type II tumors more often than 
the endoscopist (53%), although the accuracy for type I tumors was lower (77%). 
The overall accuracy of CT in determining the location of the tumor according to the 
Siewert classification was 72% (36/50) if allowing a a type I or type II tumor on the 
CT-scan to predict a type I/II tumor and a type II or type II tumor to predict a type 
II/III tumor. In 7 patients (14%) in whom the endoscopist encountered a stenosis on 
endoscopy/EUS, the radiologist was able to correctly determine the location of the 
tumor on the CT-scan in 6 out of 7 patients (86%). 
B. Accuracy of assessing N-stage per lymph node station 
The endoscopist was not able to fully complete the preoperative evaluation in 7 
patients (14%) as the tumor could not be passed by the echoendoscope. In 5 of 
these 7 patients no suspected nodes were seen proximally to the tumor (cNx=5, 
cN1=2). In 26 patients an extended lymphadenectomy was performed by means of 
TTE. In most of these patients high paratracheal (N=26), low paratracheal (N=24), 
aortopulmonary window (N=24) and subcarinal lymph node stations (N=26) were 
harvested intraoperatively. In all fifty patients paraesophageal and lesser curvature 
lymph nodes were identified by the pathologist in the resection specimen, whereas 
the surgeon had always sampled the celiac trunk nodes separately. Therefore, a total 
number of 250 lymph node stations was assessed in the current study. 
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Table 2A-B. Accuracy of preoperative staging of the location of the tumor according 
to the Siewert classification by upper gastrointestinal endoscopy in combination with 
EUS (2A) and CT (2B). The histopathologic findings (tumor location in the surgical 
resection specimen) were considered the gold standard.
2A.
Pathology
Endoscopy / EUS
Type I Type II Type III NA
Type I       (N=22) 22 0 0 0
Type II      (N=15) 9 5 0 1
Type III     (N=2) 0 1 1 0
Type I/II    (N=8) 5 1 0 2
Type II/III  (N=3) 2 1 0 0
NA = not available; as the tumor appeared to be stenotic on endoscopy (N=3), assessment of 
its location according to the Siewert classification was not feasible
2B.
CT 
Pathology Type I Type II Type III NA
Type I (N=22) 17 2 0 3
Type II (N=15) 6 7 0 2
Type III (N=2) 0 0 2 0
Type I/II (N=8) 7 0 0 1
Type II/III (N=3) 1 2 0 0
 NA = not available; tumor was not visible on CT (N=6), thereby impeding an evaluation of its 
location according to the Siewert classification.
When comparing the tumor infiltration depth and overall lymph nodal status as 
assessed preoperatively by EUS (cTNM-stage) with the histopathologic outcome as 
evaluated in the resection specimen (pTNM-stage), the overall accuracy of EUS was 
79% for patient’s T-stage and 66% for N-stage (N=43). The overall accuracy of CT 
was 52% for patient’s N-stage (N=50). The overall accuracy for predicting patient’s 
N-stage per station was 66% (166/250) for EUS and 68% (170/250) for CT. The 
accuracy for all stations as assessed preoperatively by EUS or CT and compared with 
the histopathologic outcome is shown in Table 3. The accuracy of EUS and CT in 
predicting the N-stage per lymph node station was good for those stations located 
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high in the thorax (paratracheal and aortopulmonary window nodes). The accuracy 
declined to 50-70% for the predominantly peritumoral lymph nodes (subcarinal, 
paraesophageal and lesser curvature nodes). 
Table 3. Accuracy in the evaluation of the N-stage of 250 lymph node stations, when 
comparing the preoperative assessment by means of EUS and CT, respectively, with 
the postoperative histopathologic outcome.
Pathology
EUS CT
PT-high (N=23) 20/23 (87%) 20/23 (87%)
PT-low (N=24) 22/24 (92%) 21/24 (88%)
AOP (N=24) 20/24 (83%) 22/24 (92%)
SC (N=26) 13/26 (50%) 15/26 (58%)
PE (N=50) 34/50 (68%) 31/50 (62%)
LC (N=50) 24/50 (48%) 26/50 (52%)
TR (N=50) 29/50 (58%) 35/50 (70%)
PT-high = high-paratracheal lymph nodes
PT-low = low-paratracheal lymph nodes
AOP = aortopulmonary window lymph nodes
SC = subcarinal lymph nodes
PE = paraesophageal lymph nodes
LC = lesser curvature lymph nodes
TR = celiac trunk lymph nodes
For staging celiac trunk nodes, EUS and CT showed an accuracy of 58% and 68%, 
respectively. This relatively low accuracy was mainly caused by understaging (false-
negative rate 34% with EUS and 25% with CT). When the results of the 7 patients in 
whom the preoperative evaluation by EUS could not be completed due to a stenotic 
tumor are discarded, a total number of 202 lymph node stations was available for 
analysis (Table 4). EUS and CT showed similar results in terms of false-positive and 
false-negative staging. Notably, approximately one out of five lymph node stations 
had been classified with a false-negative status (23% for EUS and 22% for CT). For 
EUS, these data result in an overall sensitivity of 35% and a specificity of 81% in 
determining N-status per lymph nodal status with EUS, and for CT 34% and 86%, 
respectively. 
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Table 4. Staging the lymph nodal status of 202 lymph node stations, when comparing 
the preoperative assessment by means of EUS and CT with the postoperative 
histopathologic outcome: accurate, false-positive or false-negative prediction.
Accurate 
prediction
False-positive
prediction
False-negative 
prediction
EUS 137/202 (68%) 18/202 (9%) 47/202 (23%)
CT 138/202 (68%) 20/202 (10%) 44/202 (22%)
Discussion
In the present study the accuracy of preoperative assessment of primary tumor 
location according to the Siewert classification and lymph nodal status per 
station were evaluated prospectively in patients with adenocarcinoma of the GEJ. 
The predicted tumor location and N-stage per nodal station as determined by 
endoscopy/EUS and CT were compared with the histopathologic findings in the 
resection specimen (gold standard). First of all, the overall accuracy in predicting the 
location of the tumor according to the Siewert classification was 70% for endoscopy/
EUS and 72% for CT. These results are in line with an other study that attempted to 
evaluate the Siewert classification by means of a retrospective comparison between 
endoscopic and pathologic results, in which an accuracy of 72.5% was achieved by 
examining the tumor location with endoscopy/EUS in 54 patients over a 15-year 
time period.30 However, in the present study a proper comparison between the 
preoperative data and the pathologic outcome was not feasible in 11/50 patients 
(22%) as large tumors obscured the landmarks in such way that a clear assignment 
to one of the Siewert classes was impossible. Previous studies have also shown that 
determining the precise location of the GEJ can be difficult, reflecting a practical 
problem with regard to the implementation of the Siewert classification in daily 
clinical practice. Even pathologists sometimes struggle to correctly classify these 
tumors. Another illustration of this problem was shown in a randomized controlled 
trial on esophageal and GEJ adenocarcinomas, in which a substantial difference 
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was demonstrated between the endoscopic tumor classification and the pathologic 
tumor classification in the resection specimen.22 The endoscopists tended to classify 
tumors at the GEJ as type I, whereas the pathologists decided in favor of type II 
relatively more often.22 This shift from type I to type II tumors was also observed in 
the present study. An other study analyzed retrospectively the endoscopy reports of 
613 patients in order to assign the location of the tumors according to the Siewert 
classification. However, in 96 cases (16%) the size of the tumor precluded a precise 
classification due to obscured landmarks.31 In general, practical problems with the 
Siewert classification in case of a locally advanced tumor with invasion of the GEJ 
have been recognized before. Although not specified in the official classification, it 
has been described by Siewert and colleagues that in patients with locally advanced 
tumors, the tumor mass must be used as a guide for classification rather than the 
tumor center.2 If more than 50% of the tumor mass is located within the tubular 
esophagus, the presence of a type I tumor can be assumed.2 However, this does not 
solve the problem, because determination of the tumor location remains difficult in 
case the anatomical landmarks of the GEJ are invisible.
Secondly, the overall accuracy for predicting the N-stage per lymph node station 
was 66% (166/250) for EUS and 68% (170/250) for CT. The endoscopist was not able 
to fully complete the preoperative evaluation in 7/50 patients (14%) as the tumor 
could not be passed by the echoendoscope. The evaluation of stenotic tumors (a 
subgroup of up to 25% of patients with esophageal cancer32) is a well-recognized 
major limitation of EUS. Partial staging of the tumor (only up to the proximal margin 
of the stenosis) has a poor accuracy (<50%).32 Smaller calibre probes have been 
introduced that can address this problem, as dilation of the tumor for staging is in 
general not advisable.33 However, these mini-probes have no value in the staging of 
stenotic esophageal cancer since the penetration depth is very limited and acoustic 
coupling below the level of the stenosis is almost impossible. In the present study it 
appeared that the accuracy of EUS and CT in predicting the N-stage per lymph node 
station was good for those stations located high in the thorax, which play a large 
role in the decision making whether to perform an extended lymphadenectomy. 
The accuracy declined to 50-70% for the lymph node stations located peritumorally, 
although these results are without clinical consequences in patients with advanced 
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tumors. More disappointingly, EUS showed an accuracy in terms of predicting the 
N-stage of celiac trunk nodes of 58% (with a high false-negative rate), which is much 
lower than reported in literature (approximately 80%).34, 35 Also, both EUS and CT 
tend to understage in our study, as one out of five lymph node stations was classified 
as false-negative by these imaging-modalities. When evaluating retrospectively the 
false-negative classified lymph nodes, it appeared that in most cases these nodes 
have not been seen on EUS (29/47) or CT (34/44), rather than misinterpretation 
has played a role. In many institutes EUS has a significant impact on deciding which 
treatment modality should be offered to an individual patient with esophageal 
cancer.36, 37 However, based on the results of the current study, this should be done 
with caution in case the status of the celiac trunk nodes plays a large role in the 
clinical decision-making.
 
To optimize treatment for patients with adenocarcinoma of the GEJ, improvement 
in the preoperative assessment of the location of the primary tumor and positive 
lymph nodes is required. The Siewert classification is based on the anatomical 
location of the tumor center or, in patients with an advanced tumors, the location 
of the tumor mass.4 Rather than focusing on whether the epicenter of the primary 
tumor or tumor mass is located in the esophagus or stomach, information on to 
what extent the other organ is involved (e.g. a distal esophageal tumor with invasion 
into the proximal stomach) will provide more useful information. After all, it is the 
presence and extent of tumor invasion across the GEJ (either from the proximal or 
distal side) that will influence the surgical approach. A total gastrectomy is usually 
not performed in case of proximal gastric cancer if substantial tumor invasion (>1-
2 cm) of the distal esophagus is present: the risks of a positive proximal resection 
margin as well as lymphatic dissemination to the thoracic basins are too high. On the 
other hand, in case a distal esophageal tumor largely invades the cardia (>4-5 cm), it 
is questionable whether a resection with gastric tube reconstruction is oncologically 
safe. Information about tumor invasion across the GEJ and about total tumor length 
(which determines the extent of the radiotherapeutic field) can also be of importance 
when deciding whether a patient is eligible for neoadjuvant chemoradiation. The 
extent of tumor invasion at both sides of the GEJ can be assessed by means of 
conventional endoscopy with the proximal end of the gastric folds as landmark. In 
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case the GEJ is not visible due to advanced tumor growth, the diaphragm can be 
taken as landmark on EUS, although this will not supply accurate results in patients 
with a hiatus hernia.
The moderate overall accuracy for EUS and CT in predicting the N-stage per station 
will require a more objective and reliable assessment of lymph node involvement. 
EUS-guided fine needle aspiration (FNA) that allows a cytological diagnosis can play 
an important role in this field.38 Indeed, EUS-FNA has proven to be more accurate in 
comparison to EUS alone and CT for nodal staging16, although sampling error may 
occur in daily clinical practice. Furthermore, EUS-FNA is not feasible in case lymph 
nodes are located peritumorally and in stenotic tumors. Because of these practical 
problems, we have restricted the use of EUS-FNA to those lymph nodes of which the 
status will influence the therapeutic approach.39, 40 
Furthermore, lymph node detection by magnetic resonance imaging has improved 
since a new contrast agent USPIO (ultrasmall superparamagnetic iron oxide) has been 
introduced. Early clinical studies have shown that USPIO–enhanced MRI improves 
sensitivity and specificity for detection of nodal metastases based on enhancement 
patterns.41-43 Nevertheless, further evidence for a possible additional value of USPIO-
enhanced MRI is lacking thus far.
In conclusion, we evaluated prospectively the accuracy of preoperative assessment 
of primary tumor location according to the Siewert classification and lymph nodal 
status per station. The overall accuracy in predicting the location of the tumor was 
moderate (EUS 70%, CT 72%). Moreover, given the frequent discrepancy between 
the endoscopic and pathologic location of the GEJ and the encountered problem 
with advanced tumors obscuring the commonly used landmarks, the usefulness 
of the Siewert classification in the assessment of primary tumor location in daily 
clinical practice is limited. Assessment of tumor invasion across the GEJ rather than 
focusing on the anatomical location of the GEJ and the epicenter of the tumor might 
be a useful alternative. Finally, the overall accuracy for EUS and CT in predicting the 
N-stage per lymph node station was moderate (EUS 66%, CT 68%). The accuracy 
was good for those stations located high in the thorax, but poor for the celiac trunk 
nodes. In case the status of a nodal station will influence the therapeutic approach, a 
more objective and reliable assessment of lymph nodal involvement (e.g. EUS-FNA) 
should be considered.
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Abstract
Introduction: The sentinel node concept is of great value in the treatment of 
various malignancies. In this study we investigated whether the application of 
the sentinel node procedure is feasible in esophageal adenocarcinoma and 
whether it can tailor surgical treatment of the individual patient.
Methods: In 40 patients with an adenocarcinoma of the distal esophagus or 
gastroesophageal junction, blue dye was injected around the tumor intra-
operatively. Sentinel nodes (blue-stained) as well as non-sentinel nodes 
were identified and dissected during transhiatal esophagectomy. In sentinel 
nodes negative for tumor cells on routine H&E examination, multi-level 
sectioning and immunohistochemical staining were performed to search for 
micrometastases. 
Results: The sentinel node procedure was technically successful in 39/40 
patients (98%). The median number of sentinel nodes identified was 4. 
Sentinel nodes were present in more than one nodal station in 8 patients 
(21%). In 6 patients in whom the sentinel node was negative for metastasis, 
non-sentinel nodes were positive for tumor cells (false-negative rate 
6/39=15%). Micrometastases and isolated tumor cells were detected in 7/19 
(37%) sentinel node-negative patients, but this finding did not affect the false-
negative rate.  
Conclusion: Detection of sentinel nodes is technically feasible during 
esophagectomy for cancer. However, given the relatively high false-negative 
rate of 15% and the high frequency of sentinel nodes in more than one 
nodal station, the clinical relevance of the sentinel node concept (through 
application of the blue dye technique) in the current treatment of patients 
with an adenocarcinoma of the distal esophagus or gastroesophageal junction 
seems limited.
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Introduction
Most esophageal adenocarcinomas arise from the lower esophagus and the 
gastroesophageal junction (GEJ).1,2 Prognosis after diagnosis is still poor as overall five-
year survival rates rarely exceed 20%. One of the strongest predictors of long-term 
survival after radical (R0) esophagectomy is the presence of lymph node metastasis.3-5 
However, extended lymphadenectomy for the removal of all locoregional nodes 
can be at the cost of increased peri-operative morbidity.6,7 Therefore this approach 
should ideally be restricted to those patients who are most likely to benefit. 
A tailored surgical treatment for the individual patient may be applicable with help 
of the sentinel node concept. It states that the first lymph nodes (or a single lymph 
node) that receive the most direct lymph drainage from the primary tumor have 
the greatest potential to harbor metastatic disease when present.8,9 On this basis, 
examination of the sentinel node can be used to predict overall lymph node status. 
Hence, applying the sentinel node concept to esophageal cancer could potentially 
have two important clinical implications. First, it may allow for the selection of 
patients who are not likely to benefit from an extended lymphadenectomy. If the 
sentinel node is not involved, then patients could be spared more extensive surgery 
by tailoring the extent of lymphadenectomy. Secondly, it may affect the process 
of pathological examination of the resected lymph nodes. Immunohistochemical 
detection of micrometastases and isolated tumor cells has been reported10-12 and was 
found to be clinically relevant in one study.12 
The sentinel node concept has not been studied extensively in esophageal cancer. We 
hypothesize that identification of the sentinel node(s) in esophageal adenocarcinoma 
can be achieved with a low false-negative rate and a high accuracy. In this study 
we determined the feasibility of application of the sentinel node procedure in 
adenocarcinomas of the distal esophagus and GEJ (with the false-negative rate as 
primary outcome parameter), and evaluated its value in the clinical setting. 
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Patients and methods
Patients
Over a 14-months period (May 2000 – June 2001), 101 patients underwent an 
esophageal resection and reconstruction for cancer of the distal esophagus or GEJ 
in our hospital. These patients were evaluated for inclusion in the study based on 
the following criteria: histologically proven adenocarcinoma of the distal esophagus 
or GEJ pre-operatively (Siewert type I or type II, respectively) and no application of 
neoadjuvant chemo- and/or radiotherapy. Induction chemo- and/or radiotherapy 
was given in patients with either a cT4-tumor without distant metastases or in 
patients with involvement of celiac trunk lymph nodes (M1a), who were not 
considered eligible for primary surgical therapy. There were 30 patients who received 
chemo- and/or radiotherapy before surgery; in 20 patients histological examination 
confirmed a squamous cell carcinoma; 2 patients underwent surgery for high-grade 
dysplasia and in one patient a double tumor of the esophagus lead to exclusion. Eight 
patients did not participate in the study due to logistic reasons. Consequently, 40 
patients were included in this study and the sentinel node procedure was performed 
as described below. Informed consent was obtained from the patients before 
operation. The Medical Ethics Committee of the Erasmus MC approved the study.
Sentinel node mapping
Mapping of the sentinel nodes was carried out in vivo after opening the hiatus of the 
diaphragm and mobilization of the gastroesophageal junction under direct vision. 
Minimal dissection was performed in order to maintain intact lymph channels. At 3 
different sites in the vicinity of the tumor, 1-2 cc Patent Blue V (Guerbet-Laboratories, 
Issy les Moulineaux, France) was injected in the submucosal layer. Within the next 5 
minutes, the sentinel node(s) were identified by following the blue-stained lymphatic 
vessels. These nodes were tagged with a suture. Once the resection specimen 
was taken out, the sentinel nodes were harvested ex vivo and sent as a separate 
specimen to the Department of Pathology. The remaining non-blue-stained lymph 
nodes present in the resection specimen (non-sentinel nodes) were identified by 
the pathologist and categorized according to the location as para-esophageal, peri-
gastric or celiac trunc nodes.
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Surgery
All patients underwent a transhiatal esophagectomy. The primary tumor and its 
adjacent lymph nodes were dissected under direct vision through the widened 
hiatus of the diaphragm up to the level of the inferior pulmonary vein. Subsequently, 
a gastric tube was created. The left gastric artery was transected at its origin, with 
en bloc resection of celiac trunc lymph nodes. After mobilization and transection of 
the cervical esophagus, the intrathoracic esophagus was mobilized bluntly from the 
neck to the abdomen with a vein stripper. Esophagogastrostomy was performed in 
the neck, without a formal cervical lymphadenectomy. 
Pathology
Pathologic evaluation of all lymph nodes consisted of conventional hematoxylin-
eosin (H&E) staining. If no tumor cells were identified in the sentinel node(s), multi-
level serial sectioning was performed. These lymph nodes were cut at 10 levels of 
approximately 100 μm (dependent on lymph nodes’ size). Subsequently, sections were 
cut with a thickness of 4 μm which were examined for tumor cells with H&E staining 
as well as immunohistochemistry (IHC) to reveal micrometastases (metastatic lesions 
larger than 0.2 mm in dimension but smaller than 2.0 mm) and isolated tumor cells 
(metastatic lesions no larger than 0.2 mm in dimension).13-14 The mouse-monoclonal 
antibody CAM 5.2 (NCL5D3, Novo Castra, Wetzlar, Germany) which is specific for 
intracellular cytokeratin-8 and –18, was used for this experiment.15
Statistics
To allow for intra-patient dependencies between outcomes of the investigated 
lymph nodes, the method of generalized estimating equations was used (SAS 
PROC GENMOD, SAS Institute Inc., Cary, NC, USA). Two-sided p-values <0.05 were 
considered to be significant.  
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Results
The sentinel node procedure was attempted in 40 patients who underwent a 
transhiatal esophagectomy. Patients’ characteristics are described in Table 1. In 3 
patients a large tumor covered both the distal esophagus and the gastroesophageal 
junction (type I/II), and no proper distinction between a type I or type II tumor could 
be made. 
The sentinel node procedure was successful in identifying one or more sentinel 
nodes in 39 of 40 patients (98%). Technical failure occurred in one patient: the blue 
specimen that was presumed to be the sentinel node did not contain any lymphatic 
tissue when examined by the pathologist. Hence, the data of this patient are excluded 
from further analysis.  
Table 1. Patients’ characteristics.
Gender Male 30 (75%)
 Female 10 (25%) 
Age* 62 (range 41-80)
pT-stadium pT1 9 (23%)
 pT2 5 (13%)
 pT3 26 (65%)
Barrett’s metaplasia Yes 24 (60%)
 No 16 (40%)
Tumor location Siewert I 20 (50%)
 Siewert II 17 (43%)
 Siewert I/II 3 (8%)
* Age is given as median  
A total of 424 lymph nodes were resected, comprising both sentinel nodes (N=143) 
and non-sentinel nodes (N=281). The median number of sentinel nodes identified 
per patient was 4 (range 1-9), whereas the number of non-sentinel nodes accounted 
for a median of 7 nodes per patient (range 1-22). The location of the identified 
sentinel nodes in relation to tumor site is shown in Table 2. The percentage of 
para-esophageal sentinel nodes was significantly higher in patients with a Siewert 
type I tumor than in patients with a Siewert type II tumor: 64% (45/70) versus 11% 
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(7/64), p<0.001. On the other hand, for sentinel nodes situated in the peri-gastric 
area, these percentages amounted 29% (20/70) for Siewert type I and 77% (49/64) 
for Siewert type II tumors, p=0.002. In one patient with a type I tumor no sentinel 
node could be identified during the abdominal phase of the operation; however, 
two blue nodes (5%) were detected coincidentally in the cervical region, implicating 
an upwards lymphatic drainage. Eight patients (21%) had sentinel nodes present in 
more than one nodal station. In the 39 patients in whom the sentinel node concept 
was applied successfully, the sentinel node was located adjacent to the tumor in 30 
patients (77%). 
Table 2. Relation between location of the sentinel node and tumor site. 
Sentinel Node Location
Tumor site Cervical Paraesophageal Perigastric Celiac trunk TOTAL
Siewert I      (N=20) 2 45 20 3 70
Siewert II     (N=16) 0 7 49 8 64
Siewert I/II   (N=3) 0 2 7 0 9
TOTAL        (N=39) 2 54 76 11 143
Of the total number of 424 lymph nodes examined by means of standard H&E 
staining, the sentinel nodes were more likely to contain tumor cells than the non-
sentinel nodes: 40 of 143 (28%) sentinel nodes were positive versus 52 of 281 (19%) 
non-sentinel nodes (p=0.046, Table 3). 
Table 3. Total number of lymph nodes derived from esophagectomy specimens of 39 
patients: relation between (non-)sentinel nodes and tumor involvement as judged 
by H&E examination. 
Sentinel node Non-sentinel node TOTAL
Positive (N+) 40 52 92
Negative (N-) 103 229 332
TOTAL 143 281 424
In 20/39 (51%) patients the sentinel node contained tumor metastasis diagnosed 
on routine H&E examination. In 8 patients (21%) it was the sentinel node only that 
accounted for the N1-status of the patient; in 12 patients (31%) there were also non-
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sentinel nodes in which a metastasis was found. In the remaining 19 patients (49%), 
the sentinel node was scored negative for tumor cells (Table 4A). However, in 6 of 
these 19 patients metastases were found in the non-sentinel nodes, which involved 
one patient with a pT1 tumor, one with a pT2 tumor and four patients in whom a pT3 
tumor was diagnosed. These data correspond with a false-negative rate of 15% (6 of 
39 patients), a negative predictive value of 68% (13/19), an accuracy of 85% (33/39), 
a sensitivity of 77% (20/26) and a specificity of 100% (13/13) of the sentinel node 
procedure in our study (see Table 5). 
In patients in whom no metastasis was detected in the sentinel node by H&E 
staining (N=19), multi-level serial sectioning and immunohistochemical staining 
with CAM 5.2 was performed (in the sentinel nodes only). In one patient this 
revealed a macrometastasis that was not present in the conventional H&E section; a 
micrometastasis was identified in one patient and isolated tumor cells in five patients, 
resulting in upstaging of the histological diagnosis in seven patients (Table 4B). These 
results did not affect the false-negative rate of 15% (Table 5) because patients’ lymph 
node status was not revised in any of the 6 patients in whom only non-sentinel nodes 
were scored positive (false-negatives in this study).
Table 4A and B. Nodal status - tumor positive (+) and negative (-) - of 39 patients 
after esophagectomy for cancer: relation between sentinel and non-sentinel nodes.
Table 4A. Before multi-level sectioning and immunohistochemistry.
Non-sentinel Node + Non-sentinel Node - TOTAL
Sentinel Node + 12 8 20
Sentinel Node - 6 13 19
TOTAL 18 21 39
Table 4B. After multi-level sectioning and immunohistochemistry.
Non-sentinel Node + Non-sentinel Node - TOTAL
Sentinel Node + 12 15 27
Sentinel Node - 6 6 12
TOTAL 18 21 39
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Table 5. Definitions of diagnostic test parameters and corresponding values in 39 
patients (before and after multi-level sectioning and immunohistochemistry).
Definition Value –
before IHC
Value –
after IHC
False-negative rate Number of false-negative SN / 
Number of pts with an identified SN
6/39=15% 6/39=15%
Negative predictive 
value
Number of true node negative pts (SN + 
NSN) / 
Number of true node negative pts + false 
negative pts
13/19=68% 6/12=50%
Accuracy Number of positive SN pts + number of pts 
with a true negative SN /
Number of pts with an identified SN
33/39=85% 33/39=85%
Sensitivity Number of true positive SN pts / 
Number of true positive SN pts + false 
negative pts
20/26=77% 27/33=82%
Specificity Number of pts with a true negative SN / 
Number of true node negative pts + false 
positive pts
13/13=100% 6/6=100%
SN = sentinel node; NSN = non-sentinel node; pts = patients.
Discussion
In this study we investigated the application of the sentinel node procedure in the 
surgical treatment of patients with esophageal adenocarcinoma. The sentinel node 
procedure was technically successful in 39 of 40 patients (98%). The median number 
of sentinel nodes identified per patient was 4 (range 1-9) and these sentinel nodes 
were present in more than one nodal station in 8 patients (21%). In 6 patients in whom 
the sentinel node was negative for metastasis, non-sentinel nodes were positive for 
tumor cells (false-negative rate 6/39 = 15%). Micrometastases and isolated tumor 
cells were detected in 7/19 (37%) sentinel node-negative patients, but this finding 
did not affect the false-negative rate.  
The term ‘sentinel node’ was introduced in 1960 by Gould et al. in their study to 
detect lymphatic metastases in parotid carcinoma.16 The procedure was further 
refined in patients with melanoma8 and in breast cancer.9 Especially in breast cancer 
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it has become a widely accepted element in the routine surgical management.17 In 
gastrointestinal tumors, the use of this procedure is still under investigation. Over 
the last 10 years a considerable number of clinical trials evaluating the feasibility and 
accuracy of the sentinel node procedure in mainly gastric and colorectal carcinoma 
have been published. With regards to gastric cancer, a complex lymphatic drainage 
is considered to result in high frequencies of skip metastases (15-20%).18-19 These 
trials show high false-negative rates (ranging from 0 – 39%).20-21 Hence, a tailored 
surgical approach with regard to lymphadenectomy on the basis of this procedure in 
gastric cancer patients is not justified. In colorectal cancer all regional lymph nodes 
are routinely removed with the resected bowel segment. Hence, minimizing surgical 
resection is not a major goal of the sentinel node procedure in colorectal cancer 
patients. Instead, improved prognostication is the main target here.22 
The lymphatic drainage of the esophagus is complex with abundant lymph-capillary 
networks especially in the submucosa.23,24 This results in a longitudinal lymphatic 
drainage which is presumed to be the reason for the phenomenon of skipping lymph 
node metastases in esophageal cancer.25 Skip metastases are present when there is 
no tumor cell spread from the primary tumor into the adjacent peritumoral lymph 
nodes in the presence of positive distant nodes. For esophageal adenocarcinomas 
skip metastases have been reported in 0-35% of patients.7,25,26 Since all patients from 
our study underwent transhiatal esophagectomy, a thorough analysis of the lymphatic 
spread in the upper part of the chest was not possible. In patients with a Siewert 
type I tumor the sentinel node was mainly located along the esophagus, whereas 
in most patients with a Siewert type II tumor the gastric nodal station contained 
the sentinel node. These results correlate with the patterns of lymphatic spread for 
these tumor entities as described in literature.27 Furthermore, two sentinel nodes 
were found coincidentally in the cervical region (5%), representing the complex and 
unpredictable lymphatic spread of esophageal cancer cells.
We found a false-negative rate of 15%, which is higher in comparison with other 
malignancies. For example, false-negative rates between 0-5% for breast cancer have 
been reported and are worldwide considered to be acceptable.17,28 Furthermore, 
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sentinel nodes were identified in more than one nodal station in 8 patients (21%), 
while ideally the sentinel node presents as a solitary lymph node, to enhance the 
usefulness of the sentinel node concept in clinical practice. Also, in our study a median 
of 4 sentinel nodes per patient were detected, indicating that half of the patients had 
4 or more (up to 9) blue-stained nodes. These sentinel nodes were harvested during 
a transhiatal approach with a limited lymphadenectomy. One could hypothesize 
that, if a transthoracic esophagectomy with a two-field lymphadenectomy had been 
performed, the false-negative rate could have been lower (blue-stained lymph nodes 
may have been present in the upper mediastinum) as well as higher (if mediastinal non-
sentinel nodes positive for tumor could have been detected). One study investigating 
the use of the sentinel node procedure in esophageal adenocarcinomas showed 
that when extended lymphadenectomy was performed, the lower paraesophageal 
and left gastric artery nodal stations were the most common sites of sentinel node 
identification.29 In contrast, the upper mediastinal nodal basins accounted for only 
3% (4/131) of the sentinel node stations. Therefore, we do not believe that the 
applied transhiatal approach with a limited lymphadenectomy is a major drawback 
in the current study. 
Two other studies have been published thus far which investigated the sentinel node 
procedure in esophageal adenocarcinomas.29,30 In the first study Lamb et al. identified 
at least one sentinel node by means of peritumoral injection (prior to the operation) 
of radioactive nanocolloid in all 57 patients with a type I or type II tumor (no blue 
dye was used).29 A false-negative rate of 5% was reported. Hence, one could argue 
that in our study the use of blue dye only, is a technical shortcoming. However, this 
approach has been described before.20,21 Nonetheless, in breast cancer blue dye and 
radiocolloid are considered to act as complementary techniques.28
The second study demonstrated that sentinel node detection was feasible in 17 out 
of 20 patients using a combination of blue dye and radiocolloid injection (N=10) and 
radiocolloid injection only (N=10).30 No data were shown to clarify whether the use 
of blue dye and radiocolloid are complementary. Lymph node status was correctly 
predicted in all type I tumors, and in 75% of type II and type III tumors. Furthermore, 
advanced tumors had a higher false-negative rate and therefore it was concluded 
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that the sentinel node procedure was only applicable in patients with early (pT1-2) 
cancer. However, in our study both early and advanced tumors belonged to the group 
of false-negatives (one T1-, one T2- and four T3-tumors).  
Overall, in our study the use of blue dye only without radiocolloid injection as a 
complementary technique, may be a potential drawback in this study. Nevertheless, 
in our opinion, the two above-mentioned studies together with our present findings 
do not justify the application of the sentinel node concept in clinical decision-making 
in patients with an adenocarcinoma of the distal esophagus or gastroesophageal 
junction in our institution at the moment. 
In summary, we conclude that the sentinel node procedure is technically feasible 
during transhiatal esophagectomy for esophageal cancer. However, given the high 
false-negative rate and the high frequency of sentinel nodes in more than one nodal 
station, the clinical relevance of the sentinel node concept by application of the blue 
dye technique only in the current treatment of patients with an adenocarcinoma 
of the distal esophagus or gastroesophageal junction seems limited. More studies 
are needed that should focus on using the blue-dye technique in combination with 
radiocolloid injection as well as extended lymphadenectomy.
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Abstract 
Introduction: Both endoscopic and surgical treatments are recommended for 
m3- or sm1-adenocarcinomas of the esophagus, depending on patients’ lymph 
nodal status. Lymphatic dissemination is related to tumor infiltration depth, 
but varying incidences have been reported in m3- and sm1-adenocarcinomas. 
The study aim was to investigate whether the presence of occult tumor cells 
in lymph nodes could explain this variation.
Methods: Sixty-three node-negative (N0) patients with early esophageal 
adenocarcinoma (m2/m3/sm1-tumors) were included. Multilevel-sectioning 
of lymph nodes was performed; sections were stained by means of 
immunohistochemistry with cytokeratin-marker CAM5.2. Two pathologists 
searched for micrometastases (0.2-2.0mm) and isolated tumor cells (ITCs, 
<0.2mm).
Results: Positive CAM5.2 staining in lymph nodes was not seen in any of 
the 18 m2-patients. In 2/25 m3-tumors (8.0%) an ITC was found, but no 
micrometastases. Tumor cells were identified in 4/20 sm1-tumors (20.0%): 
3 micrometastases and one ITC. Median follow-up was 121 months. Two m3-
patients (3.2%) died due to disease recurrence, including one patient in whom 
an ITC was detected. 
Conclusions: Lymphatic migration of tumor cells was found in node-
negative m3- and sm1-adenocarcinomas of the esophagus (8.0% and 20.0%, 
respectively). However, the clinical relevance of these occult tumor cells 
should become apparent from large series of endoscopically treated patients. 
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Introduction
Lymph node status is the most important prognostic factor in esophageal cancer.1-3 
The presence of lymph node metastases has a strong adverse impact on patient 
survival, even after radical esophagectomy with extended lymphadenectomy. Some 
studies have shown that lymph node micrometastases and isolated tumor cells (ITCs) 
can be detected by immunohistochemistry (IHC) in up to 50% of N0-patients with 
esophageal cancer. However, contradictory results have been reported with regard 
to their prognostic importance.4-16 
Current treatment options for early esophageal cancer (T1-tumors) vary from 
organ preserving endoscopic mucosal resection (EMR) to limited surgical resection 
(Merendino procedure or subtotal transhiatal esophagectomy) and radical 
esophagectomy with extended lymphadenectomy.17-20 In patients with early 
esophageal cancer, otherwise fit for operation, the decision whether to perform EMR 
or an esophagectomy mainly depends on patients’ lymph nodal status.21 An overview 
of reports on the frequency of lymph node involvement in mucosal (m1-m2-m3) and 
submucosal (sm1-sm2-sm3) esophageal adenocarcinoma is given in Table 1. 
Lymphatic dissemination is related to the depth of infiltration of the primary 
tumor.22-25 Lymph node metastases have not been reported in m1 and m2 mucosal 
adenocarcinomas (thereby allowing endoscopic treatment), whereas positive lymph 
nodes can be found in 0-12% of m3 patients.22-25 In submucosal adenocarcinomas, it 
appears that sm1 tumors are associated on average with a lower rate of lymph node 
metastases than sm2-sm3 tumors.22-25 Because of the high incidence of lymph node 
metastases in patients with deep submucosal tumor infiltration, an esophagectomy 
is considered the standard therapy for sm2 and sm3 tumors.19, 26, 27 Nevertheless, the 
management of carcinomas with invasion into the muscularis mucosae (m3) or the 
most superficial layer of the submucosa (sm1) is still under debate; on average 5-7% 
of m3- and sm1-patients are classified as N1 postoperatively (Table 1). 
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In a previous publication we reported that lymphatic dissemination was limited to 
tumors infiltrating the middle and deepest layer of the submucosa (sm2 and sm3).23 
However, subsequent reports from other institutes described lymphatic tumor spread 
already at an earlier stage (m3 and sm1). In an attempt to explain this discrepancy 
we re-evaluated the resection specimens from our previously published series and 
searched for micrometastases and ITCs. Also, we have attempted to address the 
question whether the presence of occult metastases in patients with m3 and sm1 
adenocarcinomas will influence the decision to undertake an endoscopic or surgical 
resection. 
Table 1. Overview of reports on the frequency of lymph node involvement in mucosal 
(m1-m2-m3) and submucosal (sm1-sm2-sm3) esophageal adenocarcinoma. 
m1
n       %
m2
n       %
m3
n       %
sm1
n       %
sm2
n       %
sm3
n       %
Liu22 36       0 --        -- 17      12 12       8 --       -- 25     36
Westerterp23 13       0 18       0 23       4 25       0 23     26 18     67
Bollschweiler25, 47 9        0     2        0 3        0 10     20 6       0 10     70
Ancona24 12 m1-m2-m3: 0% 12       0 7 sm2-sm3: 43%
TOTAL 58       0 20       0 43       7 59       5 29     21 53     53
T1a
n                   %
T1b
n                   %
TOTAL 133                2 148               25
n = number of included patients
% = percentage of patients with positive lymph nodes on routine examination
m1 = carcinoma in situ without invasion through the basement membrane
m2 = intramucosal carcinoma extending beyond the basement membrane into the lamina 
propria
m3 = carcinoma with invasion into the muscularis mucosae 
sm1 = carcinoma infiltrating the submucosa but limited to the upper third of the submucosa
sm2 = carcinoma infiltrating the submucosa but limited to the middle third of the submucosa
sm3 = carcinoma infiltrating the submucosa but limited to the lower third of the submucosa
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Patients and methods
Patients
The outcome of patients who underwent transhiatal esophagectomy with regional 
lymphadenectomy for early adenocarcinoma of the esophagus or gastro-esophageal 
junction (pT1-tumors) between 1980 and 2002 in two university hospitals in The 
Netherlands (Erasmus Medical Center, Rotterdam, and Academic Medical Center, 
Amsterdam) has been described previously.23 Patients did not receive (neo)adjuvant 
chemo- and/or radiotherapy at that time. We have reported on the operation 
technique in previous studies.28, 29 Patients in whom the tumor was classified as 
m2, m3 or sm1, and in whom the lymph nodes were scored as tumor-free (N0) on 
conventional histopathological examination (one N1-patient with a m3 tumor was 
excluded from the previous series), were selected for the present study (N=65). We 
included m2 tumors as a negative control, as we expected no lymphatic migration of 
tumor cells in these patients. Patients with sm2 or sm3 carcinomas were excluded 
in view of their high potential of lymphatic dissemination as already shown in the 
previous publication. Tissue blocks of resected lymph nodes of two patients were 
not available for this study. Therefore, a total number of 63 patients were included 
in the present series. 
Histopathologic assessment
Tumors were assigned pathologic tumor-node-metastasis stages according to the 
Union Internationale Contre le Cancer (UICC) 2002 system.30 The depth of tumor 
invasion was measured and subclassified based on the criteria proposed by the 
Japanese Society for Esophageal Disease.31 Intramucosal carcinoma was defined as a 
tumor extending beyond the basement membrane into the lamina propria (m2). All 
carcinomas with invasion into the muscularis mucosae were classified as m3 tumors, 
irrespective of the presence of a double muscularis mucosae (i.e. a superficial and a 
deep layer as can be observed in Barrett’s mucosa). Carcinomas infiltrating beyond 
the (deep) muscularis mucosae but limited to the upper third of the submucosa, 
were classified as sm1. 
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Immunohistochemistry
Sectioning at three different levels was performed in all lymph nodes. Sections of the 
33 patients operated on in Rotterdam were processed in the Erasmus MC; sections of 
the remaining 30 patients were stained in the AMC, Amsterdam. IHC was performed 
using the Envision system (DAKO, Glostrup, Denmark). A mouse-monoclonal 
antibody against CAM5.2 (BD Biosciences, San Jose, CA, USA) was used for this 
experiment, which does not react with hematopoietic and lymphoid cells and which 
is specific for intracellular cytokeratin-7 and –8 (both cytokeratins are expressed 
in esophageal adenocarcinoma). Therefore, positive lesions indicate epithelial cell 
deposits in lymphoid tissue and it has previously been shown that micrometastases 
in esophageal adenocarcinoma can be detected with this marker.14, 16, 32 
In brief, the sections were dewaxed in xylene and rehydrated through a graded 
ethanol series. Endogenous peroxidase activity was inhibited by incubating the 
sections in methanol with 3% hydrogen peroxide for 20 minutes. Microwave (700 
W) pretreatment in Tris-EDTA (pH=9) was performed for 15 minutes. The antibody 
against CAM5.2 was incubated overnight at 4°C. This was followed by the secondary 
incubation step of the Envision system. Diaminobenzidene tetrachloride from 
the Envison kit, prepared according to kit instructions, was used for visualization. 
Tissues were counterstained with hematoxylin. Finally, the slides were dehydrated 
through a graded ethanol series, cleared in xylene and mounted in Malinol (Chroma-
Gesellschaft, Köngen, Germany). As the sections were stained in two different 
centers with their own IHC protocol, a crosscheck was performed by staining sections 
of three patients in both centers, which showed similar results. 
Definition of micrometastases and isolated tumor cells
All sections were examined independently by two GI pathologists (FJWtK, KB) to 
detect micrometastases (positive lesions larger than 0.2 mm in dimension but smaller 
than 2.0 mm) and ITCs (metastatic lesions no larger than 0.2 mm in dimension).30, 33, 
34 Only clusters of positive cells with malignant characteristics detected in the sinuses 
or lymphoid interstitium were designated as micrometastases. In contrast, tumor 
cells surrounding the lymph node were considered as contamination that most likely 
had occurred during the processing of the resection specimen.
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Follow-up 
Outcome data for all patients with esophageal cancer referred to both hospitals 
for treatment have been collected prospectively and stored in a database by data 
managers. Follow-up was recorded until January 2009 or until death if earlier, 
ensuring a follow-up of at least five years. There were no patients lost to follow-up. 
Disease recurrence was defined as locoregional or distant metastatic disease when 
radiologically and/or pathologically proven.
Statistics
Statistical analysis appropriate for non-parametric data was used. Grouped data 
were compared using the Chi-Square test. Overall survival was calculated from the 
date of operation until the date of last follow-up or death according to the Kaplan-
Meier method. Disease-free survival was assessed from the date of operation 
until the date of disease recurrence in case of locoregional recurrence or distant 
metastases; patients were censored at the time of their last visit or when they died 
of non-disease related causes without a previous relapse. Data-analysis was carried 
out with SPSS version 15.0 (SPSS, Chicago, IL, USA). Two-sided p-values <0.05 were 
considered to be significant. 
Results
Clinicopathological characteristics of the present study population are shown in 
Table 2. In 18 patients (28.6%) the tumor invaded into the lamina propria (m2), in 
25 patients (39.7%) the tumor’s deepest invasion was detected in the muscularis 
mucosae, and in 20 patients (31.7%) the tumor extended into the superficial layer 
of the submucosa (sm1). A median number of seven lymph nodes (range 1 – 30) 
was harvested per patient, all of which were processed for immunohistochemical 
analyses. 
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Table 2. Clinicopathological characteristics of 63 patients who underwent a transhiatal 
esophagectomy for early esophageal adenocarcinoma (m2, m3, sm1).
Age* 67 years (30-83)
Gender
- male
- female
53 (84.1%)
10 (15.9%)
Tumor location
- mid esophagus
- distal esophagus
- gastroesophageal junction
2 (3.2%)
38 (60.3%)
23 (36.5%)
Differentiation grade
- good
- moderate
- poor
14 (22.2%)
44 (69.8%)
5 (7.9%)
Barrett’s metaplasia
- yes
- no
60 (95.2%)
3 (4.8%)
Tumor infiltration depth
- m2
- m3
- sm1
18 (28.6%)
26 (41.3%)
19 (30.2%)
* Value presented as median (range in brackets)
The results of the current IHC study are shown in Table 3. In six patients (9.5%) sections 
of lymph nodes stained positively for CAM5.2. Tumors of various differentiation 
grades were involved: one well-differentiated tumor, three tumors were of a 
moderate differentiation grade, and two tumors were poorly differentiated. In all 
six patients one single lymph node was affected in which tumor cell(s) had been 
detected. It concerned paraesophageal lymph nodes (N=4) or lymph nodes located 
at the lesser curvature (N=2). None of the 18 m2 tumors showed positive CAM5.2 
staining in the lymph nodes. In two out of 25 m3 patients (8.0%) an ITC was found 
in the lymph nodes. The pathologists identified tumor cells in four out of 20 sm1 
tumors (20.0%): three micrometastases (Figure 1) and one ITC (Figure 2). Hence, 
occult metastases as detected by positive CAM5.2 staining were seen more often 
in sm1 tumors than in m3 carcinomas: 20.0% versus 8.0%, respectively, although 
this difference did not reach statistical significance in this small series of patients 
(p=0.69). No macrometastases were found in any of the lymph nodes after multi-
sectioning. 
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Table 3. Number of isolated tumor cells (ITCs) and micrometastases as detected by 
immunohistochemistry according to tumor infiltration depth.
Tumor infiltration depth ITCs Micrometastases TOTAL
m2 (n=18) 0 0 0
m3 (n=25) 2 (8.0%) 0 2 (8.0%)
sm1 (n=20) 1 (5.0%) 3 (15.0%) 4 (20.0%)
TOTAL (n=63) 3 (4.8%) 3 (4.8%) 6 (9.5%) 
Figure 1. An example of a micrometastasis (positive for CAM5.2) in a lymph node that was 
initially scored as tumor-free on conventional histopathological examination.
Median follow-up was 121 months (range 10 – 187 months). Overall and disease-free 
five-year survival for this patient group (N=63) were 75.6% and 96.3%, respectively. 
Two out of 63 patients (3.2%) developed disease recurrence and died following 
locoregional tumor recurrence without evidence of distant metastastic disease. Both 
patients were diagnosed with an m3 tumor. In one of these patients who died due to 
tumor recurrence an ITC was identified on IHC. None of the other five patients with 
a detected micrometastasis or ITC developed disease recurrence. 
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Figure 2. An example of an isolated tumor cell (positive for CAM5.2) in a lymph node that was 
initially scored as tumor-free on conventional histopathological examination.
Discussion
The aim of this study was to investigate whether the presence of occult tumor cells 
in early esophageal adenocarcinoma could (partly) explain the reported differences 
in the occurrence of lymphatic spread within the subgroup of m3 (0 – 12%) and sm1 
adenocarcinomas (0 – 20%) as reported by our group and by others (Table 1).22-25 
Indeed, in the present series we have shown that lymphatic spread can be detected 
by means of additional IHC in conventionally node-negative patients in the event 
of tumor infiltration into the muscularis mucosae (m3 – 8.0%) or most superficial 
submucosal layer (sm1 – 20.0%). No micrometastases or ITCs were detected in the 
lymph nodes of patients with an m2-tumor, which supports the widespread use of 
endoscopic treatment in these patients. 
Immunohistochemical techniques can identify micrometastases that are missed by 
standard H&E staining. Cytokeratin, a component of the cytoskeleton of epithelial cells, 
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is not found in normal lymph nodes, thus enabling monoclonal antibodies to specific 
cytokeratin markers (such as CAM5.2) to detect micrometastases. These techniques 
may identify single tumor cells or cell clusters in lymph nodes that have been staged as 
tumor free on routine H&E examination. The viability of micrometastatic tumor cells 
and their potential to form true metastases has been questioned, although evidence 
has been provided for the malignant potential of micrometastatic cells in esophageal 
cancer.35, 36 However, searching for micrometastases by means of IHC remains a 
research tool and is not currently used in daily clinical practice. Furthermore, the 
prognostic outcome of the detection of micrometastases in esophageal cancer by 
IHC is controversial as some studies have found an association with increased risk 
of tumor recurrence and decreased survival4, 6-9, 12, 15, 37, whereas others have not.5, 10, 
11, 13, 14 These findings were independent of histology type (squamous cell carcinoma 
versus adenocarcinoma). In T1-tumors in specific, the previously reported frequency 
of micrometastases or ITCs varied between 5 and 44%.7, 10-13, 16 In the present series, 
sections stained positively for CAM5.2 in 9.5% of our patients who were initially 
staged as N0 with conventional techniques. It can be questioned whether stage 
migration could have played a role in the present study due to a limited number of 
harvested lymph nodes by performing a transhiatal esophagectomy (e.g. patients 
that have falsely been classified as N0 as positive mediastinal lymph nodes had not 
been removed). However, in that case it would have become apparent from a worse 
disease-free survival curve in the present series as N1-disease undoubtedly affects 
the risk of disease recurrence: disease-free five-year survival rate accounts 95% for 
T1N0 patients and not more than 35% for T1N1 patients after an esophagectomy with 
extended or limited lymphadenectomy.23, 38 As the disease-free five-year survival was 
96% in the current study, it is not likely that stage migration has played a substantial 
role.
The clinical relevance of these micrometastases and ITCs will not become clear 
from the results of surgical series such as the current one. Obviously, lymph nodes 
with occult tumor cells have already been resected and will not influence patient’s 
long-term outcome. Hence, reports on endoscopically treated patients with early 
esophageal adenocarcinoma should provide evidence whether the presence of 
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occult tumor cells might be responsible for disease recurrence. Until now, several 
publications have shown that endoscopic resection of Barrett’s intramucosal 
carcinoma is safe and effective in experienced hands.39-43 Although local recurrences 
or metachronous lesions are known to be a major problem with endoscopic therapy, 
successful repeat endoscopic treatment has shown to be feasible in almost all of 
these patients.44 Recently, long-term results of endoscopic resection in mucosal 
adenocarcinoma have been provided in two relatively large patient series presenting 
its successful outcome after five-year follow-up.17, 45 Although none of the above-
mentioned studies reported specifically on m3 adenocarcinomas, one may assume 
that this subpopulation is well-represented in the overall group of mucosal cancers. 
Furthermore, in a small series of patients who fulfilled the definition of low-risk 
submucosal esophageal adenocarcinoma (sm1 tumors, absence of lymphangio-
invasion and no poor differentiation grade37), promising long-term results have been 
reported with regard to disease recurrence.46 However, large series reporting on the 
endoscopic treatment of patients with sm1 adenocarcinomas are lacking. 
In clinical practice, in patients with m3 or sm1 tumors without evidence of 
lymphatic dissemination it is still unclear whether a radical esophagectomy is 
indicated or if endoscopic treatment suffices. An esophagectomy with (extended) 
lymphadenectomy may prolong the recurrence-free period (5-7% of patients with 
m3 and sm1 adenocarcinomas are classified as N1 postoperatively, see Table 1), but 
major disadvantages are its invasiveness and accompanied morbidity. Moreover, 
even in specialized high-volume centers the mortality rate after esophagectomy 
is 2-5%.2, 28, 29 Therefore, it is unlikely that the morbidity and mortality of a surgical 
resection is counter-balanced by a substantial gain in long-term survival for patients 
with m3 lesions. In our previous publication we stated that sm1 adenocarcinomas 
are potentially eligible for endoscopic therapy because of the very low risk of 
lymphatic dissemination in these tumors, provided that other groups could show 
similar results.23 However, based on the presently available data and the results of 
the current study, we believe that in patients with sm1 tumors a surgical resection is 
most likely still indicated, as in 20% of these patients micrometastases or ITCs were 
detected on IHC. Again, final evidence with regard to the clinical relevance of occult 
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tumor cells should become apparent from large series of endoscopically treated 
patients with sufficiently long follow-up.
One drawback of the current study is its bicentric character. Sections of the selected 
patient group have been stained in two different hospitals, each with their own 
IHC protocols. However, a crosscheck was performed by staining sections of three 
patients in both centers, which showed similar results. Furthermore, one could 
criticize the antibody used in the present series (CAM5.2), as the antibodies AE1/
AE3 and Ber-EP4 have been used more often in other studies. It has been shown 
previously that the antibody Ber-EP4 could well be used for the detection of 
clinically relevant micrometastatic disease in patients operated upon for esophageal 
adenocarcinoma because of its high sensitivity and specificity.16 On the other hand, 
CAM5.2 has been incorporated in the day-to-day protocols of the two participating 
hospitals to detect occult tumor cells in resection specimens of several malignancies. 
Because of this wide experience with CAM5.2, we decided to employ CAM5.2 as the 
marker of choice in the current study.
In conclusion, lymphatic migration of tumor cells has been detected in conventionally 
node-negative lymph nodes of both m3 (8.0%) and sm1 (20.0%) adenocarcinomas 
of the esophagus, which can (partly) explain the reported variation in lymphatic 
dissemination in these tumors. However, the clinical relevance of these occult tumor 
cells should become apparent from large series of endoscopically treated patients 
with sufficiently long follow-up. 
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Abstract
Introduction: According to the classification established by the Japanese 
Society for Oesophageal Disease, early oesophageal cancer can be subdivided 
into six successive layers of the mucosa or submucosa, which influences 
the treatment strategy and prognosis of the individual patient. However, 
the reproducibility of this classification in terms of inter- and intraobserver 
variability is unclear.
Methods: Histological slides from 105 surgical resection specimens of patients 
who had undergone oesophagectomy for early oesophageal adenocarcinoma 
were reviewed independently by three gastrointestinal pathologists, and 
were classified according to the Japanese criteria (m1/m2/m3/sm1/sm2/
sm3 tumours). Inter- and intraobserver variation was determined by kappa-
statistics. 
Results: The interobserver reproducibility was good between pathologist 1 
and 2 (κ=0.61, 95% confidence interval (CI) 0.55-0.67), and moderate between 
pathologist 1 and 3 (κ=0.51, 95% CI 0.45-0.57) and between pathologist 2 and 
3 (κ=0.50, 95% CI 0.38-0.61). The intraobserver agreement as assessed by the 
expert pathologist was good (κ=0.76), with a 95% CI that was interpreted as 
good to very good (0.67-0.85). Most agreement was achieved at the lower 
(m1) and upper site (sm2, sm3) of the spectrum, whereas the m2 tumours 
reflected the most discrepant stage. The majority of the observed discrepancy 
included the variation in one substage only.
Conclusions: The reproducibility of the Japanese classification is good in 
terms of inter- and intraobserver variability when grading early oesophageal 
adenocarcinoma on surgical resection specimens. The present data confirm 
that dedicated gastrointestinal pathologists with broad experience are 
preferred when grading the resection specimens of patients with early 
oesophageal adenocarcinoma.
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Introduction
Oesophageal adenocarcinoma is diagnosed with increasing frequency at an early stage, 
due to the increased awareness of the clinical importance of Barrett’s oesophagus, 
more intensive surveillance programs, and improved imaging techniques.1, 2 
According to the UICC (Union Internationale Contre le Cancer) TNM classification, 
early carcinoma is defined as an invasive tumour limited to the mucosa (T1a) or 
submucosa (T1b), irrespective of the lymph nodal status.3 This dichotomy is also 
incorporated in the revised Vienna classification that has been established to resolve 
the discrepancies in nomenclature between Western and Japanese pathologists 
with regard to the grading of gastrointestinal epithelial neoplasia (Table 1).4, 5 In 
this classification intramucosal carcinoma (together with high-grade dysplasia and 
carcinoma in situ set in category 4) is separated from submucosal invasion (category 
5).4 Moreover, in 2001 the Japanese Society of Oesophageal Disease introduced its 
classification in which early cancers are subdivided in six successive layers of the 
mucosa (m1, m2, m3) or submucosa (sm1, sm2, sm3).6 However, the usefulness and 
reproducibility of this more recently introduced, extended classification has not been 
studied yet.
Table 1. Revised Vienna classification that has been established to resolve the 
discrepancies in nomenclature between Western and Japanese pathologists with 
regard to the grading of gastrointestinal epithelial neoplasia.4
DIAGNOSIS CATEGORY
Negative for neoplasia/dysplasia 1
Indefinite for neoplasia/dysplasia 2
Mucosal low-grade neoplasia/dysplasia 3
Mucosal high-grade neoplasia
- high-grade adenoma/dysplasia
- non-invasive carcinoma (carcinoma in situ)
- suspicious for invasive carcinoma
- intramucosal carcinoma
4.1
4.2
4.3
4.4
Submucosal invasive carcinoma 5
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In general, a classification should be simple, a reflection of available therapeutic 
options and reproducible. Simplicity means that a classification should have as few 
categories as possible, but as many as required clinically. Reflection of available 
therapeutic options should include the possibilities of careful observation, local 
endoscopic treatment or surgery. It appears that subdivision in six, rather than 
two categories is helpful in directing patients to the most optimal treatment 
strategy. Current treatment options for early oesophageal cancer vary from 
endoscopic mucosal resection (EMR) to surgical resection with extended or regional 
lymphadenectomy.7-10 The decision whether to perform an endoscopic or a surgical 
resection is mainly dependent on patients’ predicted lymph nodal status11, which is 
related to the depth of infiltration of the primary tumour. Lymph node metastases 
have not been reported in m1 and m2 mucosal adenocarcinomas (thereby allowing 
endoscopic treatment), whereas positive lymph nodes can be found in 0-12% of m3 
patients.12-15 In submucosal adenocarcinomas, it appears that sm2-sm3 tumours 
are associated on average with a higher rate of lymph node metastases than sm1 
tumours12-15; hence, an oesophagectomy is considered the standard therapy.9, 16, 17 
The optimal management of carcinomas with invasion into the muscularis mucosae 
(m3) or the most superficial layer of the submucosa (sm1) is still under debate. 
Finally, subdivision of early oesophageal cancer in six categories seems justified, as 
the treatment algorithm depends largely on the chance for lymphatic dissemination 
that is mainly related to the tumour infiltration depth.
 
Reproducibility of a classification includes the aspects of inter- and intraobserver 
variability. Thus far, these observer agreements have not been studied in the light 
of the Japanese classification of early oesophageal cancer. Therefore, the aim 
of the present study was to evaluate inter- and intraobserver variation among 
gastrointestinal pathologists in grading early oesophageal adenocarcinoma according 
to the criteria proposed by the Japanese Society for Oesophageal Disease, when 
analyzing surgical resection specimens.
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Material and methods
Patient material
The outcome of 120 patients who underwent transhiatal oesophagectomy with 
regional lymphadenectomy for early adenocarcinoma of the distal oesophagus or 
gastro-oesophageal junction (pT1-tumours) between 1980 and 2002 in two university 
hospitals in The Netherlands (Erasmus Medical Centre, Rotterdam, and Academic 
Medical Centre, Amsterdam) has been described previously.13 Patients did not receive 
neoadjuvant chemo(radio)therapy. Archival material of the resection specimens was 
used for the present study. Tissue blocks and slides of the resection specimens of 
thirteen patients were not available anymore, and in the resection specimens of 
another two patients the tumour was classified as a pT2 tumour (infiltration into 
the muscularis propria) by all three pathologists. Finally, resection specimens of 105 
patients were used in the present study. 
Histopathologic assessment
Tumours were assigned pathologic tumour-node-metastasis stages according to the 
UICC 2002 system.3 The depth of tumour invasion was measured and subclassified 
based on the criteria proposed by the Japanese Society for Oesophageal Disease 
(Figure 1).6 High-grade dysplasia or carcinoma in situ without invasion through the 
basement membrane was classified as m1. Intramucosal carcinoma was defined as a 
tumour extending beyond the basement membrane into the lamina propria (m2). All 
carcinomas with invasion into the muscularis mucosae were classified as m3 tumours, 
irrespective of the presence of a double muscularis mucosae (i.e. a superficial and 
a deep layer observed in Barrett’s mucosa can be classified as a m3 and m4 lesion, 
respectively18). Carcinomas infiltrating beyond the (deeper) muscularis mucosae 
but limited to the upper third of the submucosa, were classified as sm1. Equally, 
carcinomas infiltrating the submucosa but limited to the middle or lower third of the 
submucosa were defined as sm2 or sm3, respectively. 
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Figure 1. The depth of tumour invasion based on the criteria proposed by the Japanese Society 
for Oesophageal Disease6; according to the Vienna classification m1, m2 and m3 lesions 
represent category 4, whereas sm1, sm2, sm3 tumours are classified as category 5.4 Reprinted 
with permission, all rights reserved © 2006 The American Journal of Surgery.32
lp  = lamina propria
mm  = muscularis mucosae
sm  = submucosa
mp = muscularis propria
To assess interobserver agreement in analyzing early oesophageal cancer, histological 
slides of the primary tumour of 105 resection specimens were independently reviewed 
by three gastrointestinal pathologists. Pathologist 1 and pathologist 2 were highly 
experienced (more than 20 years experience) and had been closely working together 
in the same department. The third pathologist has a shorter work experience as a 
dedicated gastrointestinal pathologist (two years), but in daily practice evaluates all 
pathology specimens with regard to oesophageal cancer in a high-volume centre. The 
pathologists were blinded for the identity of the patient and the initial diagnosis. The 
resection specimen of each individual patient was categorized based on the deepest 
infiltration of the primary tumour according to the six classes of early oesophageal 
cancer (m1, m2, m3, sm1, sm2, sm3). To assess intraobserver agreement, the most 
experienced pathologist who is considered an expert on oesophageal cancer, re-
reviewed all histological slides two weeks after this first assessment. 
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Statistics
Inter- and intra-observer agreement were determined by kappa statistics. Kappa 
statistics are widely used and accepted coefficients that provide a measure of observer 
agreement accounting for agreement other than that which occurs by chance alone.19 
Coefficients <0.21, 0.21-0.40, 0.41-0.60, 0.61-0.80, 0.81-1.00 represent a poor, fair, 
moderate, good and very good agreement, respectively.20 Kappa-statistics with 
corresponding 95% confidence intervals were calculated with regard to interobserver 
agreement (pathologist 1 versus pathologists 2 and 3, respectively, and pathologist 
2 versus pathologist 3) and intraobserver agreement (as assessed by pathologist 1). 
Data-analysis was carried out with SPSS version 15.0 (SPSS, Chicago, IL, USA).  
Results
Clinicopathological characteristics of the present study population are shown in Table 
2. The infiltration depth of the primary tumour was initially classified as carcinoma in 
situ in 10 patients (9.5%), and as invasive carcinoma in 95 patients (90.5%). One m3 
patient, five sm2 patients and eleven sm3 patients were diagnosed with a N1 status. 
Table 2. Clinicopathological characteristics of 105 patients who underwent 
oesophagectomy for carcinoma in situ (m1) or early oesophageal adenocarcinoma 
(m2, m3, sm1, sm2 or sm3).
Age* 66 years (30-82)
Gender
- male
- female
92 (87.6%)
13 (12.4%)
Tumour location
- distal oesophagus
- gastro-oesophageal junction
93 (88.6%)
12 (11.4%)
Differentiation grade 
- Gx (undetermined) 
- G1 (good)
- G2 (moderate)
- G3 (poor)
7 (6.7%)
20 (19.0%)
59 (56.2%)
19 (18.1%)
Barrett’s metaplasia
- yes
- no
95 (90.5%)
10   (9.6%)
Lymph nodal involvement
- pN0
- pN1
88 (83.8%)
17 (16.2%)
Radicality of resection (R0) 105 (100%)
* Value presented as median (range in brackets)
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The interobserver variation has been tested in three ways: pathologist 1 (expert on 
oesophageal cancer) versus pathologist 2, pathologist 1 versus pathologist 3, and 
pathologist 2 versus pathologist 3. The outcome with regard to this interobserver 
variation is shown in Table 3. The interobserver reproducibility between pathologists 
1 and 2 was good (κ = 0.61), with a 95% confidence interval (CI) that can be 
interpreted as moderate to good (0.55-0.67). The interobserver agreement was 
graded as moderate between the pathologists 1 and 3 (κ = 0.51, 95% CI 0.45-0.57) 
and between the pathologists 2 and 3 (κ = 0.50, 95% CI 0.38-0.61). Furthermore, 
the most experienced pathologist re-reviewed all histological slides to assess the 
intraobserver variation of this classification. The intraobserver agreement was 
good with a kappa of 0.76, and a concomitant 95% confidence interval (CI) that was 
interpreted as good to very good (0.67-0.85).
Table 3. Inter- and intraobserver variation for the diagnosis of carcinoma in situ (m1) 
or early oesophageal adenocarcinoma (m2, m3, sm1, sm2 or sm3) as determined by 
the histopathological analysis of 105 resection specimens according to the Japanese 
classification. 
Kappa 95% CI Interpretation*
Interobserver variation
- pathologist 1 vs pathologist 2
- pathologist 1 vs pathologist 3
- pathologist 2 vs pathologist 3
0.61
0.51
0.50
0.55 – 0.67
0.45 – 0.57
0.38 – 0.61
good (moderate – good)
moderate (moderate)
moderate (fair – good)
Intraobserver variation
- pathologist 1 vs pathologist 1
0.76 0.67 – 0.85 good (good – very good)
* Interpretation of kappa-statistics, with interpretation of 95% confidence interval in brackets.
CI = confidence interval
When analyzing the discrepancies between the observers with regard to the six 
different substages as shown in Table 4, it appeared that most agreement was 
achieved at the lower (m1) and upper site (sm2, sm3) of the spectrum. The m2 
stage was the most discrepant stage (interobserver agreement 17% and 25% only), 
whereas in the m3 and sm1 stage pathologist 3 showed less agreement. However, 
when allowing variation in one substage (i.e. when the most experienced pathologist 
scored m3, both m2 and sm1 substages were not considered discrepant), it appeared 
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that there was only 4-5% discordance with regard to the interobserver variation, and 
3% disagreement for the intraobserver variation of the most experienced observer 
(pathologist 1).  
Table 4. Inter- and intraobserver agreement as assessed per tumour stage, defined 
by the depth of tumour infiltration according to the Japanese classification. 
Observations by pathologist 1 were considered the gold standard in this evaluation.
Interobserver Intraobserver
pathologist 1 pathologist 2 pathologist 3 pathologist 1
m1 (n=5) 4/5 (80%) 5/5 (100%) 5/5 (100%)
m2 (n=12) 2/12 (17%) 3/12 (25%) 11/12 (92%)
m3 (n=39) 29/39 (74%) 23/39 (59%) 28/39 (72%)
sm1 (n=18) 13/18 (72%) 8/18 (44%) 16/18 (89%)
sm2 (n=16) 12/16 (75%) 12/16 (75%) 13/16 (81%)
sm3 (n=15) 13/15 (87%) 13/15 (87%) 12/15 (80%)
Discussion
The reproducibility of the classifications that aim for the discrimination between 
Barrett’s metaplasia, dysplasia and adenocarcinoma has been studied previously. 
Various groups have demonstrated that the use of such classifications (e.g. Vienna 
classification) is still accompanied by considerable interobserver variability.21-23 
Furthermore, studies have been undertaken to assess the observer variation in the 
diagnosis of high-grade dysplasia, intramucosal adenocarcinoma (T1a) or submucosal 
adenocarcinoma (T1b).24, 25 In general, this discrimination in tumour infiltration depth 
will reflect the treatment options of endoscopic treatment (HGD, T1a) and surgery 
(T1b). When evaluating surgical resection specimens, the interobserver agreement 
was moderate when comparing HGD and intramucosal carcinoma, and good in case 
separation of intramucosal carcinoma from submucosal carcinoma was aimed for.24 
When preoperative biopsies were analyzed, these agreements appeared to be only 
fair and poor, respectively.25 However, it has been suggested that interobserver 
agreement on EMR specimens is significantly higher compared to biopsy specimens.26 
Nevertheless, it may be a drawback of this study that interobserver variability has 
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been evaluated from surgical resection specimens rather than from EMR specimens, 
as the latter will largely influence clinical decision-making. 
To our knowledge, this is the first study that reports on the reproducibility of 
the Japanese classification in grading early oesophageal adenocarcinoma into 
six categories. In the present series, the m2 stage was the most discrepant stage 
(interobserver agreement 17% and 25% only), although it can be questioned if the 
interpretation of a m2 tumour as a m1 or m3 lesion will affect largely the clinical 
decision making. In the m3 and sm1 stages, of which optimal treatment strategies 
are still under debate, pathologist 3 showed less agreement. Furthermore, there 
was no underdiagnosis of submucosal carcinoma that requires undoubtedly surgical 
resection as only little discordance in the sm2 and sm3 substages was noted, and in 
16 out of 17 N1-patients a sm2 or sm3 tumour was observed. It can be questioned 
whether the differences in agreement between pathologist 1 and 2 versus the 
agreement between pathologist 3 and pathologists 1 and 2, respectively, reflect 
a difference in years of working experience, or whether the results are influenced 
by the fact that pathologists 1 and 2 had worked closely together in the same 
department for many years. Nevertheless, the present data confirm that dedicated 
gastrointestinal pathologists are preferred when grading the resection specimens of 
this subpopulation of oesophageal cancer patients.
The Japanese classification for grading early oesophageal cancer plays an important 
role in the phase prior to the onset of treatment as well as the time period after the 
patient has undergone treatment. In the post-treatment phase, the final tumour stage 
as determined by histology of the resection specimen will define patient’s prognosis. 
In the pre-treatment phase its role is even more important, as the decision whether 
to perform an endoscopic or a surgical resection in patients with early oesophageal 
cancer is mainly dependent on patients’ predicted lymph nodal status.11 At present, 
all diagnostic modalities including endoscopic ultrasonography lack the ability to 
correctly stage the N-category with a very high accuracy (71-86% in literature).27, 
28 Nevertheless, on the basis of the T-stage as staged by the pathologist on an 
EMR-specimen, one can predict the chance for lymphatic dissemination because 
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8
of its relationship to the tumour infiltration depth as assessed by the Japanese 
classification.12-15 EMR is advocated as a staging modality to determine the T-stage 
in patients with early oesophageal cancer29, 30, although the assessment of the exact 
depth of submucosal invasion remains difficult as full thickness submucosa is virtually 
absent in these specimens.11 Therefore, if the submucosal invasion exceeds 0.5 mm, 
one may consider the tumour infiltration beyond the sm1 layer. Other factors that 
may predict lymphatic involvement in early oesophageal cancer include a diameter 
greater than 3 cm, a poor differentiation grade and lymphangio-invasion.27, 31, 32 
Although indications for endoscopic (m1, m2 tumours) and surgical treatment (sm2, 
sm3 tumours) are clear, for each individual with a m3 or sm1 adenocarcinoma it 
should be carefully considered whether a radical oesophagectomy may be beneficial. 
Therefore, individual treatment plans and a close interdisciplinary cooperation 
between surgeon, gastroenterologist and pathologist are mandatory in this patient 
population. 
In conclusion, the reproducibility of the Japanese classification system is good 
in terms of inter- and intraobserver variability when grading early oesophageal 
adenocarcinoma on surgical resection specimens. The present data confirm that 
dedicated gastrointestinal pathologists with broad experience are preferred when 
grading the resection specimens of patients with early oesophageal adenocarcinoma.
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Abstract
In this review the preoperative risk assessment and prevention of complications 
in patients undergoing esophagectomy for cancer is discussed. Age, 
pulmonary and cardiovascular condition, nutritional status, and neoadjuvant 
chemo(radio)therapy are known predictive factors. None of these factors 
is a valid exclusion criterion for esophagectomy, but may help in careful 
patient selection. Both anesthetists and surgeons play an important role in 
intraoperative risk reduction by means of appropriate fluid management and 
application of optimal surgical techniques.  
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Introduction
Surgery is the primary curative therapy for patients with esophageal cancer. However, 
esophagectomy is associated with a high operative risk.1, 2 Although operative mortality 
is below 5% in high volume centers1, 3, esophageal resection is still accompanied by 
substantial morbidity. The impact of postoperative complications on quality of life 
plays an important role in decision making whether to proceed with an operation 
in a patient with esophageal cancer. Moreover, the limited overall 5-year survival 
that does not exceed 40% after esophagectomy4, 5, has raised concerns regarding the 
advisability of such an extensive procedure in elderly patients. 
It is now widely recognized that certain high-risk surgical procedures have lower 
mortality and morbidity rates when performed in high-volume centers, which is also 
true for esophageal cancer surgery.6, 7 For continuous improvement of esophagectomy 
outcome, an optimal treatment strategy should be based on proper patient selection 
by means of accurate staging and preoperative risk assessment. In this review we 
will discuss patients’ preoperative risk assessment and the potential risk factors that 
can be taken care of both preoperatively and intraoperatively in order to prevent 
postoperative complications in patients with esophageal cancer.
Methods
A review of the recent English-language literature (January 1990 – June 2009) 
concerning esophageal cancer was performed. We focused on the one hand on 
studies that discussed patients’ preoperative risk assessment and scoring systems 
that facilitate individualized preoperative risk stratification, and on the other hand on 
studies discussing the possibility of reducing these risks. With regard to the first part 
of this review (preoperative setting), we confined our search for potential risk factors 
to those that have been revealed in studies applying multivariate analysis to identify 
risk factors predicting morbidity and mortality after esophagectomy for cancer. This 
chapter will include an in-depth discussion of these potential risk factors. In the 
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second part we summarize the most recent advances in both anesthetic and surgical 
techniques that are thought to have an impact on patients’ postoperative course.
1. Preoperative risk assessment and risk reduction
Several studies have focused on predisposing factors for complications after 
esophageal surgery for cancer. Patient characteristics have been combined in 
multivariate prognostic models for the prediction of short-term morbidity and 
mortality after esophagectomy. In general, these multivariate analyses revealed that 
advanced age, pulmonary dysfunction, a poor preoperative general performance 
status and application of neoadjuvant chemo- and/or radiotherapy are pronounced 
risk factors. 8-12 To summarize the most relevant studies published on these topics that 
can be evaluated in daily practice by both anesthetist and surgeon, we will discuss 
the potential risk factors age, pulmonary condition, cardiovascular status, nutritional 
status and application of neoadjuvant chemo- and/or radiotherapy.
However, we have to keep in mind that these studies have often been based on 
selected patient groups in specialized centers, are retrospective in nature, and the 
prognostic models have not been tested in independent patient cohorts, thus limiting 
the generalizability of the conclusions. 
1.1 Risk factors
Age
In the past, advanced age was considered a relative contraindication for 
esophagectomy because of high operative mortality rates. Multivariate analyses 
of patient cohorts have identified advanced age as an independent risk factor for 
patients eligible for esophagectomy.8-10 However, more recent studies showed 
acceptable results in patients 70 years and older undergoing esophagectomy, with 
morbidity (25-49%) and mortality rates (2-8%) that are comparable to those in 
younger counterparts.13, 14 This is true even in the presence of significantly more 
preoperative risk factors (pulmonary dysfunction, cardiac disease, hypertension, 
diabetes mellitus) in elderly patients.15 Moreover, disease-specific 5-year survival 
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did not differ between older and younger patients.13-15 The acceptable outcome for 
elderly patients can most likely be attributed to an overall improvement in surgical 
technique and perioperative patient care. For instance, avoidance of a thoracotomy 
in elderly patients with esophageal cancer may lead to a lower cardiopulmonary-
related mortality. 
A few papers on esophagectomy in octogenarians have been published.16-18 The 
percentage of patients above 80 among esophageal cancer patients is approximately 
5%, and 20-30% of these patients is eligible for surgery.18 In this highly-selected patient 
group morbidity (33-45%) and mortality (0-11%) rates were acceptable.16, 18 However, 
in one study a 19% mortality rate was observed in the octogenarian patients, and it 
was calculated that age above 80 years is associated with a significantly increased 
perioperative mortality.17 
From these studies, it can be concluded that advanced age is not a valid exclusion 
criterion for esophagectomy. There is substantial evidence that well selected elderly 
patients (based on a proper preoperative assessment of all potential risk factors) can 
survive surgical treatment with acceptable postoperative morbidity and mortality 
rates. A plausible explanation for these findings is that coexisting disease has more 
impact on perioperative morbidity and mortality than age alone.19 For octogenarians, 
more evidence is needed to draw firm conclusions.
Pulmonary condition
Pulmonary complications such as pneumonia, atelectasis and respiratory insufficiency 
occur at high incidence rates in patients undergoing esophagectomy. In fact, 
pulmonary complications are the most common cause of postoperative mortality.2, 20, 
21 Surgical exploration in two or even three separate body compartments may be an 
explanation for the high pulmonary risk after esophagectomy. The extent of surgical 
trauma is related to the extent of postoperative immune depression, resulting in 
a failing host immunity against postoperative infections.22 Furthermore, disruption 
of bronchial innervation, postoperative dysfunction of respiratory muscles and 
poor airway protection in case of recurrent laryngeal nerve injury are also likely 
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to play a role.23 Patient-bound factors that contribute to postoperative pulmonary 
complications are advanced age, abnormal lung function test, and poor performance 
status.11, 20, 21
Preoperative pulmonary dysfunction is significantly associated with the development 
of postoperative pulmonary complications.11, 21, 24 Poor pulmonary status (forced 
vital capacity (FVC) of less than 80% and forced expiratory volume in one second 
(FEV1) less than 70% of the predicted value) is related with both pulmonary and non-
pulmonary postoperative morbidity.24 Furthermore, impaired pulmonary function 
(in particular FEV1 <65% of predicted) is associated with prolonged mechanical 
ventilation and prolonged hospital stay.11 
In general, preoperative assessment of patient’s pulmonary function is a valuable 
risk indicator of postoperative pulmonary complications. Following the guidelines 
of the American College of Physicians25, at least patients older than 60 years, with 
a history of smoking and/or signs of pulmonary obstruction should perform a lung 
function test. Respiratory medicine consultation should be considered in patients 
with FEV1 <70% of the predicted value. Whether the risk of postoperative pulmonary 
complications can be reduced in patients undergoing esophagectomy by means of 
improving respiratory muscle strength and performance status is not clear yet. One 
study showed that preoperative respiratory muscle training in patients undergoing 
thoracic surgery in general (including esophagectomy) may prevent postoperative 
pulmonary complications by increasing both inspiratory and expiratory muscle 
strength.26 Other promising results have been reported in a randomized clinical 
trial (RCT) that included patients undergoing coronary artery bypass grafting: pre-
operative intensive inspiratory muscle training reduced significantly the incidence of 
postoperative pulmonary complications.27 
Cardiovascular status
Perioperative cardiac arrhythmias occur with an incidence of approximately 
20%.2, 20, 28 Atrial fibrillation (AF) in particular might reflect underlying pulmonary 
problems or surgical sepsis28, but the exact mechanisms responsible for AF after 
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9
esophagectomy remain speculative. The reported incidence of myocardial infarction 
after esophagectomy is low (1-2%).2, 9, 20 Nevertheless, because of the extensiveness 
of the surgical procedure, a thorough preoperative cardiac evaluation is indicated 
based on the level of exercise tolerance and appearance of cardiac risk predictors 
according to the Revised Cardiac Risk Index (RCRI), see Figure 1.29
Figure 1. Preoperative cardiac evaluation of esophageal cancer patients scheduled for high-
risk surgery (esophagectomy) at the outpatient clinic of the Department of Surgery and 
Department of Anesthesiology.
Little is known about the value of routine preoperative cardiac stress testing in 
patients undergoing esophagectomy in predicting outcome. Dobutamine stress 
echocardiography is able to provide prognostic information on myocardial ischemia 
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and contractile reserve in patients with ischemic left ventricular function.30 One 
study investigated the usefulness of cardiopulmonary exercise testing, in which 
oxygen uptake at increasing levels of exercise determined the cardiopulmonary 
performance under conditions of stress, thereby imitating the operative situation.31 
However, the maximum oxygen uptake (VỎ
2
-max) appeared to be a poor predictor of 
cardiopulmonary morbidity in these patients. In general, grading and rating literature 
on cardiac stress testing is a difficult process due to great variability in endpoints and 
results. More research is needed to evaluate the most optimal way of cardiac stress 
testing in patients undergoing esophagectomy.
Although it is probably beneficial for high-risk patients in general to receive 
perioperative beta-blocker therapy32, its role in patients undergoing esophagectomy 
has not been investigated thoroughly yet. A recent meta-analysis of RCTs in patients 
having non-cardiac surgery showed no clear benefit of perioperative beta-blockers 
for the prevention of cardiovascular outcomes.33 In fact, beta-blockers seemed to 
increase the risk of stroke, bradycardia and hypotension. Therefore, it is advised that 
beta-blockers should not be routinely used for perioperative treatment of patients 
undergoing non-cardiovascular surgery unless patients are already taking them 
for clinically indicated reasons following the guidelines of the European Society 
of Cardiologists (i.e. heart failure, coronary artery disease, previous myocardial 
infarction).34 
Statin use has been associated with a decreased incidence of atrial fibrillation after 
non-cardiac thoracic surgery35 as well as with decreased mortality after non-cardiac 
surgery.36 This is probably due to its anti-inflammatory and plaque-stabilizing effects. 
Moreover, as shown in patients undergoing major vascular surgery, discontinuation 
of statin therapy is associated with an increased postoperative cardiac risk.37 It may 
be valid to extrapolate this to esophagectomy patients by restarting this medication 
as soon as possible after the operation. 
In many patients anti-platelet drugs like aspirin will complement this combination 
therapy; such medications are generally ceased 7-10 days prior to surgery. A large 
meta-analysis on the risk of increased bleeding in surgical patients using low-dose 
aspirin has demonstrated that aspirin increases the rate of bleeding complications by 
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a factor 1.5.38 However, this does not implicate an increase in morbidity or mortality 
in the postoperative phase. Moreover, acute withdrawal of these drugs is associated 
with an increased risk of development of thrombotic events.39 It has been reviewed 
that the risk of coronary thrombosis on anti-platelet drugs withdrawal is higher than 
the risk of surgical bleeding when maintaining them.40 Aspirin should be considered 
a lifelong therapy and should not be stopped before surgery or before insertion of 
an epidural catheter when it has been prescribed as a secondary prevention after 
stroke, myocardial infarction or revascularization.40 As a primary prevention it can be 
withdrawn one week before surgery, and should be restarted as soon as the epidural 
catheter has been removed. There is no literature to support the use of therapeutic 
heparin as an alternative.41
More recently, the role of B-type natriuretic peptide (BNP) and its N-terminal 
fragment (NT-pro-BNP) as a biomarker in predicting cardiac complications during the 
postoperative course has been evaluated. BNP and NT-pro-BNP are neurohormones 
that are released in response to ventricular wall stress and have shown to be sensitive 
and specific predictors of left ventricular systolic dysfunction.42 In patients undergoing 
esophagectomy, it appeared that elevation of the perioperative plasma BNP level 
is a strong and independent predictor of postoperative AF, suggesting that patients 
at higher risk of postoperative AF can be identified and should be considered for 
preventive antiarrhythmic therapy.43 However, it is unlikely that this single parameter 
will change the decision on patient’s operability.  
In conclusion, until now there is no evidence for routine stress-testing or routine 
prophylactic combination therapy (beta-blocker, statin, aspirin). It remains unclear 
whether such combination therapy is beneficial to esophagectomy patients, 
or whether it is at the cost of potential adverse effects (e.g. strokes and conduit 
necrosis). If there is an indication for secondary prevention after stroke, myocardial 
infarction or revascularization, the combination therapy should be continued during 
the perioperative process. In general, the guidelines on perioperative cardiovascular 
evaluation for noncardiac surgery formulated by the American College of Cardiology/
American Heart Association can be followed.44
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Nutritional status: obesity and malnutrition
The increased incidence of adenocarcinoma of the esophagus and gastroesophageal 
junction in recent decades parallels the increasing prevalence of obesity. Surgery 
and anesthesia are more hazardous in overweighted patients, not least because 
of the increased incidence of cardiorespiratory comorbidity.45 In general, obese 
patients are at higher risk for hypoxia from atelectasis, because pulmonary function 
in obese patients is characterized by reductions in functional residual capacity and 
expiratory reserve volume.45 One retrospective study showed that obese patients 
(Body Mass Index = BMI >30) were more likely to develop respiratory complications 
than non-obese patients.46 Furthermore, the presence of excessive subcutaneous 
fat, with its relatively low blood perfusion and oxygen tension, may predispose obese 
patients to impaired wound healing and wound infections. However, obesity is not 
associated with an increased operative risk nor with worse long-term outcomes 
after esophagectomy.46-48 Thus, obesity cannot be considered a contra-indication for 
surgery. 
In general, malnutrition is associated with an increased risk for postoperative 
infectious complications.49 Pretreatment nutritional support could potentially 
decrease postoperative complications, but preoperative nutritional condition 
has received only minor attention in risk analyses for esophagectomy. One study 
showed that preoperative nutritional status determined by prognostic nutritional 
index (PNI) and nutritional risk index (NRI) has only limited value in predicting 
postoperative infectious complications.50 However, hypoalbuminemia as a marker of 
malnutrition is associated with greater risk of adverse surgical outcome in terms of 
morbidity and mortality.51, 52 Decreased serum albumin level may indicate protein-
energy malnutrition, which results from increased protein and energy requirements 
associated with the stress of illness, injury or infection.51 In patients undergoing 
esophagectomy for cancer, serum albumin concentration on the first postoperative 
day was independently associated with postoperative complications.53 
 
Neoadjuvant chemo- and/or radiotherapy
The average 5-year survival for esophageal cancer patients does not exceed 40% 
after esophagectomy.4, 5 As further improvement in survival from a single modality 
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approach such as surgery is less likely, interest in multimodal approaches has 
considerably grown. Strategies combining neoadjuvant chemo(radio)therapy and 
surgery have been investigated as a means of enhancing locoregional control and 
improving survival among patients with localized esophageal cancer.54 However, 
multivariate analyses focusing on risk factors for complications after esophagectomy 
revealed that neoadjuvant therapy was a predictor for early postoperative mortality 
and development of pulmonary complications.11, 12 Furthermore, concerns have been 
raised for a suppressed immune system55 and delayed wound healing.14 In meta-
analyses of RCTs comparing neoadjuvant therapy and surgery to surgery alone for 
resectable esophageal cancer, a significant effect of neoadjuvant chemoradiation on 
postoperative mortality was shown in one study56, whereas a nonsignificant trend 
toward increased mortality for the neoadjuvant therapy group was seen in other 
reports.57, 58 It is clear that more studies are required to investigate this potential 
negative effect of multimodality treatment on postoperative mortality rates. 
1.2 Scoring systems 
Accurate individualized preoperative risk stratification can help in informing patients, 
choosing the optimal extent of surgery, and guiding patients to high-volume centers 
when necessary. First of all, the O-POSSUM score (adapted from the Physiological and 
Operative Severity Score for the enUmeration of Mortality and morbidity-POSSUM59) 
has been developed for the individualized prediction of postoperative mortality and 
morbidity in esophageal and upper gastro-intestinal surgery.60 In-hospital mortality 
can be predicted based on a combination of patients’ age, a physiological score (based 
on 12 variables) and three intra-operative parameters. However, external validation 
of the O-POSSUM score revealed its inability to predict accurately postoperative 
mortality and morbidity in patients undergoing esophagectomy.61, 62 
Various other risk-adjusted models have been developed by means of multivariable 
prognostic models to predict in-hospital mortality for individual patients undergoing 
esophagectomy.9, 63, 64 However, these models have often been based on selected 
patient groups in specialized centers and on retrospective data, thereby limiting the 
generalizability of the results. Moreover, independent validation on new patients or 
other patient cohorts was often not accomplished or was performed in relatively 
small external series. One study managed to analyze predictive variables in a large 
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patient cohort, to develop a simple risk score and to validate this score in three other 
cohorts (Figure 2).65 The risk score showed good agreement of predicted risks with 
observed mortality rates (calibration), but low discrimination. Therefore, this risk 
score is probably insufficient for risk assessment in the individual patient. Recently, 
three existing prognostic models for mortality after esophagectomy63-65 were 
validated in two independent patient cohorts in Australia and Switzerland, but it was 
concluded that none of the scores was suitable for application in daily practice.66 
Predicting the severity of complications after esophagectomy may supply important 
information for both patient and surgeon. Although not independently validated, a 
risk score has been developed in order to predict pulmonary complications based 
on three preoperative variables (age, FEV1 and performance status).21 Furthermore, 
a nomogram (giving a graphical representation of the predictive strength of 
specific predictors and enabling the calculation of an overall risk score for the 
individual patient) has been developed to predict the severity of complications 
in esophagectomy patients.67 Factors including high age, myocardial infarction, 
Figure 2. Score chart to 
estimate 30-day mortality 
after surgery for esophageal 
cancer. Reprinted with 
permission, all rights 
reserved © 2006 American 
Society of Clinical Oncology.  
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stroke or transient ischemic attack in the medical history, low FEV1, presence 
of electrocardiographic changes and more extensive surgery (i.e. transthoracic 
esophagectomy) were taken into account (Figure 3). This model was validated in a 
second group of patients within the same institution, which showed a good overall 
agreement, but a substantial overlap in the risk scores between patient groups 
resulted in a moderate discrimination. Overall, this nomogram may play a role in 
preoperative risk assessment of morbidity after esophagectomy, provided that 
external validation will show good calibration and discrimination.67
In conclusion, there is no scoring system available yet that can be used preoperatively 
in order to predict reliably patient’s morbidity and mortality after esophagectomy. 
2. Intraoperative risk reduction
2.1 Optimal intraoperative management: role of the anesthetist
It is evident that perioperative anesthetic management contributes directly to 
the postoperative course after esophagectomy. Intraoperative cardiorespiratory 
instability (measured by intraoperative hypoxemia, hypotension, need for inotropic 
support) has shown to be associated with the occurrence of acute lung injury in the 
postoperative course.68 During transthoracic esophagectomy one-lung ventilation 
(leading to a total collapse of the other lung) is used to create surgical exposure to 
the esophagus. Hypoxia may occur in this stage due to shunting of blood via the non-
ventilated lung or surgical compression of the mediastinum.69 Furthermore, patients 
undergoing esophagectomy are at risk of aspiration. Prophylactic pharmacological 
management of gastroesophageal reflux, application of continuous low-grade 
nasogastric suction, adequate tracheal cuff inflation, use of a gel lubricant on the 
tracheal cuff and avoiding vocal cord injury at intubation will be beneficial in reducing 
the risk of tracheal aspiration.70, 71
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Figure 3. Nomogram for prediction of severity of complications with use of preoperative risk 
factors. Reprinted with permission, all rights reserved © 2008 Annals of Thoracic Surgery.
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More important for patient’s postoperative course is an appropriate fluid management 
in the intraoperative setting. A strict balance is required between the maintenance 
of cardiac output and perfusion pressure for oxygen-delivery of vital organs and the 
prevention of pulmonary and peripheral edema. Performing esophagectomy induces 
a systemic stress response with subsequent release of inflammatory mediators causing 
vasodilatation, severe capillary leakage and a fluid shift from the intravascular space 
into the interstitium.72 Together with the vasodilatory effects of general anesthetics 
and thoracic epidural analgesia, this can easily lead to excessive fluid administration 
and, subsequently, pulmonary edema. In patients undergoing esophagectomy it was 
found in retrospective analyses that limited intraoperative fluid administration is 
associated with a low morbidity rate in general, reduced postoperative pulmonary 
complications and shortened length of hospital stay.73, 74 However, it remains unclear 
whether restriction of fluid administration or use of diuretics after esophagectomy 
can reduce postoperative morbidity and mortality; prospective studies are needed 
in order to address these issues. Until then, the amount of fluid should be titrated 
for the individual patient according to the perioperative hemodynamic changes as 
detected by intraoperative monitoring. 
In order to reduce the systemic inflammatory response to surgical trauma, it has 
been suggested that intraoperative steroid therapy could reduce the inflammatory 
cytokine release from macrophages. However, it is believed that steroids may 
also suppress wound healing and the patient’s immune defense after operation. 
One RCT showed that preoperative administration of steroid therapy significantly 
decreased postoperative morbidity following esophagectomy.75 No adverse clinical 
effects were observed, especially no increase in infectious complications or delayed 
wound healing.75 Careful investigation to what extent the release of proinflammatory 
cytokines should be suppressed is required.   
Another factor that influences the postoperative course is the application of thoracic 
epidural analgesia. Potential benefits after major surgery include proper pain relief 
and reduction in respiratory complications. Pain relief provided by epidural analgesia 
has been shown superior in achieving effective cough and early mobilization in the 
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postoperative period.76, 77 A reduced incidence of respiratory complications with 
epidural analgesia after esophagectomy has been demonstrated, which can lead to a 
reduced length of stay at the intensive care unit.78 Moreover, the absence of effective 
epidural analgesia is an independent risk factor for pneumonia.79 
1.2 Prevention of complications – surgical technique
The optimal surgical approach for patients with esophageal cancer is still 
debatable. Three operation techniques are widely performed nowadays: transhiatal 
esophagectomy without formal intrathoracic lymphadenectomy, extended 
transthoracic esophagectomy with en bloc lymphadenectomy, and esophagectomy 
with extension of the lymphadenectomy to the cervical region (‘three-field 
dissection’). One RCT in which the transhiatal and transthoracic approach in patients 
with adenocarcinoma of the esophagus were compared, it was shown that an ongoing 
trend towards better overall 5-year survival could be achieved with the extended 
transthoracic esophagectomy, especially in patients with a Siewert type I tumor.80 
However, the additive thoracotomy may be at the cost of increased postoperative 
morbidity; in particular a higher incidence of pulmonary complications was seen.81 
Hence, it is believed that an extended transthoracic esophagectomy is the procedure 
of first choice in patients with a Siewert type I tumor, and a limited transhiatal 
esophagectomy in type II carcinoma. A transhiatal approach may also be considered 
the optimal surgical strategy in patients with significant co-morbidities or in elderly 
patients, in order to minimize the risk of postoperative complications. It is believed 
that the high prevalence of cervical lymph node involvement (approximately 30% 
in certain series) is the rationale for three-field lymphadenectomy.82, 83 Depending 
on the level of the primary tumor, cervical lymph nodes are involved in 60, 20 and 
12% of upper, middle and lower third tumors, respectively.82, 83 However, a convincing 
survival benefit for three-field lymphadenectomy has not been proven84 and the high 
incidence of recurrent laryngeal nerve palsy, related to extensive dissection of the 
recurrent laryngeal nerve chain, remains a major concern.85 
As surgical blood loss correlates with postoperative mortality, excessive bleeding 
should be prevented.2 Recurrent laryngeal nerve function should be carefully 
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preserved because it is required for effective tracheal clearance.23 The integrity of 
the thoracic duct or the adequacy of its distal ligation should always be checked with 
care in order to prevent the development of a chylothorax. 
Anastomotic leakage and conduit necrosis are amongst the most serious postoperative 
complications. Measurement of gastric tissue blood flow reflecting the quality of 
arterial and venous blood supply, can predict anastomotic failure.86, 87 Other factors 
that influence the risk of anastomotic leakage include tension on the anastomosis, 
location of the anastomosis and, most likely, the experience of the operating surgeon 
(reviewed in reference88). No clear difference in outcome could be demonstrated 
between circular stapled and hand-sewn anastomoses.89, 90 More recently, the 
modified Collard anastomotic technique has been described, which encompasses a 
semi-mechanical (i.e. partially stapled, partially hand-sewn) technique for a side-to-
side cervical anastomosis.91 Although not randomized, this trial suggests a reduced 
anastomosis-related morbidity risk. 
In cases of a major anastomotic leakage, the leak can be accompanied by (partial) 
conduit necrosis, which may induce a severe sepsis. Etiologic factors are comparable 
to those indicated for anastomotic leaks, but include also conduit torsion and 
lesions caused during gastric pull-up.92 It has been hypothesized that the use of 
pharmacological agents enhancing conduit’s blood flow may decrease anastomotic 
failure. Prostaglandin E1 has been studied extensively, but this powerful vasodilator 
did not show beneficial effects on conduit viability or anastomotic leak rate.93 
Furthermore, a RCT was performed to evaluate the role of nitroglycerin, which can 
lead to an enhanced microvascular blood flow of the gastric tube.94 Administration 
of intravenous nitroglycerin during gastric tube reconstruction could not prevent 
deterioration in gastric microvascular perfusion and no significant difference in 
anastomotic failure could be detected between the nitroglycerin and control group.94 
To improve the anatomic vascular supply of the gastric conduit, several experimental 
studies have concentrated on preoperative gastric ischemic conditioning (‘delay 
phenomenon’).95 The procedure consists of surgical or radiological partial gastric 
devascularization by occlusion of the left gastric vessels, thereby inducing an ischemic 
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insult leading to the development of collateral submucosal blood flow. Ideally, this 
procedure should result in an improved gastric tissue perfusion prior to pull-up and 
anastomosis to the esophagus. Recently, gastric ischemic conditioning was reported 
in patients by laparoscopic mobilization of the stomach including partial gastric cardia 
stapling with division of the left gastric and gastroepiploic arteries.96 After a mean 
delay of 4 days, a conventional transthoracic esophagectomy was performed, after 
which anastomotic leakage was reported in 6% of patients.96 Overall, laparoscopic 
ischemic conditioning of the gastric conduit is feasible, but its effectiveness in 
reducing the incidence of anastomotic leakage remains to be determined. 
Conclusion 
 
Esophagectomy is still associated with high operative risks. Age, pulmonary and 
cardiovascular condition, nutritional status, and application of neoadjuvant chemo- 
and/or radiotherapy have shown to be important predictive factors for postoperative 
morbidity and mortality that can be evaluated preoperatively. None of these factors 
is in itself a valid exclusion criterion for esophagectomy, but may contribute to 
careful patient selection. Both the surgeon and the anesthetist play an important 
role in intraoperative risk reduction. Adequate fluid management and application of 
appropriate surgical techniques are of great importance in terms of risk reduction 
in patients with esophageal cancer. In order to improve the short-term outcome 
of esophagectomy, an optimal perioperative treatment strategy can be tailored for 
the individual patient by a multidisciplinary team consisting of surgeons, physicians, 
anesthetists and intensive care specialists. 
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Abstract
Introduction: Cachexia and obesity have been suggested to be risk factors for 
postoperative complications. However, high BMI might result in a higher R0-
resection rate because of the presence of more fatty tissue surrounding the 
tumor. The aim of this study was to investigate whether BMI is of prognostic 
value with regard to short-term and long-term outcome in patients undergoing 
esophagectomy for cancer.
Methods: In 556 patients who underwent esophagectomy (1991-2007), 
clinical and pathological outcome were compared between different BMI 
classes (underweight, normal weight, overweight, obesity).
Results: Overall morbidity, mortality, and reoperation rate did not differ in 
underweight and obese patients. However, severe complications seemed to 
occur more often in obese patients (p=0.06), and the risk for anastomotic 
leakage increased with higher BMI (12.5% in underweight patients to 27.6% 
in obese patients, p=0.04). Histopathological assessment showed comparable 
pTNM stages, although an advanced pT-stage was seen more often in patients 
with low/normal BMI (p=0.02). A linear association between BMI and R0-
resection rate was detected (p=0.02): 60.0% in underweight patients to 
81.0% in obese patients. However, unlike pT-stage (p<0.001), BMI was not 
an independent predictor for R0-resection (p=0.12). There was no significant 
difference in overall or disease-free five-year survival between the BMI classes 
(p=0.25 and p=0.60, respectively).
Conclusion: BMI is not of prognostic value with regard to short-term and 
long-term outcome in patients undergoing esophagectomy for cancer, and is 
not an independent predictor for radical R0-resection. Patients oncologically 
eligible for esophagectomy should not be denied surgery on the basis of their 
BMI class. 
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Introduction
Among patients with esophageal cancer weight loss is common, which is caused by 
malnutrition due to reduced food intake (mostly related to dysphagia) and increased 
demands because of systemic inflammation (cancer cachexia).1 Malnutrition has long 
been recognized as a condition associated with an increased risk of postoperative 
complications2, in particular infectious complications.3 It is unclear which mechanism 
is responsible for the relationship between malnutrition and an adverse short-
term clinical outcome, but a combination of immune, inflammatory and metabolic 
processes is thought to play a role.3 
The prevalence of obesity (defined as body mass index (BMI) > 30.00) among 
adults has increased over the past decades in the Western world.4, 5 Obesity is 
associated with several medical comorbidities, including diabetes, hypertension and 
coronary artery disease.6 In addition, increased BMI is associated with a higher risk 
of several types of cancers7, including esophageal adenocarcinoma.8 Surgery and 
anesthesia are more hazardous in overweight patients, not least because of the 
increased incidence of cardiorespiratory comorbidity.9 Obese patients are at higher 
risk for developing respiratory complications, because their pulmonary function is 
characterized by reductions in functional residual capacity and expiratory reserve 
volume.9, 10 11 The presence of excessive subcutaneous fat may also predispose obese 
patients to impaired wound healing and wound infections.12 On the other hand, it 
might be hypothesized that in patients with a high BMI (and increased visceral fatty 
tissue) a higher percentage of tumor-free circumferential resection margins might 
be achieved because of the presence of more fatty tissue surrounding the tumor as 
compared to patients with a low BMI when performing esophagectomy for cancer.
To improve outcome after esophagectomy, an optimal treatment strategy should be 
based on appropriate patient selection, which is strongly influenced by preoperative 
risk assessment. However, preoperative nutritional condition has received minor 
attention in risk analyses for esophagectomy thus far. The aim of the present study 
was to investigate whether BMI is of prognostic value with regard to postoperative 
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short-term and long-term outcome in patients undergoing esophagectomy for cancer. 
We hypothesized on the one hand that patients with either underweight or obesity 
are at higher risk for perioperative morbidity and mortality after esophagectomy, and 
that on the other hand increased BMI with excessive peritumoral fatty tissue might 
facilitate a radical (R0-) resection. 
Patients and methods
Patients
Between January 1991 and December 2007, 791 patients underwent an 
esophagectomy for cancer of the esophagus or gastroesophageal junction in the 
Erasmus Medical Center in Rotterdam, The Netherlands. Only patients in whom 
no chemo- and/or radiotherapy was applied and who underwent a transthoracic 
or transhiatal esophagectomy were included in the present study. In the Erasmus 
MC, patients received neoadjuvant chemo(radio)therapy in the context of clinical 
trials.13 Induction chemo- and/or radiotherapy was given to patients with either a 
cT4-tumor without distant metastases or to patients with gross involvement of celiac 
trunk lymph nodes (M1a), who were not considered eligible for primary surgical 
therapy. There were 214 patients who were excluded because of chemo- and/or 
radiotherapy prior to surgery, and 21 patients because of unknown preoperative 
BMI. The remaining 556 patients were included in this study. 
Surgery 
The majority of patients underwent a transhiatal esophagectomy (N=541). The 
primary tumor and its adjacent lymph nodes were dissected under direct vision 
through the widened hiatus of the diaphragm up to the level of the inferior pulmonary 
vein. In addition, all adjacent fatty tissue surrounding the tumor was removed 
simultaneously, until the lateral resection margins were reached (diaphragm, pleura, 
pericardium, aorta). Subsequently, a gastric tube was created. The left gastric 
artery was transected at its origin, with resection of celiac trunk lymph nodes. After 
mobilization and transection of the cervical esophagus, the normal intrathoracic 
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esophagus proximal to the primary tumor was mobilized bluntly from the neck to 
the abdomen with a vein stripper. Esophagogastrostomy (hand-sewn or by using 
a circular stapler) was performed in the neck. Posterolateral thoracotomy was the 
first step in transthoracic resection with extended lymphadenectomy (N=15). The 
thoracic duct, azygos vein, ipsilateral pleura, and all periesophageal tissue in the 
posterior mediastinum were dissected en bloc. The resection specimen included 
the lower and middle mediastinal, subcarinal, and right-sided paratracheal lymph 
nodes. The aortapulmonary-window nodes were dissected separately. Through a 
midline laparotomy, the paracardial, lesser curvature, left-gastric-artery, celiac trunk, 
common-hepatic-artery, and splenic-artery nodes were dissected, and a gastric tube 
was constructed. The cervical phase of the transthoracic procedure was identical to 
that of the transhiatal procedure. Tumors were assigned pathologic tumor-node-
metastasis stages according to the Union Internationale Contre le Cancer (UICC) 
2002 system.14
Data collection
Patients’ weight and length were measured at their first visit to the outpatient clinic. 
Patients’ BMI was calculated and classified according to the World Health Organization 
criteria (underweight: BMI < 18.50 kg/m2, normal weight: BMI 18.50 – 24.99 kg/m2, 
overweight: BMI 25.00 – 29.99 kg/m2, obesity: BMI ≥ 30.00 kg/m2).15 Outcome data 
(including half-yearly follow-up) for all patients with esophageal cancer referred to 
our hospital for further analysis and treatment had been collected prospectively and 
stored in a database by a specialized data manager. Follow-up was recorded until 
December 2008 or until death if earlier, and was complete for all patients.
Statistics
To address the question whether patients with either underweight or obesity are at 
higher risk for perioperative morbidity and mortality after esophagectomy, short-
term outcome of underweight and obese patients was compared with outcome of 
the control group (patients with normal weight or overweight). The potential impact 
of BMI on histopathological outcome was considered to be on a linear scale (i.e. 
increased BMI might result in a higher percentage R0-resections), and was analyzed 
by comparing patients’ outcome of the four BMI classes. 
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Statistical analysis appropriate for non-parametric data was used. Grouped data as 
presented in Table 2 and 3 were compared using the Chi-Square-, Mann-Whitney 
U- or Kruskall-Wallis H-test. In case these tests were significant (thereby indicating 
that there were differences but not indicating the where the differences are), groups 
were compared pair-wise with adding the Bonferroni correction. Trend-analysis and 
logistic regression were performed to reveal linear associations with regard to BMI. 
Overall survival was calculated from the date of operation until the date of last 
follow-up or death according to the Kaplan-Meier method. Patients who died due 
to complications following esophagectomy (in-hospital mortality) were not excluded 
from survival-analysis. Univariate analyses were performed to identify prognostic 
variables associated with overall survival after esophagectomy. 
Data-analysis was carried out with SPSS version 15.0 (SPSS,Chicago,IL,USA). Two-
sided p-values <0.05 were considered to be significant.  
Results
Patients’ characteristics
Patients’ characteristics are described in Table 1. Forty patients (7.2%) were classified 
as underweight (BMI < 18.50 kg/m2), 244 patients (43.9%) had a normal weight (BMI 
18.50 – 24.99 kg/m2), 214 patients (38.5%) were overweight (BMI 25.00 – 29.99 kg/
m2), whereas obesity (BMI > 30.00) was diagnosed in 58 patients (10.4%). 
Short-term outcome
Median operative time for all patients was 280 minutes (range 120-572 minutes). 
Operative time increased among the different BMI classes: median operative time 
was 266 minutes in underweight patients, 274 minutes in normal weight, 285 
minutes in overweight and 307 minutes in obese patients (p=0.04). There was no 
significant difference in length of ICU-MCU- (median 4 days) or hospital-stay (median 
14 days) between the different groups.
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Table 1. Clinicopathological characteristics of 556 patients who underwent surgical 
resection for esophageal cancer.
Age (in years)* 65 (range 28 – 89)
Gender
- Male
- Female
450 (80.9%)
106 (19.1%)
ASA classification
- I
- II
- III
- IV
  82 (14.7%)
364 (65.5%)
106 (19.1%)
  4 (0.7%)
BMI class
- Underweight (BMI < 18.50)
- Normal weight (BMI 18.50 – 24.99)
- Overweight (BMI 25.00 – 29.99)
- Obesity  (BMI ≥ 30.00)
40 (7.2%)
244 (43.9%)
214 (38.5%)
  58 (10.4%)
Tumor location
- Proximal esophagus
- Mid esophagus
- Distal esophagus
- Gastroesophageal junction
   9 (1.6%)
32 (5.8%)
232 (41.7%)
283 (50.9%)
Histology
- Squamous cell carcinoma
- Adenocarcinoma
  83 (14.9%)
473 (85.1%)
*Age is given as median
ASA classification  = American Society of Anesthesiologists classification
BMI = body mass index
When analyzing the effect of either underweight or obesity on patients’ short-
term outcome, overall morbidity, reoperation rate and in-hospital mortality were 
similar to those of the patients in the control group (normal weight or overweight; 
Table 2). However, when the grade of complications was taken into account, severe 
complications seemed to occur more often in obese patients than in the control group 
(36.4% versus 21.8%, p=0.06). Furthermore, the incidence of anastomotic leakage 
(radiological as well as clinical) did not seem comparable between the three groups 
(p=0.09). On trend-analysis, a linear association between BMI and anastomotic 
leakage was detected (p=0.04): the risk for anastomotic leakage increased with 
higher BMI (from 12.5% in underweight patients to 27.6% in obese patients). Also, a 
trend for a linear association between BMI and wound infection was seen (p=0.07): 
from 2.5% in underweight patients to 12.1% in obese patients.
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Table 2. Impact of underweight and obesity on postoperative complications and in-
hospital mortality in patients undergoing esophagectomy for cancer, as compared to 
the control group (normal weight and overweight patients). 
Underweight
BMI <18.50
N=40
Control group
BMI 18.50 – 29.99
N=458
Obesity
BMI ≥ 30.00
N=58
p-value
Postoperative complications 20 (50.0%) 294 (64.2%) 34 (58.6%) 0.17
Surgical complications
-Bleeding
-Chyle leakage
-Anastomotic leakage
-Conduit necrosis
-Vocal cord paresis
-Wound infection
1 (2.5%)
1 (2.5%)
  5 (12.5%)
0 (0.0%)
  4 (10.0%)
1 (2.5%)
13 (2.8%)
  12 (12.6%)
  77 (16.8%)
11 (2.4%)
  67 (14.6%)
43 (9.4%)
0 (0.0%)
1 (1.7%)
16 (27.6%)
1 (1.7%)
4 (6.9%)
  7 (12.1%)
0.43
0.92
0.09
0.59
0.16
0.25
Medical complications
-Sepsis
-Pneumonia 
-Respiratory insufficiency*
-Atrial fibrillation
-Myocardial infarction
-Thromboembolism
1 (2.5%)
11 (27.5%)
  5 (12.5%)
3 (7.5%)
0 (0.0%)
0 (0.0%)
29 (6.3%)
149 (32.5%)
40 (8.7%)
39 (8.5%)
 5 (1.1%)
10 (2.2%)
3 (5.2%)
12 (20.7%)
  6 (10.3%)
3 (5.2%)
2 (3.4%)
2 (3.4%)
0.60
0.16
0.69
0.67
0.24
0.51
Reoperation 3 (7.5%)   54 (11.8%) 5 (8.6%) 0.58
In-hospital mortality 1 (2.5%) 27 (5.9%) 5 (8.6%) 0.45
 
* Respiratory insufficiency was defined as pulmonary dysfunction requiring prolonged 
ventilation (>10 days) or reintubation.
BMI = body mass index
Histopathological assessment for the four different BMI classes is shown in Table 
3. Advanced pT-stage was seen significantly more often in patients with a low or 
normal BMI (p<0.01). Patients with overweight or obesity appeared to participate 
more often in a surveillance program than patients with a low or normal BMI (28.8% 
versus 17.1%, p=0.21). Underweight patients mostly suffered from squamous cell 
carcinoma (55%), whereas the majority of patients with normal weight, overweight 
or obesity were diagnosed with adenocarcinoma (89%; p<0.001). A trend towards a 
higher rate of radical resection (R0) across the BMI classes was noted (p=0.06). On 
trend-analysis, a linear association between BMI and R0-resection rate was detected 
(p=0.02): 60.0% in underweight patients versus 81.0% in obese patients. However, 
unlike pT-stage (p<0.001), BMI was not an independent predictor for R0-resection 
on logistic regression (p=0.12). Stratification for tumor location (esophagus versus 
gastroesophageal junction) did not influence the R0-resection rate. 
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Table 3. Histopathological assessment of the resection specimens in relation to four 
BMI classes in 556 patients who underwent surgical resection for esophageal cancer. 
Underweight
BMI <18.50
N=40
Normal weight
BMI 18.50 – 24.99
N=244
Overweight
BMI 25.00 – 29.99
N=214
Obesity
BMI ≥ 30.00
N=58
p-value
Histology
- SCC
- AC
22 (55.0%)
18 (45.0%)
  29 (11.9%)
215 (88.1%)
26 (12.1%)
188 (87.9%)
  6 (10.3%)
52 (89.7%)
<0.001
pT-status
- T1 – T2
- T3 – T4
10 (25.0%)
30 (75.0%)
  65 (26.6%)
179 (73.4%)
  83 (38.8%)
131 (61.2%)
23 (39.7%)
35 (60.3%)
0.02
pN-status
- N0
- N1
16 (40.0%)
24 (60.0%)
  84 (34.4%)
160 (65.6%)
  81 (37.9%)
133 (62.2%)
24 (41.4%)
34 (58.6%)
0.94
pM-status
- M0
- M1a – M1b
32 (80.0%)
  8 (20.0%)
194 (79.5%)
  50 (20.5%)
164 (76.6%)
  50 (23.4%)
47 (81.0%)
11 (19.0%)
0.84
Differentiation grade
- G1 (good)
- G2 (moderate)
- G3 (poor)
  4 (10.0%)
26 (65.0%)
10 (25.0%)
14 (5.7%)
111 (45.5%)
119 (48.8%)
17 (7.9%)
  95 (44.4%)
102 (47.7%)
4 (6.9%)
22 (37.9%)
32 (55.2%)
0.17
Type of resection
- R0
- R1 – R2
24 (60.0%)
16 (40.0%)
167 (68.4%)
 77 (31.6%)
154 (72.0%)
  60 (28.0%)
47 (81.0%)
11 (19.0%)
0.06
Number of positive 
lymph nodes*
 1 (1 – 19)  2 (0 – 23)  2 (0 – 43)  1 (0 – 11) 0.14
Total number of 
harvested lymph nodes*
10 (3 – 45) 12 (1 – 56) 10 (1 – 43) 9 (2 – 31) 0.10
Lymph node ratio* 0.10 0.17 0.16 0.10 0.14
*Values presented as median (range in brackets)
BMI = body mass index
SCC = squamous cell carcinoma
AC = adenocarcinoma
Lymph node ratio  = number of positive lymph nodes / total number of harvested lymph nodes
Long-term outcome
Median survival time was 20 months (range 0-193 months). Overall five-year 
survival was 27.9%, whereas disease-specific five-year survival was 33.4%. Disease 
recurrence was noted in 315 patients (56.7%): locoregional recurrence in 27.2% and 
distant metastases in 47.1% of patients. There was no significant difference in overall 
five-year survival between the different BMI classes (Figure 1: underweight 26.8%, 
normal weight 25.2%, overweight 28.5% and obesity 34.4%; p=0.25) or in disease-
free five-year survival (28.8%, 32.5%, 33.2%, and 35.1%, respectively; p=0.60). 
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Parameters found to be associated with overall survival in univariate analyses are 
shown in Table 4. Age younger than 65 years, early pT-stage (pT1 or pT2), no lymph 
node involvement (pN0), absence of distant metastatic disease (pM0), lymph node 
ratio smaller than 0.17, good differentiation grade of the tumor, and R0-resection 
were favorable for improved survival.
Figure 1. Overall five-year survival in relation to BMI classes in 556 patients who underwent 
surgical resection for esophageal cancer.
No. at risk 0 months 12 months 24 months 36 months 48 months 60 months
Underweight 40 26 15 11 11 9
Normal weight 244 147 97 75 56 46
Overweight 214 138 89 59 47 40
Obesity 58 47 33 23 14 10
Follow-up in months
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Table 4. Univariate analyses of variables associated with overall survival in esophageal 
cancer patients who underwent surgical resection.
VARIABLE 5-YEAR SURVIVAL p-value
BMI class
Underweight
Normal weight
Overweight
Obesity
26.8%
25.2%
28.5%
34.4%
0.25
Gender
Male
Female
26.6%
33.4%
0.50
Age
< 65 years
≥ 65 years
33.7%
22.3%
<0.001
ASA classification
I / II
III / IV
28.5%
25.9%
0.11
Histology
Squamous cell carcinoma 
Adenocarcinoma
26.0%
28.3%
0.53
pT-stage
pT1-2
pT3-4
55.5%
14.5%
<0.001
pN-stage
pN0
pN1
52.7%
12.9%
<0.001
pM-stage
pM0 
pM1a / M1b
32.3%
  8.1%
<0.001
Lymph node ratio
< 0.17
≥ 0.17
44.9%
11.5%
<0.001
Differentiation grade of tumor
Good
Moderate
Poor
70.2%
30.3%
19.1%
<0.001
Radicality of resection 
R0
R1 / R2
37.9%
  4.8%
<0.001
BMI = body mass index
ASA classification  = American Society of Anesthesiologists classification
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Discussion
In this large cohort of patients who underwent esophagectomy for cancer, no 
differences in overall morbidity, in-hospital mortality, or reoperation rate were 
detected among the different BMI classes. However, severe complications seemed 
to occur more often in obese patients than in the control group. Furthermore, a 
linear association between BMI and anastomotic leakage was detected: the risk for 
anastomotic leakage increased with higher BMI. 
Cancer cachexia has been recognized as a condition associated with an increased risk 
of postoperative complications2, in particular infectious complications.3 However, in 
the present series it appeared that underweight did not influence patient’s short-
term outcome after esophagectomy. When analyzing infectious complications in 
particular (esp. wound infection and pneumonia), incidences in underweight patients 
were similar to those in the control group. 
Obese patients are also thought to have a higher risk for developing wound 
infections.6, 12, 16, 17 This might be related to the presence of excessive fatty tissue (with 
a low regional oxygen tension), which may predispose to impaired wound healing. 
Furthermore, it has been shown that obese patients have an underlying immune 
impairment, which may further contribute to higher rates of wound infection.18 
Although other reports could not confirm this hypothesis11, 19, 20, the risk for wound 
infection seemed to increase with higher BMI on trend-analysis in the present 
series. Furthermore, we found a linear association between BMI and anastomotic 
leakage: a higher incidence of anastomotic leakage was found with increasing BMI. 
In one study in which a significantly increased incidence of anastomotic leakage 
in obese patients was demonstrated, it was speculated that this might be due to 
a compromised vascularity of the conduit (because of an increased tension on the 
conduit in the thoracic compartment or because of medical comorbidities in general 
such as diabetes or cardiovascular disease). 
In contrast to previous studies, we did not find differences in respiratory complications 
nor in laryngeal nerve injury between the BMI classes.11, 20 This discrepancy with 
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the literature might be explained by a difference in the applied surgical technique. 
While the majority of our patients underwent a transhiatal esophagectomy, in the 
previously reported patient group a transthoracic technique was applied.11 It is known 
that transthoracic esophagectomy is associated with more pulmonary complications 
compared with the transhiatal approach.21 
In this study advanced pT-stage was seen significantly more often in patients with 
a low or normal BMI when compared to patients with a high BMI (p=0.02). This 
might be explained by the fact that overweight people experience more reflux 
symptoms, and are offered upper gastro-intestinal endoscopy more frequently, 
thereby facilitating an early detection of the esophageal tumor. Furthermore, in the 
underweight group patients with a squamous cell carcinoma were overrepresented, 
who would not have entered a Barrett’s esophagus surveillance program. Indeed, 
patients with overweight or obesity were participating more often in a surveillance 
program than patients with a low or normal BMI (28.8% versus 17.1%), although this 
difference did not reach statistical significance (p=0.21). It is well-established that 
stage of disease and survival are more favorable for patients who have undergone 
endoscopic surveillance than for patients who have not participated in a surveillance 
program.22, 23
We hypothesized that a higher percentage of tumor-free circumferential resection 
margins might be achieved when performing esophagectomy for cancer in overweight 
or obese patients because of the presence of more substantial fatty tissue surrounding 
the tumor. Indeed, on trend-analysis, a significant linear association between BMI and 
R0-resection rate was found (p=0.02): 60.0% in underweight patients versus 81.0% in 
obese patients. However, pT-stage acted as a confounder for this relationship, as BMI 
was not an independent predictor for R0-resection on logistic regression. Therefore, 
our hypothesis that a higher percentage of tumor-free circumferential resection 
margins might be achieved in obese patients because of the presence of more fatty 
tissue surrounding the tumor could not be confirmed. Furthermore, higher BMI did 
not result in an improved long-term survival following resection and BMI class was 
not a predictor of survival after esophagectomy in univariate analysis. 
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Selection-bias can be a limitation of the present study. Only patients who have 
been considered fit enough for operation have entered this study. Therefore, 
severely malnourished patients or patients with severe obesity-associated medical 
comorbidites (including diabetes, hypertension and coronary artery disease) are 
more likely to have been excluded from surgery. This may have lead to a properly 
selected patient group, sufficiently fit to undergo esophagectomy, in whom no impact 
of either underweight or obesity on patient’s short-term and long-term outcome 
could thus be demonstrated.
In summary, BMI is not of prognostic value with regard to short-term complications 
or long-term survival in patients undergoing esophagectomy for cancer. A radical 
R0-resection was achieved more often in patients with high BMI. However, this was 
not due to the presence of more substantial fatty tissue surrounding the tumor 
(potentially facilitating a radical resection). This observation should rather be 
explained by a confounding effect of pT-stage, as early pT-stage was seen more often 
in patients with high BMI. We conclude that patients who are oncologically eligible 
for esophagectomy should not be denied surgery on the basis of their BMI class only. 
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Abstract
Introduction: Esophageal cancer should preferably be detected and treated 
at an early stage, but this may be prohibited by late onset of symptoms and 
delays in referral, diagnostic work-up and treatment. The aim of this study 
was to investigate the impact of these delays on outcome in patients with 
esophageal cancer. 
Methods: For 491 patients undergoing esophagectomy for cancer between 
1991 and 2007, patients’ short-term and long-term outcome were analyzed 
according to different time intervals between onset of symptoms, diagnosis 
and surgical treatment. 
Results: Length of prehospital-delay (from onset of symptoms until endoscopic 
diagnosis) did not affect patient’s short-term or long-term outcome. A shorter 
hospital-delay between establishing the diagnosis of esophageal cancer on 
endoscopy and surgery was associated with lower overall morbidity and in-
hospital mortality. Patients of ASA-class I and II experienced a shorter hospital-
delay than patients of ASA-class III and IV. Length of hospital-delay between 
endoscopic diagnosis and surgery did not affect pTNM-stage or R0-resection 
rate. Longer hospital-delay did not result in worse survival: overall survival 
after esophagectomy for cancer was not significantly different between 
patients with hospital-delay <5 weeks, 5-8 weeks or >8 weeks (24.7%, 21.7% 
and 32.3%, respectively; p=0.12).
Conclusion: A longer hospital-delay (between endoscopic diagnosis and 
surgery) resulted in worse patient’s short-term outcome (higher overall 
morbidity and mortality rates), but not in a worse long-term outcome (overall 
survival). This may be explained by a more time-consuming diagnostic work-
up in patients with a poorer physical status and not by tumor progression.
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Introduction
The five-year survival rate for esophageal cancer patients after esophagectomy with 
curative intent has improved up to 40%.1-3 As further improvement in survival from a 
single modality approach such as surgery is unlikely, considerable interest has grown 
in other strategies that may improve patients’ survival (neoadjuvant chemo- and/or 
radiotherapy in particular). In many types of cancer, the prognosis of patients with 
small, localized tumors is better than with locally advanced or metastatic disease. 
Similar to other malignancies such as colorectal and breast cancer, the outcome 
of esophageal cancer is related to the pTNM-stage of the disease.2, 4, 5 Therefore, 
detection and treatment of esophageal cancer at an early stage could also improve 
long-term survival. 
Early detection of esophageal cancer may be prohibited not only by the late onset of 
symptoms, but also by delays in referral to an appropriate specialist, establishment 
of the diagnosis, further diagnostic work-up, and start of treatment. However, the 
impact of these delays on both short-term and long-term outcome for patients 
undergoing esophagectomy for cancer is unclear.
In patients with breast cancer, delays of 3-6 months between the onset of symptoms 
and start of treatment are associated with lower survival, caused by a more advanced 
tumor stage.6 In two systematic reviews, no association was found between diagnostic 
and therapeutic delay and survival in colorectal cancer patients7, nor between these 
delays and disease stage.8 A few studies have investigated the impact of delays 
in diagnosis and treatment of esophageal cancer. Drawbacks of these studies are 
small numbers of patients included9, analyses that do not cover the complete track 
between onset of symptoms and surgical treatment10, 11, combined patient groups 
with gastric and esophageal carcinoma12, 13, and studies lacking survival analyses.9, 
11-13
We hypothesized that longer delays between onset of symptoms, endoscopic 
diagnosis and surgical treatment are associated with a worse short-term outcome 
(morbidity, reoperation rate and in-hospital mortality), worse tumor-stage and, 
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hence, worse long-term outcome (overall survival) following potentially curative 
esophagectomy in patients with esophageal cancer. 
Patients and methods
The Erasmus Medical Center in Rotterdam is a tertiary referral center for patients with 
esophageal cancer in The Netherlands. Most patients are referred to the Erasmus MC 
outpatient clinic for (surgical) treatment after the diagnosis of esophageal cancer has 
been established in a referring hospital (group A). The minority of patients is directly 
referred by the general practitioner (GP) to the Erasmus MC for clinical investigations 
of symptoms suggestive of cancer (group B). In all patients (group A and B) upper 
gastro-intestinal endoscopy with biopsy is (re)done in the Erasmus MC to confirm 
the diagnosis of esophageal cancer and to determine the exact location of the tumor. 
Staging is performed routinely with endoscopic ultrasonography (EUS), CT scanning of 
thorax and abdomen and external ultrasound of the neck. Every patient is discussed 
in a weekly multidisciplinary oncology meeting in which a definitive treatment plan 
is designed. If eligible for surgery, patients are put on the waiting list for surgery. 
On the same day, the patient is referred to the Department of Anesthesiology for 
preoperative counseling. If needed, additional cardiac and/or pulmonary function 
tests are scheduled. 
Between January 1991 and December 2007, 791 patients underwent esophagectomy 
for cancer of the esophagus or gastroesophageal junction in the Erasmus MC. To obtain 
a homogeneous cohort of patients in terms of treatment and to circumvent possible 
stage migration following chemo- and/or radiotherapy, patients receiving (neo)
adjuvant therapy were excluded from this analysis. In our hospital, patients received 
neoadjuvant chemo(radio)therapy in the context of randomized controlled trials.14, 15 
Induction chemo- and/or radiotherapy was given in patients with either a cT4-tumor 
without distant metastases or in patients with gross involvement of celiac trunk lymph 
nodes (M1a), who were not considered eligible for primary surgical therapy. There 
were 214 patients who were excluded because of chemo- and/or radiotherapy prior 
to surgery. In 44 patients the hospital-delay from endoscopic diagnosis to surgery 
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could not be calculated, as the date of their first upper gastro-intestinal endoscopy 
performed in the referring hospital was unknown. Another 42 patients were excluded 
as they participated in a Barrett’s esophagus surveillance program. Over recent 
years, multiple attempts for endoscopic treatment of early lesions delayed referral 
to the Department of Surgery in such way that this group was not representative 
for patients treated for (more advanced) esophageal cancer. Finally, data of 491 
patients were analyzed in the present study. The vast majority of these patients 
underwent a transhiatal esophagectomy with locoregional lymphadenectomy only 
(N=477). In 14 patients a transthoracic resection with extended lymphadenectomy 
was performed. The applied surgical techniques have been described previously.3, 
16 Tumors were assigned pathologic tumor-node-metastasis stages according to the 
Union Internationale Contre le Cancer (UICC) 2002 system.17 
Data on patients’ demographics, diagnostic tests, surgery, postoperative morbidity, 
in-hospital mortality and survival have been collected prospectively and stored in 
a database by a data manager. From this database the following time points were 
defined:
-	 Date of upper gastro-intestinal endoscopy in the referring hospital, on which 
the diagnosis of esophageal cancer had been established by histology from 
biopsies (only applicable for group A);
-	 Date of first visit at the Erasmus MC outpatient clinic: Department of 
Surgery, Gastroenterology or Medical Oncology;
-	 Date of upper gastro-intestinal endoscopy in the Erasmus MC, on which 
the diagnosis of esophageal cancer had been established by histology from 
biopsies;
-	 Date of the multidisciplinary oncology meeting, after which the patient had 
been put on the operative waiting list if eligible for surgery;
-	 Date of surgery.
To summarize all different time points that have been marked in the process between 
onset of symptoms and surgery, we divided this time-span into two major time-
intervals that have been analyzed separately: pre-hospital and hospital-delay (see 
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Figure 1). Subsequently, data were analyzed in three different ways: 
-	 Impact of prehospital-delay: time from onset of symptoms until diagnosis 
on first endoscopy (either in the referring hospital for group A or in Erasmus 
MC for group B);
-	 Impact of hospital-delay: time from diagnosis on patient’s first endoscopy 
undertaken until surgery; 
-	 Impact of specific time intervals between diagnosis on first endoscopy and 
surgery. In order to examine the hospital-delay in more detail, the effect 
of specific time intervals between diagnosis in the referring hospital, first 
visit at the outpatient clinic in Erasmus MC, diagnosis on endoscopy in 
Erasmus MC, multidisciplinary oncology meeting and surgery on short-term 
and long-term outcome were analyzed. For this purpose, only data from 
patients in group A were used.
Figure 1. Analysis of prehospital-delay and hospital-delay encountered by patients who 
underwent surgical resection for esophageal cancer in Erasmus MC.
Statistics
Follow-up was recorded until December 2008 or until death if earlier, and was complete 
for all patients. Statistical analysis for non-parametric data was used. Grouped data 
were compared using the Chi-Square-, Mann-Whitney U- or Kruskall-Wallis H-test. 
Patients who died due to complications following esophagectomy (in-hospital 
mortality) were not excluded from survival-analysis. Overall survival was calculated 
from the date of operation until the date of last follow-up or death according to the 
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Kaplan-Meier method. Disease-free survival was assessed from the date of operation 
until the date of disease recurrence in case of locoregional recurrence or distant 
metastases. Univariate analyses were performed with the log-rank test to identify 
prognostic variables associated with overall survival after esophagectomy. Data-
analyses were carried out with SPSS version 15.0 (SPSS, Chicago, IL, USA). 
Results
Patients’ characteristics are shown in Table 1. Three hundred and sixty-five patients 
(74.3%), in whom the diagnosis esophageal cancer was established in an other 
hospital, were referred to the Erasmus MC for further staging and treatment 
(group A). Hundred and twenty-six patients (25.7%) were referred directly to the 
Erasmus MC by the general practitioner for investigation of symptoms suggestive 
of esophageal cancer (group B). Patients’ first visit to the Erasmus MC was at the 
Department of Surgery (N=338, 68.8%), Department of Gastroenterology (N=147, 
29.9%) or Department of Medical Oncology (N=6, 1.3%).
Table 1. Clinicopathological characteristics of 491 patients who underwent surgical 
resection for esophageal cancer and who were included in the present study.
Age (in years)* 65 (28 – 89)
Gender
- Male
- Female
399 (81.3%)
 92 (18.7%)
ASA classification
- I
- II
- III
- IV
  77 (15.7%)
316 (64.4%)
  96 (19.6%)
  2 (0.4%)
Tumor location
- Proximal esophagus
- Mid esophagus
- Distal esophagus
- Gastroesophageal junction
  8 (1.6%)
27 (5.5%)
196 (39.9%)
260 (53.0%)
Histology
- Squamous cell carcinoma
- Adenocarcinoma
  73 (14.9%)
418 (85.1%)
*Age is given as median (range)
ASA classification = American Society of Anesthesiologists classification
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Impact of prehospital-delay: time from onset of symptoms until first endoscopy
The majority of patients underwent endoscopy for investigation of obstructive 
symptoms suggestive of cancer like dysphagia, odynophagia and weight loss 
(N=462, 94.1%). Other indications for endoscopy encompassed investigation of 
hematemesis (N=12, 2.4%), anemia (N=9, 1.8%), or melena (N=8, 1.6%). Prehospital-
delay (from onset of symptoms until first endoscopy) lasted a median time period 
of 3.0 months (range 0 – 36 months). Patient’s short-term (morbidity, reoperation 
rate and in-hospital mortality) and long-term outcome (overall five-year survival) 
after esophagectomy were comparable for patients who experienced symptoms 
for a period of 3 months or less versus more than 3 months until endoscopy was 
performed (Table 2).
Table 2. Impact of prehospital-delay from onset of symptoms to first endoscopy on 
short-term and long-term outcome after esophagectomy; comparison of prehospital-
delay ≤ 3 months (N=308) versus > 3 months (N=183). 
Prehospital-delay ≤3 months
N=308
Prehospital-delay >3 months
N=183
p-value
Morbidity 199 (64.6%) 104 (56.8%) 0.09
Reoperation   34 (11.0%) 16 (8.7%) 0.42
In-hospital mortality 18 (5.8%)   9 (4.9%) 0.66
Overall five-year survival 24.0% 29.3% 0.10
Impact of hospital-delay: time from endoscopic diagnosis until surgery
The hospital-delay from establishing the diagnosis of esophageal cancer on endoscopy 
(either in the referring hospital for group A or in Erasmus MC for group B) until 
surgery was 49 days (given as median, range 5 – 175 days). This delay encompassed 
a median time period of 28 days (range 0 – 147 days) from diagnosis on patient’s 
first endoscopy until the multidisciplinary oncology meeting (staging-delay), and a 
median time period of 15 days from this meeting until surgery (operative waiting list, 
range 1 – 67 days). Median hospital-delay between diagnosis and surgery increased 
during the study period (1991-2007): 3.9 weeks in 1991 towards 10.9 weeks in 2007 
(Figure 2). This increase in hospital-delay should rather be ascribed to the 3.4 times 
increase in length of the operative waiting list (1.6 weeks in 1991 towards 5.6 weeks 
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in 2007) than to the 1.5 times increase in staging-delay (3.3 weeks in 1991 towards 
4.9 weeks in 2007).
A shorter hospital-delay between establishing the diagnosis of esophageal cancer on 
patient’s first endoscopy and surgery was associated with significantly lower overall 
morbidity and mortality (Table 3). These associations appeared to be linear: morbidity 
(p=0.001) and in-hospital mortality (p=0.01) increased with longer hospital-delay. 
Patients of ASA-class I and II experienced a shorter hospital-delay than patients of 
ASA-class III and IV (hospital-delay <5 weeks 28.8%, 5-8 weeks 36.9% and >8 weeks 
34.4% versus < 5 weeks 15.3%, 5-8 weeks 41.8% and > 8 weeks 42.9%, respectively; 
p=0.02). Length of hospital-delay did not affect pTNM-stage or R0-resection rate 
(Table 3). 
Figure 2. Median hospital-delay (in weeks) between endoscopic diagnosis and surgery 
increased during the study period (1991-2007): 3.9 weeks in 1991 towards 10.9 weeks in 2007.
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Table 3. Impact of the hospital-delay from diagnosis on patient’s first endoscopy until 
surgery: hospital-delay < 5 weeks (N=128), 5-8 weeks (N=186) and > 8 weeks (N=177). 
Delay <5 weeks
N=128
Delay 5-8 weeks
N=186
Delay >8 weeks
N=177
p-value
Morbidity 62 (48.4%) 122 (65.6%) 119 (67.2%) <0.01
In-hospital mortality 2 (1.6%) 10 (5.4%) 15 (8.5%) 0.03
Reoperation 7 (5.5%)   20 (10.8%)   23 (13.0%) 0.10
pT-stage
-	 pT1-pT2
-	 pT3-pT4
30 (23.4%)
98 (76.6%)
  57 (30.6%)
129 (69.4%)
  54 (30.5%)
123 (69.5%)
0.31
pN-stage
-	 pN0
-	 pN1
42 (32.8%)
86 (67.2%)
  66 (35.5%)
120 (64.5%)
  62 (35.0%)
115 (65.0%)
0.88
pM-stage
-	 pM0
-	 pM1a-M1b
103 (80.5%)
  25 (19.5%)
150 (80.6%)
  36 (19.4%)
131 (74.0%)
  46 (26.0%)
0.24
Radicality of resection
-	 R0
-	 R1-R2
86 (67.2%)
42 (32.8%)
124 (66.7%)
  62 (33.3%)
130 (73.4%)
  47 (26.6%)
0.32
Longer hospital-delay did not result in worse survival (Figure 3): overall five-year 
survival was 24.7% in patients with a hospital-delay less than 5 weeks, 21.7% in 
patients with a hospital-delay between 5 and 8 weeks, and 32.3% in patients in whom 
the hospital-delay was more than 8 weeks. Although overall survival appeared to be 
longer in patients with a longer hospital-delay, this difference was not statistically 
significant (p=0.12). Parameters found to be associated with overall survival in 
univariate analyses are shown in Table 4: age younger than 65 years, early pT-stage 
(pT1 or pT2), no lymph node involvement (pN0), absence of distant metastatic 
disease (pM0), good differentiation grade of the tumor, R0-resection and lymph 
node ratio smaller than 0.24 were favorable of improved overall survival. Survival 
analysis with regard to five-year disease-free survival paralleled the overall five-year 
survival curves (27.0%, 27.7% and 38.3%, respectively; p=0.09).
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No. at risk 0 months 12 months 24 months 36 months 48 months 60 months
> 8 weeks 177 107 68 48 38 24
5 – 8 weeks 186 122 78 54 39 34
< 5 weeks 128 80 53 42 32 30
Figure 3. Overall five-year survival for esophageal cancer patients appeared longer for patients 
with a hospital-delay between diagnosis on first endoscopy and surgery > 8 weeks (N=177) 
versus patients with a hospital-delay < 5 weeks (N=128) or 5 – 8 weeks (N=186), although this 
difference did not reach statistical significance (p=0.12).
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Table 4. Univariate analyses of potential prognostic variables associated with overall 
survival after esophagectomy for cancer (N=491).
VARIABLE FIVE-YEAR SURVIAL P-VALUE
Age 
≤ 65 years 
> 65 years
30.2%
21.4%
0.001
Sex
Male
Female
25.4%
28.5%
0.84
ASA classification
I – II
III – IV
27.0%
22.2%
0.12
pT-stage
pT1 – T2 
pT3 – T4
53.3%
15.0%
<0.001
pN-stage
pN0 
pN1
50.3%
12.2%
<0.001
pM-stage
pM0
pM1a – M1b 
39.8%
  9.5%
<0.001
Histology
Squamous cell carcinoma 
Adenocarcinoma
27.1%
25.8%
0.98
Differentiation grade of tumor
Good 
Moderate
Poor
69.1%
29.5%
16.0%
<0.001
Radicality of resection
R0
R1 – R2
35.5%
  5.5%
<0.001
Lymph node ratio
≤ 0.24 
> 0.24
36.0%
12.0%
<0.001
Referral
By another hospital (group A) 
By GP (group B)
25.9%
26.2%
0.65
Prehospital-delay
≤ 3 months 
> 3 months
24.0%
29.3%
0.10
Hospital-delay
<5 weeks 
5 – 8 weeks 
>8 weeks
24.7%
21.7%
32.3%
0.12
 
ASA classification  = American Society of Anesthesiologists classification 
GP   = general practitioner
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Impact of specific time intervals between endoscopic diagnosis and surgery (group A)
The median hospital-delay was 53 days (range 5 – 175 days) for patients in group 
A in whom the diagnosis esophageal cancer had been established in an other 
hospital and who were referred to the Erasmus MC for surgical treatment (N=365). 
The breakdown of this delay is shown in Table 5, according to the different time 
intervals between diagnosis in the referring hospital, first visit to the outpatient clinic 
in Erasmus MC, diagnosis on endoscopy in Erasmus MC, multidisciplinary oncology 
meeting and surgery. 
Table 5. Delays encountered by esophageal cancer patients who have been referred 
from an other hospital to the Erasmus MC for surgical treatment (group A, N=365). 
Lengths of delays are given as a median values with the corresponding range in 
brackets.
Diagnosis on endoscopy elsewhere →
First visit outpatient clinic Erasmus MC
17 days (1 – 138)
First visit outpatient clinic Erasmus MC →
Diagnosis on endoscopy Erasmus MC
  6 days (0 – 36)
Diagnosis on endoscopy Erasmus MC →
Multidisciplinary oncology meeting
  7 days (0 – 95)
Multidisciplinary oncology meeting →
Surgery 
15 days (1 – 67)
HOSPITAL-DELAY
Diagnosis on endoscopy elsewhere → Surgery 53 days (5 – 175)
When analyzing the impact of the separate time intervals, it appeared that the 
delay between the multidisciplinary oncology meeting and surgery (median 15 days, 
reflecting the length of the operative waiting list) was the only time interval that 
influenced short-term outcome post-esophagectomy. Although in-hospital mortality 
was comparable between patients who had been on the waiting list for 15 days or 
shorter versus patients who were waiting for more than 15 days (p=0.14), length of 
the operative waiting list did influence morbidity (55.7% versus 67.1%, p=0.03) and 
a trend towards an increased reoperation rate could be noted (7.8% versus 13.9%, 
p=0.06). However, in contrast with the hospital-delay between endoscopic diagnosis 
and surgery, none of the separate time intervals affected long-term survival.
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Discussion
When initiating the current study, we hypothesized that longer delays between onset 
of symptoms, diagnosis and surgical treatment are associated with worse short-term 
outcome (in terms of morbidity, reoperation rate and mortality) and worse long-term 
outcome (overall survival) following esophagectomy for cancer. In the present series, 
it appeared that length of prehospital-delay (from onset of symptoms until endoscopic 
diagnosis) did not influence patient’s short-term outcome or overall five-year survival. 
Onset of symptoms is a subjective measurement, and it may be that patients are not 
able to recall the exact moment that they first experienced discomfort. Furthermore, 
although little information is known about the tumor doubling time of esophageal 
cancer, the period of time in which a patient is symptomatic may be relatively short 
when compared to the total period between the first presence of malignant cells in 
the esophagus and the diagnosis of esophageal cancer. Unfortunately we did not 
have information on delays caused by the GP (i.e. time between onset of symptoms 
and referral for endoscopy). Nevertheless, we do want to emphasize the importance 
of both patient and primary care education that will result in earlier notification of 
alarming symptoms such as dysphagia and weight loss.
A longer hospital-delay from endoscopic diagnosis until surgery was associated 
with higher overall morbidity and mortality. This could be explained by a more 
thorough and time-consuming diagnostic work-up in patients with a poorer physical 
status. Indeed, in the present study patients of ASA-class I and II experienced a 
shorter hospital-delay than patients of ASA-class III and IV. Alternatively, a longer 
delay prior to surgery may also have caused a worse physical status in esophageal 
cancer patients by means of malnutrition. However, this remains speculative, as our 
database did not provide detailed information with regard to patients’ preoperative 
nutritional status (e.g. nutritional risk indices). When analyzing the impact of the 
separate time intervals between patient’s first endoscopy and surgery, it appeared 
that the length of the operative waiting list was the time interval that influenced 
short-term outcome following esophagectomy the most. From the literature, it is 
also known that the quality of life in newly diagnosed esophageal cancer patients 
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who are waiting for surgery is seriously impaired.18 Hence, it should be aimed for to 
keep this time-interval to a minimum.
Our second hypothesis was that patients with longer delays would generally present 
with more advanced disease and that this relation between delay and stage would 
result in a poorer survival. However, pTNM-stages were comparable in patients 
with a hospital-delay <5 weeks, 5–8 weeks or >8 weeks between endoscopy and 
surgery. Surprisingly, it appeared that overall survival was improved in patients with 
a longer hospital-delay, although this difference was not statistically significant. This 
is in line with the results of Kötz et al. who showed that a longer delay between 
diagnosis and surgical resection was associated with improved survival in esophageal 
cancer patients.10 However, the delay between diagnosis and surgery was not an 
independent prognostic variable on multivariate analysis in their study. Kötz et al. 
noted that patients with a longer delay had a higher rate of complete tumor resection 
suggesting that they were more appropriately selected for surgical treatment.10 In our 
series we could not find evidence that patients were selected more appropriately, 
as both pTNM-stage and R0-resection rate did not differ between patients with a 
shorter or longer hospital-delay. However, hospital-delay substantially increased 
especially over the last few years in our hospital (Figure 2). This can probably explain 
the counter-intuitive correlation between longer hospital-delay and improved long-
term survival, which is rather reflecting state-of-the-art staging modalities, refined 
surgical techniques and improved intensive care that have been introduced over 
the past years. Theoretically, it could also be possible that in our hospital patients 
did not undergo surgery anymore after a longer hospital-delay in case the tumor 
progressed to a stage that was considered irresectable. However, in our patient group 
the increased hospital-delay can rather be ascribed to an increase in length of the 
operative waiting list than to an increased staging-delay. As the decision on whether 
to operate or not has been made during the multidisciplinary oncology meeting, it 
is unlikely that a longer hospital-delay led to a dropout of patients with irresectable 
tumors and, hence, a more selected patient group that underwent esophagectomy.
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It is evident that efforts are taken to minimize delays experienced by patients with 
esophageal cancer between onset of symptoms, diagnosis and surgical treatment. 
The National Health Service cancer plan was implemented in 2000 in the UK, 
indicating that all patients with relevant symptoms and suspected cancer should 
be able to see a specialist within two weeks of their GP referral. The introduction 
of these guidelines was associated with reductions in times to first outpatient visit, 
endoscopy and diagnosis in patients with upper gastrointestinal cancer (esophageal 
or gastric).19, 20 However, the effectiveness of the NHS cancer plan is uncertain, as it 
can be questioned whether the slightly improved survival rates after 2000 can be 
ascribed to this plan.21 
In our hospital, we recently introduced a new schedule of diagnostic services for 
patients with suspected esophageal cancer. It is attempted to see patients at the 
outpatient clinic of the Department of Surgery or Department of Gastroenterology 
within one week after referral. Furthermore, patients are offered all imaging 
modalities in one week, including upper gastro-intestinal endoscopy, endoscopic 
ultrasonography, CT-scanning of thorax and abdomen and external ultrasound of the 
neck. Aim of this schedule is to minimize the delay between referral to our hospital 
and establishment of a definitive treatment plan for each individual patient.
In conclusion, length of prehospital-delay (from onset of symptoms until diagnosis) 
did not affect patient’s short-term or long-term outcome. A longer hospital-delay 
(between endoscopic diagnosis and surgery) resulted in worse patient’s short-term 
outcome (higher overall morbidity and mortality rates), but not in worse long-
term outcome (overall survival). This may be explained by a more time-consuming 
diagnostic work-up in patients with a poorer physical status and not by tumor 
progression. 
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Abstract
Introduction: A nomogram has been developed recently in order to predict the 
occurrence and severity of postoperative complications after esophagectomy 
for cancer. In the present study, we externally validated this nomogram in 
a new cohort of patients who underwent esophagectomy for cancer in a 
different high-volume center. 
Methods: An independent dataset of 777 patients who underwent 
esophagectomy for cancer was used for validation. The discriminatory 
capability of the nomogram was determined by using the concordance index 
(c-statistic). Calibration was evaluated by comparing the observed with the 
expected number of patients with complications, as predicted by the original 
nomogram across patients with different risk profiles. We also examined 
whether adjusting the value of the original coefficients of the predictors or 
adding new predictors would improve the fit of the nomogram. 
Results: Discrimination of the original nomogram was similar in the validation 
cohort: the c-statistic hardly decreased from 0.65 in the original cohort to 
0.64 in the validation cohort. Observed and expected number of patients with 
complications were in close agreement, reflecting a good calibration (p=0.84). 
Re-estimation of the coefficients in the validation cohort did not lead to any 
significant changes of the original nomogram values.
Conclusion: External validation of a nomogram predicting the occurrence 
and severity of complications after esophagectomy showed that the model 
is applicable in other high-volume hospitals. Nevertheless, preoperative 
prediction of complications in individual patients remains difficult, most likely 
due to the complexity of mechanisms causing these complications.
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Introduction
Surgery is the primary curative therapy for patients with esophageal cancer. 
However, esophagectomy is associated with a high operative risk.1, 2 Although 
operative mortality is below 5% in high volume centers1, 3, esophageal resection is 
still accompanied by substantial morbidity. Early postoperative complication rates 
vary between 40% and 80%, depending on the applied criteria and on the extent of 
resection.1, 4, 5 Complications can range from minor complications (e.g. urinary tract 
infection) to major complications (e.g. respiratory failure). Several previous studies 
focused on predisposing factors for complications after esophagectomy for cancer, 
but this did not result in reliable predictive models6-10, except for the prediction of 
pulmonary complications.11 
Predicting the severity of complications after esophagectomy may supply important 
information for both patient and surgeon. The impact of postoperative complications 
on quality of life plays an important role in decision making whether to proceed 
with an operation in an individual patient with esophageal cancer. Furthermore, 
the prediction of severity of complications in the preoperative phase may help in 
choosing the extent of the operation and in informing patients. Recently, a nomogram 
has been developed to predict the occurrence and severity of complications in 
esophagectomy patients.12 A nomogram gives a graphical representation of the 
predictive strength of specific predictors and enables clinicians to calculate an overall 
risk score for individual patients reflecting their personal risk. In this nomogram the 
severity of complications was predicted at three levels: no complications, minor 
complications or severe complications. Specific patients’ characteristics (i.e. more 
advanced age, myocardial infarction, stroke or transient ischemic attack in the 
medical history, lower forced expiratory volume in one second (FEV
1
) and presence 
of electrocardiographic changes) and the application of more extensive surgery (i.e. 
transthoracic esophagectomy) were associated with a higher risk of (more severe) 
postoperative complications. 
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This new nomogram has been validated in a second group of patients within the same 
institution (temporal validation), which did not reveal any statistically significant 
changes in the predictive strength of the included prognostic factors. However, the 
power of that validation study was only moderate given the limited sample size of 
100 patients13, and validation within the same institute may not reveal inherent 
problems of a prognostic model that can become apparent when differences in 
patient populations, surgeons, applied surgical techniques and postoperative care 
between institutions are taken into account.14 Therefore, the aim of the present 
study was to externally validate this nomogram in a new and large cohort of patients 
who underwent esophagectomy for cancer in a different high-volume center. 
Patients and methods
Patients
Between January 1991 and September 2008, a consecutive series of 777 patients 
underwent a potentially curative esophagectomy for adenocarcinoma or squamous 
cell carcinoma of the esophagus or gastroesophageal junction (GEJ) in the Erasmus 
Medical Center, a tertiary referral center with wide experience in esophageal surgery. 
Patients who received neoadjuvant chemo(radio)therapy or induction chemotherapy 
were not excluded from the present study. In this hospital, patients mainly received 
neoadjuvant chemo(radio)therapy in the context of randomized controlled trials.15, 
16 Induction chemotherapy was given in patients with either a cT4-tumor without 
distant metastases or in patients with gross involvement of celiac trunk lymph nodes 
(M1a), who were not considered eligible for primary surgical therapy. Transhiatal 
esophagectomy (THE) was the preferred technique in this series of patients (N=744). 
A minority of patients (N=33) underwent transthoracic esophagectomy (TTE), mainly 
in the context of a randomized controlled trial.1, 17 Surgical techniques have been 
described before.1, 17 Clinicopathological data of all patients had been collected 
routinely in an ongoing registry. 
The Medical Ethics Committees of the participating hospitals that provided the 
derivation cohort (Academic Medical Center, Amsterdam) and the validation cohort 
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(Erasmus Medical Center, Rotterdam) have approved the ongoing registry of data of 
esophageal cancer patients in prospective databases that are managed by dedicated 
data managers.
Definitions of complications
The severity of postoperative complications was graded according to the morbidity 
scale proposed by Dindo and colleagues.18 This classification system is based on 
the therapeutic consequences of complications and consists of five grades and two 
subgrades. Grade I complications do not need any medical or surgical intervention 
(e.g. atelectasis, vocal cord paralysis, radiological anastomotic leakage). Grade 
II complications need pharmacologic treatment (e.g. pneumonia, chyle leakage, 
pulmonary embolus). Grade III complications need an intervention (grade IIIa: 
e.g. anastomotic leakage requiring drainage of the neck, pneumothorax or pleural 
empyema requiring drainage of the chest; grade IIIb: any reoperation). Grade IV 
complications are life threatening and represent single organ failure (grade IVa: 
e.g. pulmonary dysfunction requiring artificial ventilation, heart failure requiring 
intravenous inotropic agents, renal insufficiency requiring dialysis) or multiorgan 
failure (grade IVb). Finally, grade V complications are complications leading to death. 
Grading of complications was performed according to the most severe complication 
in each patient. Similar to the original study, complications were categorized into 
three groups: no complications, minor to moderate complications (grades I to IIIb) 
and severe complications (grades IVa, IVb, and V).
Statistical analysis
Clinicopathological characteristics of the derivation cohort (Academic Medical 
Center, Amsterdam) and the validation cohort (Erasmus Medical Center, Rotterdam) 
were analyzed in a descriptive way. Data on daily alcohol intake and presence of 
preoperative dyspnea were not available for the Rotterdam patients. In Rotterdam, 
weight loss was classified as a categorical value rather than a continuous variable 
(Amsterdam). 
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Ordinal logistic regression was used to examine the association between predictors 
and the occurrence of complications classified in three categories of severity (no 
complications, minor complications, severe complications). The ordinal logistic 
regression (proportional odds model) is an extension of the binary logistic regression 
model that is used in case of three or more outcome states that are naturally ordered.19 
Univariate analyses of potential predictors for the severity of complications were 
performed with the data set of the Rotterdam cohort. Because missing data result in 
loss of statistical power and can lead to possible bias, multiple imputation techniques 
were applied.20 All predictors as well as the observed outcome were used to impute 
missing values based on multivariate normal distributions using the Markov chain 
Monte Carlo method. The coefficients of ten rounds of imputations were combined 
to obtain the final estimates of odds ratios and their 95% confidence intervals. 
The nomogram predicting the occurrence and severity of complications previously 
developed in Amsterdam was validated in several ways on the Rotterdam patient 
cohort. First, discrimination was evaluated by calculating a risk score for each patient 
in the validation cohort based on the original coefficients from the derivation 
cohort. The discriminatory properties of the model were examined by visualizing 
the distribution and overlap in risk scores of individual patients within and between 
the three outcome categories. Furthermore, the discriminative capability was 
quantified by using the concordance (c) statistic. The c-statistic is a measure that 
can be interpreted as the probability among all possible pairs between patients from 
different outcome categories that the patient with the more severe complication also 
has the higher risk score. Values can range from 0.5 (due to chance, no discrimination) 
to 1.0 (perfect discrimination). We calculated c-statistics for the three categories 
(no complications versus minor complications, minor complications versus severe 
complications, no complications versus severe complications) as well as the overall 
c-statistic in the validation cohort. These data were compared with the original 
c-values in the derivation cohort.
Second, calibration was evaluated by comparing the expected and observed number 
of patients in each of the three outcome categories across seven-quantiles of 
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expected risk (i.e. seven groups of each 111 patients with an increasing mean risk 
score). Calibration was tested for significance by using an extension of the Hosmer-
Lemeshow goodness-of-fit statistic.21 
The third analysis examined whether the importance of the individual predictors or 
intercepts within the original nomogram was different in the validation cohort. For 
each predictor a proportional odds model was fitted with only that predictor using the 
risk score based on the original coefficients as an offset variable. Ideally, if the weight 
(importance) of the predictor is comparable between the validation cohort and the 
derivation cohort, the coefficient of each predictor would be zero as its weight is 
already incorporated in the risk score. The likelihood ratio test was used to indicate 
whether reweighing of the predictor will significantly improve the model. Similarly, 
potential predictors that did not significantly improve the prognostic performance 
of the original nomogram were re-evaluated in the derivation cohort whether they 
improved the prognostic performance of the model in the new cohort. 
All analyses were performed using SAS software version 9.1 (SAS Institute Inc, Cary, 
NC, USA).
Results
Clinicopathological characteristics of the two study populations are shown in Table 1. 
The groups were comparable with regard to general patient characteristics such as age, 
sex, ASA-classification, BMI and comorbidities. More patients with a tumor located 
in the proximal or mid-esophagus underwent an esophagectomy in the Amsterdam 
group, which is also reflected in the higher proportion of patients who underwent 
an extended lymphadenectomy by means of a transthoracic esophagectomy (TTE). 
The median preoperative risk score as calculated by the original nomogram was 
significantly lower in Rotterdam than in Amsterdam (0.82 versus 1.07, p<0.001), 
indicating that the case mix with respect to the presence of predictors included in 
the nomogram was more favorable in Rotterdam. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R11
R12
R13
R14
R15
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
228
Table 1. Clinicopathological characteristics and risk score of patients who underwent 
esophagectomy for cancer in Rotterdam (validation cohort) and Amsterdam 
(derivation cohort).
ROTTERDAM 
validation cohort
N=777
AMSTERDAM 
derivation cohort
N=663
age* 64 (55–70) 64 (56-71)
sex
-female
-male
150 (19%)
627 (81%)
154 (23%)
509 (77%)
ASA
-1
-2
-3
-4
117 (15%)
508 (65%)
147 (19%)
5   (1%)
112 (17%)
404 (62%)
137 (21%)
3   (0%)
BMI* 24.7 (22.5-27.4) 24.5 (21.9-26.9)
smoking 278 (36%) 275 (42%)
history pulmonary disease 99 (13%) 52 (8%)
preoperative FVC* 4.11 (3.37-4.74) 4.19 (3.43-4.95)
preoperative FEV1* 2.89 (2.29-3.50) 3.07 (2.41-3.60)
serum creatinin* 79 (69-90) 75 (64-84)
history MI 98 (13%) 44 (7%)
history stroke/TIA 34 (4%) 22 (3%)
history hypertension 209 (27%) 140 (21%)
ECG changes 58 (8%) 54 (8%)
history DM 54 (7%) 39 (6%)
neoadjuvant therapy 221 (28%) 140 (21%)
location tumor
-proximal or mid-esophagus
-distal esophagus or GEJ
72 (9%)
705 (91%)
150 (23%)
513 (77%)
type operation
-transthoracic esophagectomy
-transhiatal esophagectomy
33 (4%)
744 (96%)
239 (36%)
424 (64%)
risk score* ** 0.82 (0.51-1.16) 1.07 (0.71-1.58)
*  Values presented as median, with 25th and 75th percentiles within brackets 
**  Preoperative risk score based on the original nomogram
BMI   = body mass index
ASA   = American Society of Anesthesiologists
FVC  = forced vital capacity (lung function) 
FEV1  = forced expiratory volume in one second (lung function)
MI  = myocardial infarction
TIA  = transient ischemic attack
ECG changes = q-waves  and/or ST-T changes on electrocardiogram
DM  = diabetes mellitus 
GEJ   = gastroesophageal junction
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The frequency and severity of complications in the validation cohort (Rotterdam) and 
the derivation cohort (Amsterdam) are shown in Table 2. More patients in Rotterdam 
did not develop any complications postoperatively (40% Rotterdam versus 30% 
Amsterdam). In-hospital mortality was comparable (5% Rotterdam versus 4% 
Amsterdam). 
Table 2. Frequency and severity of complications in the Rotterdam study population 
(validation cohort) versus the Amsterdam patients (derivation cohort).
ROTTERDAM 
validation cohort
N=777
AMSTERDAM 
derivation cohort
N=663
complication category N (%) N (%)
no complications 307 (40%) 197 (30%)
minor complications
- grade I
- grade II 
- grade IIIa
- grade IIIb
367 (47%)
  90 (11%)
211 (27%)
26 (3%)
42 (5%)
354 (53%)
133 (20%)
113 (17%)
36 (5%)
  72 (11%)
severe complications
- grade IVa
- grade IVb
- grade V
103 (13%)
47 (6%)
15 (2%)
41 (5%)
112 (17%)
  71 (11%)
17 (3%)
24 (4%)
 
In the first validation step, we examined the discriminatory capability of the original 
risk score in the validation cohort. The distribution and overlap in risk scores of 
individual patients within and between the three outcome categories are shown 
in Figure 1. The mean risk scores (± SD) in the three complication categories were 
significantly different: 0.74 (±0.48) in patients without complications, 0.94 (±0.59) 
in patients with minor complications and 1.30 (±0.70) in patients with severe 
complications (p<0.001). However, there was a substantial overlap in scores between 
the three categories (Figure 1). This was also reflected in the pairwise c-statistics 
(overall measure of discriminatory capability): 0.61 for the discrimination between 
the group without complications versus patients with minor complications, 0.68 
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for the group with minor complications versus severe complications, and 0.77 for 
patients without complications versus severe complications. The overall c-statistic of 
the model in the Rotterdam validation cohort was 0.64, which was only marginally 
lower than the c-statistic (0.65) in the original Amsterdam derivation cohort12, 
reflecting a moderate individual discriminatory capability of the model.  
Figure 1. Distribution of risk score (as calculated with the original nomogram) in the patients 
of the validation cohort who experienced no complications, minor complications or severe 
complications.
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Concordance (c) statistic = a measure that can be interpreted as the probability among all 
possible between patients from different outcome categories that the patient with the more 
severe complication also has the higher risk score.
Secondly, we evaluated the calibration of the nomogram score in the validation 
cohort (i.e. the closeness of predicted and observed frequency of outcomes). In 
Figure 2 the expected number of patients in each outcome category is depicted next 
to the observed number of patients in each category, across seven equally sized 
groups of 111 patients in the validation cohort ordered according to their risk score. 
In general, there was a tendency that complications in the validation cohort occurred 
less frequently or were less severe than expected (except for group 4 in which more 
severe complications were observed than expected). These discrepancies became 
smaller when the intercepts (i.e. background risk for an individual hospital) were 
re-estimated in the validation cohort while still using the original risk score (data not 
shown). The fit of the nomogram was evaluated by means of the goodness-of-fit test 
(p=0.84), which indicated that the differences between the probabilities predicted by 
the model and the actual probabilities were small and non-significant. 
In the third validation step, we examined whether adjusting the original coefficients 
(weight) of the predictors would improve the fit of the nomogram model in the 
validation cohort. The outcome is shown in Table 3: only for the predictor age there 
was an indication (p=0.07) that a change in coefficient would improve the model. 
Furthermore, the optimal coefficients in the validation cohort did not significantly 
differ from the coefficients of the original nomogram model. Finally, predictors 
which were not incorporated in the original nomogram were re-evaluated in the 
derivation cohort in order to determine whether they might improve the prognostic 
performance of the nomogram in the new cohort. The addition of ASA classification 
(p=0.14), BMI (p=0.62), smoking (p=0.47), or application of neoadjuvant chemo(radio)
therapy (p=0.17) to the existing model did not result in a significant improvement 
in predicting the occurrence and severity of postoperative complications in the 
validation cohort.
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Figure 2. Expected (exp) versus observed (obs) number of patients in each of the three 
outcome categories (no complications, minor complications or severe complications) across 
seven-quantiles of increasing expected risk, with a p-value for goodness-of-fit of 0.84 (i.e. 
differences between observed and expected number of patients are non-significant). 
Table 3. Comparison of the importance of each predictor in the validation cohort with 
that within the derivation cohort (original nomogram). Coefficients are presented as 
odds ratios with their 95% confidence intervals in brackets.
Predictor validation 
coefficient
derivation 
coefficient
difference p-value for 
difference
age 
(one year increment)
1.04 (1.02-1.05) 1.02 (1.00-1.04) +0.02 0.07
history of MI 1.45 (0.95-2.22) 1.79 (0.96-3.32) -0.34 0.33
history of stroke/TIA 2.59 (1.32-5.12) 3.06 (1.33-7.05) -0.47 0.62
preoperative FEV1 (per l/s) 0.92 (0.76-1.11) 0.81 (0.67-0.98) +0.11 0.20
ECG changes 1.63 (0.96-2.78) 2.16 (1.23-3.81) -0.53 0.32
type of operation
(TTE versus THE)
3.50 (1.78-6.90) 2.64 (1.91-3.66) +0.86 0.42
MI  = myocardial infarction
TIA  = transient ischemic attack
FEV1  = forced expiratory volume in one second (lung function)
ECG changes = q-waves  and/or ST-T changes on electrocardiogram
TTE  = transthoracic esophagectomy
THE  = transhiatal esophagectomy
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Discussion
In the present study we externally validated a previously published nomogram 
predicting the occurrence and severity of complications in an independent cohort of 
patients who underwent esophagectomy for cancer in a different high-volume center.12 
This nomogram had been developed to assist surgeons in assessing preoperatively 
the risk of complications after esophagectomy. In the original nomogram, there was a 
considerable overlap in nomogram scores between patients with no, minor or severe 
complications (i.e. moderate discriminative capability), despite the identification of 
several factors associated with postoperative complications.12 It was concluded that 
the complication nomogram could be of value if an adequate performance of the 
model would be examined in other settings (hospitals) with possible differences in 
case mix, surgical procedures and perioperative care. 
The clinicopathological characteristics of patients undergoing esophagectomy for 
cancer in the validation cohort in Rotterdam and the derivarion cohort in Amsterdam 
were comparable with regard to potential prognostic factors such as age, ASA 
classification, BMI and comorbidities (Table 1). However, the median preoperative 
risk score as calculated by the original nomogram was significantly lower in Rotterdam 
than in Amsterdam. Apparently, the preoperatively determined risk factors were 
more prevalent in Amsterdam. An other explanation could be the fact that a TTE was 
performed more often in the original cohort (36% Amsterdam versus 4% Rotterdam). 
The weight or importance of the predictor operation technique in the validation 
cohort did not significantly differ from that in the original nomogram, but it can 
be questioned whether the power of this parameter in the validation cohort was 
sufficient to evaluate this issue adequately. Overall, no large differences in grades 
of complications impeded an adequate evaluation of the two patient cohorts in this 
study (Table 2), although the comparison of occurrence and severity of complications 
between hospitals is subject to bias because of variable definitions of complications 
and different scoring systems. 
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When analyzing the discriminatory capability of the original risk score in the validation 
cohort, it appeared that the mean risk scores in the three outcome categories 
were significantly different, but a substantial overlap in scores between the three 
categories was noted (Figure 1). This was also reflected in the pairwise c-statistics 
between the three complication categories, and the overall moderate discriminative 
power of the model (0.64 in the validation cohort, 0.65 in the derivation cohort). 
Apparently, patient related factors are not the only determinators responsible for 
developing complications after esophageal cancer surgery. The intraoperative course 
(e.g. fluid management by the anesthetist22, 23 and surgical complications resulting in 
a longer operative time or more blood loss2) as well as the early postoperative phase 
(e.g. application and effectiveness of epidural analgesia24-26) will also influence the 
final outcome of patients who undergo esophagectomy for cancer. However, these 
factors cannot be predicted in a preoperative risk assessment. 
Nevertheless, the overall fit of the model and the calibration of the nomogram score 
in the validation cohort (i.e. the closeness of predicted and observed frequency of 
outcomes) were good: the predictions for groups of patients with a similar risk profiles 
matched the observed probabilities (Figure 2). The expected frequency of patients 
with no or minor complications was higher than expected on basis of the nomogram, 
while these differences improved after adjusting the intercept (i.e. background risk 
for the new cohort) suggesting that the general level of complications was lower 
in the validation cohort. One could hypothesize that this may reflect differences in 
postoperative care between the two hospitals (e.g. more specialized ICU-care and 
faster detection of complications, preventing an increase in complication grade). On 
the other hand it can be questioned whether the complication registration in the 
validation cohort was as efficient and complete as in the derivation cohort. 
 
Despite the complexity of mechanisms that can lead to the development of 
complications (preoperative, intraoperative and early postoperative factors as 
well as intrinsic (patient-related) and extrinsic (hospital-related) elements) and 
the subjectivity in the registration of complications, the optimal coefficients of 
the prognostic factors in the validation cohort did not significantly differ from 
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the coefficients of the original nomogram model. This indicates that the current 
nomogram is applicable in other high-volume hospitals performing esophagectomies 
for cancer. The model can give a preoperatively estimated risk of the occurrence 
and severity of postoperative complications. Furthermore, as we have shown that 
adequate model performance can be achieved, this model can be used to adjust for 
case-mix when comparing hospital performances: the nomogram can play a role in 
the risk-adjusted audit of morbidity after esophagectomy for cancer.
In conclusion, a recently developed nomogram predicting the occurrence and 
severity of complications was externally validated in a new cohort of patients 
who underwent esophagectomy for cancer in a different high-volume center. The 
model showed good overall calibration when applied in the validation cohort. Re-
estimating the coefficients of the prognostic factors within the nomogram in the 
validation cohort did not reveal significant improvement compared to the original 
values. Nevertheless, preoperative prediction of complications in individual patients 
remains difficult, most likely due to the complexity of mechanisms causing these 
complications.
Acknowledgment
The authors are indebted to Mrs. C.M. Vollebregt-Uiterwijk for her dedicated 
prospective collection of data.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R11
R12
R13
R14
R15
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
236
References
 1. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited 
transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347(21):1662-9.
 2. Whooley BP, Law S, Murthy SC, et al. Analysis of reduced death and complication rates after esophageal 
resection. Ann Surg 2001; 233(3):338-44.
 3. Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical 
therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000; 
232(3):353-61.
 4. Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of 
the esophagus: a meta-analysis. Ann Thorac Surg 2001; 72(1):306-13.
 5. Swisher SG, Deford L, Merriman KW, et al. Effect of operative volume on morbidity, mortality, and hospital use 
after esophagectomy for cancer. J Thorac Cardiovasc Surg 2000; 119(6):1126-32.
 6. Abunasra H, Lewis S, Beggs L, et al. Predictors of operative death after oesophagectomy for carcinoma. Br J Surg 
2005; 92(8):1029-33.
 7. Gockel I, Exner C, Junginger T. Morbidity and mortality after esophagectomy for esophageal carcinoma: a risk 
analysis. World J Surg Oncol 2005; 3:37.
 8. Law S, Wong KH, Kwok KF, et al. Predictive factors for postoperative pulmonary complications and mortality 
after esophagectomy for cancer. Ann Surg 2004; 240(5):791-800.
 9. Sauvanet A, Mariette C, Thomas P, et al. Mortality and morbidity after resection for adenocarcinoma of the 
gastroesophageal junction: predictive factors. J Am Coll Surg 2005; 201(2):253-62.
 10. Avendano CE, Flume PA, Silvestri GA, et al. Pulmonary complications after esophagectomy. Ann Thorac Surg 
2002; 73(3):922-6.
 11. Ferguson MK, Durkin AE. Preoperative prediction of the risk of pulmonary complications after esophagectomy 
for cancer. J Thorac Cardiovasc Surg 2002; 123(4):661-9.
 12. Lagarde SM, Reitsma JB, Maris AK, et al. Preoperative prediction of the occurrence and severity of complications 
after esophagectomy for cancer with use of a nomogram. Ann Thorac Surg 2008; 85(6):1938-45.
 13. Vergouwe Y, Steyerberg EW, Eijkemans MJ, Habbema JD. Substantial effective sample sizes were required for 
external validation studies of predictive logistic regression models. J Clin Epidemiol 2005; 58(5):475-83.
 14. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000; 19(4):453-73.
 15. Kok TC, van Lanschot JJ, Siersema PD, van Overhagen H, Tilanus HW. Neoadjuvant chemotherapy in operable 
esophageal squamous cell cancer: final report of a phase III multicenter randomized controlled trial. Proc Am 
Soc Clin Oncol 1997; 17:984.
 16. van Heijl M, van Lanschot JJ, Koppert LB, et al. Neoadjuvant chemoradiation followed by surgery versus surgery 
alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg 2008; 
8:21.
 17. Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal 
resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann 
Surg 2007; 246(6):992-1000.
 18. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a 
cohort of 6336 patients and results of a survey. Ann Surg 2004; 240(2):205-13.
 19. Hosmer DW LS. Applied Logistic Regression. New York: Wiley, 2000.
 20. Arnold AM, Kronmal RA. Multiple imputation of baseline data in the cardiovascular health study. Am J Epidemiol 
2003; 157(1):74-84.
 21. Pulkstenis E, Robinson TJ. Goodness-of-fit tests for ordinal response regression models. Stat Med 2004; 
23(6):999-1014.
 22. Kita T, Mammoto T, Kishi Y. Fluid management and postoperative respiratory disturbances in patients with 
transthoracic esophagectomy for carcinoma. J Clin Anesth 2002; 14(4):252-6.
 23. Neal JM, Wilcox RT, Allen HW, Low DE. Near-total esophagectomy: the influence of standardized multimodal 
management and intraoperative fluid restriction. Reg Anesth Pain Med 2003; 28(4):328-34.
 24. Flisberg P, Tornebrandt K, Walther B, Lundberg J. Pain relief after esophagectomy: Thoracic epidural analgesia is 
better than parenteral opioids. J Cardiothorac Vasc Anesth 2001; 15(3):282-7.
 25. Rudin A, Flisberg P, Johansson J, et al. Thoracic epidural analgesia or intravenous morphine analgesia after 
thoracoabdominal esophagectomy: a prospective follow-up of 201 patients. J Cardiothorac Vasc Anesth 2005; 
19(3):350-7.
 26. Cense HA, Lagarde SM, de Jong K, et al. Association of no epidural analgesia with postoperative morbidity and 
mortality after transthoracic esophageal cancer resection. J Am Coll Surg 2006; 202(3):395-400.
 27. van Sandick JW, Gisbertz SS, ten Berge IJ, et al. Immune responses and prediction of major infection in patients 
undergoing transhiatal or transthoracic esophagectomy for cancer. Ann Surg 2003; 237(1):35-43.
13
Surgical management of submucosal 
esophageal cancer: extended or regional 
lymphadenectomy?
Brechtje A Grotenhuis
Mark van Heijl
Joerg Zehetner
Johnny Moons
Bas PL Wijnhoven
Mark I van Berge Henegouwen
Hugo W Tilanus
Tom R DeMeester
Toni Lerut
J Jan B van Lanschot
Annals of Surgery – in press
R1
R2
R3
R4
R5
R6
R7
R8
R9
R11
R12
R13
R14
R15
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
238
Abstract
Introduction: Radical esophagectomy is considered the standard therapy 
for tumors that infiltrate the submucosa of the esophagus (T1b) as the 
prevalence of lymph node metastases has been reported in up to 40% of these 
patients. It remains unclear whether a radical esophagectomy with extended 
lymphadenectomy is needed or whether a surgical procedure with only 
regional lymphadenectomy suffices. The aim of this study was to compare 
outcome of patients who underwent esophagectomy for T1b cancer through 
a transthoracic approach with extended lymphadenectomy (TTE), with that of 
patients in whom a transhiatal esophagectomy (THE) was performed with a 
regional lymph node dissection.
Methods: Patients who underwent esophagectomy for T1b cancer between 
1990 and 2004 and who did not receive (neo) adjuvant therapy were 
included. Data were collected from prospective databases of four centers. 
In Leuven, Belgium (n=101) and Los Angeles, USA (n=31), patients with T1b-
tumors had been operated via TTE with extended lymphadenectomy while in 
Amsterdam (n=43) and Rotterdam (n=47), The Netherlands, THE with regional 
lymphadenectomy had been performed. 
Results: The two patient groups (TTE, n=132; THE, n=90) were comparable 
with regard to age, BMI and ASA classification. Operative time was longer in 
patients who underwent TTE (390 minutes) versus THE (250 minutes; p<0.001). 
The yield of lymph nodes resected was higher in the TTE group (median 32) 
versus THE (median 10); p<0.001. Overall morbidity, in-hospital mortality 
and length of hospital stay were comparable between both groups. In the 
TTE-group 27.3% of complications were classified as major versus 14.4% in 
the THE-group (p<0.001) however the reoperation rate was higher after THE 
(12.2%) versus TTE (3.8%, p=0.01). There was no difference in pathological 
outcome (infiltration depth, pN-stage, pM-stage, positive lymph node ratio) 
between both groups. Overall five-year survival (63.4% TTE versus 69.4% THE, 
p=0.55) and disease-free five-year survival (76.9% TTE versus 78.3% THE, 
p=0.65) were comparable between both groups. In patients with N1 disease, 
disease-free five-year survival was 49.8% in the TTE-group versus 40.0% in the 
THE-group (p=0.57).
Conclusions: In patients with submucosal esophageal cancer (T1b), TTE with 
extended lymphadenectomy and THE with regional lymphadenectomy had 
similar short-term outcome and long-term survival. In the selected group 
of T1bN1 patients TTE may be the preferred operative technique due to a 
potential disease-free survival benefit; in patients with T1bN0 disease THE 
with en bloc dissection of the esophagus and regional lymph nodes offers an 
oncologically safe and less invasive treatment.
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Introduction
The management of early esophageal cancer is controversial. Current treatment 
options range from endoscopic organ preserving mucosal resection or limited surgical 
resection with or without regional lymphadenectomy to radical esophagectomy 
with extended lymphadenectomy.1-3 Complete macroscopic and microscopic tumor 
resection with an adequate tumor free margin and removal of all potentially involved 
lymph nodes are known to be key factors for cure. It would therefore be helpful to 
have greater insight into the relationships between the stage of disease, the extent 
of the surgical procedure and outcome. 
Lymph node metastases are very rare in patients with esophogeal carcinoma 
limited to the mucosa.4-7 In contrast, the prevalence of lymph node metastases in 
patients with submucosal tumor infiltration (T1b), is 20-25% in adenocarcinomas 
and can be up to 40% in squamous cell carcinomas.2, 4-6, 8-10 Therefore, endoscopic 
treatment options are reserved for patients with strictly mucosal disease. A surgical 
esophagectomy is still considered the standard therapy for tumors that extend into 
the submucosa.3, 11, 12    
At present, it is unclear whether an esophagectomy with extended lymphadenectomy 
is needed or if a surgical procedure with regional lymphadenectomy may suffice in 
order to obtain optimal outcome for patients with T1b esophageal cancer.13 Extended 
lymphadenectomy is believed to prolong the recurrence-free period, but it has the 
major disadvantages of being more invasive with concomitant higher morbidity.14, 
15 On the other hand, the five-year recurrence-free survival of patients with early 
tumors and lymph nodal invasion after a transhiatal resection with limited regional 
lymphadenectomy has been reported to be as low as 35%.4, 9 Thus a more extended 
lymphadenectomy by means of a transthoracic approach might be justified, if it leads 
to a higher chance for cure or a prolonged disease free survival notwithstanding a 
potentially higher surgical complication rate. 
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The aim of the present study was to compare short-term and long-term outcomes 
of patients who underwent esophagectomy for cancer with submucosal tumor 
infiltration (T1b) through a transthoracic approach with extended lymphadenectomy, 
to those of patients in whom a transhiatal esophagectomy was performed with only 
regional lymph node dissection. To address this issue, data were collected from 
four large expert centers, where patients with submucosal esophageal cancer had 
been operated predominantly either through the transthoracic route (Leuven, Los 
Angeles) or through the transhiatal route (Amsterdam, Rotterdam). 
Patients and methods
Patients
Patients with squamous cell carcinoma or adenocarcinoma of the esophagus or 
gastroesophageal junction with infiltration into the submucosa were included. Only 
patients who did not receive (neo) adjuvant chemo- and/or radiotherapy and of 
whom complete five-year follow-up data were available were included. Patients with 
submucosal cancer of the cervical or proximal thoracic esophagus were excluded, 
as a transhiatal resection is generally considered inappropriate under these 
circumstances. Staging routinely included CT scanning of thorax and abdomen and 
external ultrasound of the neck. Endoscopic ultrasonography (EUS) was incorporated 
in staging as it became available in the four centers.
In total, 248 patients met the inclusion criteria in four centers (Leuven – Belgium, Los 
Angeles – USA, Amsterdam and Rotterdam – The Netherlands). Over a 14-year period 
(May 1990 – June 2004), these patients underwent transthoracic esophagectomy 
(TTE) or transhiatal esophagectomy (THE) for cancer limited to the submucosa (T1b) 
and located below the carina. TTE was the preferred operation technique in Leuven 
(TTE, n=101) and Los Angeles (TTE, n=31; THE, n=15), whereas THE was preferred 
in Amsterdam (THE, n=43; TTE, n=9) and Rotterdam (THE, n=47; TTE, n=2). To avoid 
selection bias (especially in patients who underwent THE in Los Angeles because of 
severe co-morbidities that precluded a thoracotomy), only patients who underwent 
TTE in Leuven (n=101) or Los Angeles (n=31) were included. In Amsterdam and 
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Rotterdam a few patients underwent TTE in the context of a randomized controlled 
trial (n=11), in which the outcome of patients with adenocarcinoma of the 
esophagus or gastroesophageal junction who underwent extended transthoracic 
esophagectomy was being compared to the outcome of those in whom limited 
transhiatal esophagectomy was performed.15, 16 To minimize the number of hospitals 
per treatment arm (TTE versus THE), only patients who underwent THE in Amsterdam 
(n=43) and Rotterdam (n=47) were included in the present study. Thus, it was possible 
to compare short- and long-term outcome for patients with T1b esophageal cancer 
who had been operated upon by either TTE (n=132) or THE (n=90).
Surgery
A thoracotomy was the first step in a transthoracic esophagectomy with extended 
lymphadenectomy (n=132). The surgical techniques used in Leuven (left thoraco-
abdominal approach in 87 patients and right posterolateral thoracotomy in 14 
patients) and in Los Angeles (right posterolateral thoracotomy) have been described 
previously.17-20 The thoracic duct, ipsilateral pleura, and all periesophageal tissue in 
the posterior mediastinum were dissected en bloc. The resection specimen included 
the lower and middle mediastinal, subcarinal, and paratracheal lymph nodes. The 
aortopulmonary-window nodes were dissected separately. Through a midline 
laparotomy or left-sided thoracotomy with peripheral phrenotomy, the paracardial, 
lesser curvature, left-gastric-artery, celiac trunk, common-hepatic-artery, and splenic-
artery nodes were dissected, and a gastric tube was constructed. The cervical phase 
of the transthoracic procedure was identical to the transhiatal procedure, unless a 
formal cervical lymphadenectomy was performed (three-field lymphadenectomy).17 
The surgical technique for THE (N=90) performed in Amsterdam as well as in 
Rotterdam has been described previously.15, 16 In short, the primary tumor and 
its adjacent lymph nodes were dissected en bloc under direct vision through the 
widened hiatus of the diaphragm up to the level of the inferior pulmonary vein. 
Subsequently, a gastric tube was created. The left gastric artery was transected at its 
origin, with resection of celiac trunk lymph nodes. After mobilization and transection 
of the cervical esophagus, the intrathoracic esophagus (up to the level of the inferior 
pulmonary vein) was mobilized with a vein stripper. Esophagogastrostomy was 
performed in the neck, without a formal cervical lymphadenectomy. 
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Tumors were assigned pathologic tumor-node-metastasis stages according to 
the tumor–node–metastasis (TNM) cancer staging system of the American Joint 
Committee on Cancer and the International Union for Cancer Control.21 Based on 
the depth of invasion, submucosal lesions were classified by expert pathologists as 
sm1 for tumors invading the more superficial layer of the submucosa (corresponding 
to one-third of its thickness), sm2 for those invading the middle-third, and sm3 for 
those invading the deeper submucosal layer.22 
Data collection
Data in all four centers were collected prospectively.. Severity of complications was 
scored according to Dindo et al.23 Retrospectively, complications were classified as 
minor (grade 1, 2, 3a) or major (grade 3b, 4a, 4b, 5). Patient outcome was recorded 
until April 2009 or until death if earlier, ensuring a follow-up of at least five years. 
Disease recurrence was primarily suspected on clinical grounds, which lead to further 
investigations. Recurrence was defined as locoregional or distant metastatic disease 
when radiologically or pathologically proven.
Statistics
Data-analysis was carried out with SPSS version 15.0 (SPSS, Chicago, IL, USA). 
Statistical analysis appropriate for non-parametric data was used. Grouped data 
were compared using the Chi-Square, Mann-Whitney U or Kruskall-Wallis H test 
when appropriate. Overall survival was calculated from the date of operation until 
the date of last follow-up or death according to the Kaplan-Meier method. Patients 
who died due to complications following esophagectomy (in-hospital mortality) as 
well as deaths from all causes during follow-up were not excluded from survival-
analysis. The primary endpoint in the present study was disease-free survival, which 
was assessed from the date of operation until the date of disease recurrence in case 
of locoregional recurrence or distant metastases; patients were censored at the time 
of their last visit or when they died of non-disease related causes without a previous 
relapse. Univariate analyses were performed to identify prognostic variables 
associated with disease-free survival after esophagectomy. Variables achieving a 
probability of less than 0.10 in univariate analysis were introduced in a multivariate 
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proportional-hazard analysis (Cox model) to identify those variables independently 
associated with disease-free survival. Results are given as hazard ratios (HR) or 
relative risks with their 95% confidence interval (CI). 
Results
Patients’ characteristics are shown in Table 1. The two groups were comparable with 
regard to age, BMI, ASA-classification, but there were significantly more females in 
the TTE-group. Early cancer was predicted correctly more often in the TTE-group 
(cT1-stage 45.5% versus 33.3% in the THE-group, p=0.01); preoperative lymph node 
status was comparable between both groups. In patients operated through the 
transthoracic route, more squamous cell carcinomas were seen (p<0.001) and more 
tumors were located in the mid-esophagus than in patients who underwent THE.
Operative time was significantly longer in the TTE-group (median 390 minutes, range 
240-780) when compared to that in the THE-group (median 250 minutes, range 141-
468; p<0.001). Intraoperative complications occurred in eleven patients (7.9%) in 
the TTE-group (myocardial infarction or splenectomy), and in four patients (4.4%) 
in the THE-group (ventricular fibrillation or splenectomy; p=0.25). Median length of 
hospital stay did not differ between both groups (16 days in both groups, p=0.26). 
Postoperative short-term outcome is shown in Table 2. Overall morbidity was 
comparable for both groups (TTE 45.5% versus THE 55.6%; p=0.14). However, 
when the grade of complications was taken into account, it appeared that more 
complications were classified as major in patients operated through the transthoracic 
route (27.3% versus THE 14.4%; p<0.001) (Table 2) Vocal cord paralysis occured more 
often in the THE-group, whereas more patients in the TTE-group required prolonged 
ventilation or re-intubation due to respiratory insufficiency. Reoperation rate was 
higher for patients in whom a limited lymphadenectomy was performed (TTE 3.8% 
versus THE 12.2%; p=0.01). In-hospital mortality was comparable for both groups 
(TTE 4.5% versus THE 4.4%, p=0.97). 
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Table 1. Clinical characteristics of 222 patients who underwent primary surgical 
resection by TTE or THE for esophageal cancer limited to the submucosa.
TTE 
(N=132)
THE 
(N=90)
p-value
Age* 63 years (37-85) 66 years (40-83) 0.29
Gender
- Male
- Female
100 (75.8%)
32   (24.2%)
79 (87.8%)
11 (12.2%)
0.03
Body Mass Index* 25.4 kg/m2 (16.7-45.4) 25.4 kg/m2(17.2-37.3) 0.55
ASA classification
- I/II
- III/IV
- Unknown
86 (65.2%)
37 (28.0%)
9     (6.8%)
66 (73.3%)
19 (21.1%)
5     (5.6%)
0.49
Preoperative T-stage**
- cTx
- cT1
- cT2-3
12   (9.1%)
60 (45.5%)
60 (45.4%)
15 (16.7%)
30 (33.3%)
45 (50.0%)
0.01
Preoperative N-stage**
- cN0
- cN1
95 (72.0%)
37 (28.0%)
73 (81.1%)
17 (18.9%)
0.12
Histology
-Squamous cell carcinoma
-Adenocarcinoma
46 (34.8%)
86 (65.2%)
12 (13.3%)
78 (86.7%)
<0.001
Tumor location
- Mid-esophagus
- Distal esophagus
- GE-junction 
33 (25.0%)
75 (56.8%)
24 (18.2%)
8     (8.9%)
47 (52.2%)
35 (38.9%)
<0.001
Barrett’s metaplasia
- Yes
- No
74 (56.1%)
58 (43.9%)
60 (66.7%)
30 (33.3%)
0.11
*  Values presented as median (range in brackets)
**  Preoperative T- and N-stage as determined by endoscopic ultrasound. In case the 
endoscopic ultrasound had not been incorporated in the staging procedure, the 
tumor was diagnosed as cTx and its N-stage was determined by CT-scanning.
ASA classification = American Society of Anesthesiologists classification
GE-junction = gastroesophageal junction
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Table 2. Postoperative complications and in-hospital mortality in relation to operation 
technique (TTE versus THE) in 222 patients who underwent primary surgical resection 
for submucosal esophageal cancer.
TTE 
(N=132)
THE 
(N=90)
p-value
Overall morbidity 60 (45.5%) 50 (55.6%) 0.14
Severity of complications*
- Minor
- Major
24 (18.2%)
36 (27.3%)
37 (41.1%)
13 (14.4%) <0.001
Surgical complications
- Bleeding
- Chyle leakage
- Anastomotic leakage
- Vocal cord paralysis
- Wound infection
2 (1.5%)
1 (0.8%)
11 (8.3%)
2 (1.5%)
8 (6.1%)
2 (2.2%)
2 (2.2%)
12 (13.3%)
9 (10.0%)
5 (5.6%)
0.70
0.35
0.23
<0.01
0.88
Non-surgical complications
- Sepsis
- Pneumonia 
- Respiratory insufficiency**
- Pleural effusion requiring drainage
- Myocardial infarction
- Thromboembolism
4 (3.0%)
37 (28.0%)
23 (17.4%)
11 (8.3%)
2 (1.5%)
10 (7.6%)
2 (2.2%)
21 (23.3%)
5 (5.6%)
4 (4.4%)
3 (3.3%)
2 (2.2%)
0.72
0.43
0.01
0.26
0.37
0.08
Re-operation 5 (3.8%) 11 (12.2%) 0.01
In-hospital mortality 6 (4.5%) 4 (4.4%) 0.97
Median length of hospital stay (range) 16 days (9 – 132) 16 days (1 – 171) 0.26
 
Severity of complications as determined by Dindo23:
Minor complications (grade 1, 2, 3a, 3b) versus major complications (grade 4a, 4b, 5)
** Respiratory insufficiency was defined as pulmonary dysfunction requiring prolonged 
ventilation (>10 days) or re-intubation.* 
Histopathological assessment (Table 3) showed no differences in pT-stage (tumor 
infiltration depth) or pN-stage (lymph node involvement) between both groups, 
despite a higher number of harvested lymph nodes in the TTE-group (mean 32 lymph 
nodes versus 10 lymph nodes in the THE-group, p<0.001). Lymph nodal status was 
related to infiltration depth of the tumor: in 9.9% of sm1-patients positive lymph 
nodes were found, while 28.8% of sm2 patients and 45.2% of sm3 patients were 
diagnosed with N1-status. Histology type did not influence pN-stage: 24.1% of 
patients with squamous cell carcinoma were lymph node positive versus 25.6% of 
patients with adenocarcinoma.  
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Table 3. Histopathological assessment of the resection specimens in relation to 
operation technique (TTE versus THE) in 222 patients who underwent primary 
surgical resection for submucosal esophageal cancer.
TTE 
(N=132)
THE 
(N=90)
p-value
pT-status
- sm1
- sm2
- sm3
- unspecified
64 (48.5%)
25 (18.9%)
36 (27.3%)
7 (5.3%)
37 (41.1%)
27 (30.0%)
26 (28.9%)
0 (0.0%)
0.19
pN-status
- N0
- N1
97  (73.5%)
35  (26.5%)
69 (76.7%)
21 (23.3%)
0.59
pM-status
- M0
- M1
122 (92.4%)
10 (7.6%)
86 (95.6%)
4 (4.4%)
0.35
Differentiation grade
- G1 (good)
- G2 (moderate)
- G3 (poor)
13 (19.8%)
60 (45.4%)
59 (44.7%)
13 (14.4%)
49 (54.4%)
28 (31.1%)
0.10
Type resection
- R0
- R1
132 (100.0%)
0 (0.0%)
88 (97.8%)
2 (2.2%)
0.09
Number positive lymph nodes*  1 (0 – 31) 1 (0 – 8) 0.40
Total number harvested lymph nodes* 32 (1 – 104)  10 (1 – 28) <0.001
Lymph node ratio* 0.04 (0 – 1.00) 0.06 (0 – 0.60) 0.92
*Values presented as mean (range in brackets)
Lymph node ratio = number of positive nodes / total number of harvested nodes
Ten patients who underwent an extended lymphadenectomy were classified 
postoperatively as M1 because of positive lymph nodes in the cervical (N=9) and/
or lower abdominal lymph node stations below the superior mesenteric artery 
(N=4). Location of positive lymph nodes in relation to histology type and operation 
technique is shown in Table 4. No patients with squamous cell carcinoma who 
underwent THE showed positive lymph nodes. In 12 of 35 (34%) patients with N1 
disease who underwent TTE with extended lymphadenectomy, positive lymph nodes 
were located high in the mediastinum (6 adenocarcinomas and 6 squamous cell 
carcinomas). Five of these 12 patients were initially staged as cN0 and seven as cN1.
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Table 4. Location of positive lymph nodes in 56 patients diagnosed with pN1-stage, 
in relation to histology and operation technique (patients can have positive nodes in 
more than one location).
Cervical Thoracic Abdominal- 
regional
Abdominal- 
distant
Squamous cell carcinoma
TTE (N=14) 6 7 8 2
THE (N=0) 0 0 0 0
Adenocarcinoma
TTE (N=21) 3 9 15 2
THE (N=21) 0 0 21 0
 
Median survival time was 124 months (range 0-209 months). For both groups 
combined, overall and disease-free five-year survival rates were 65.8% and 77.5%, 
respectively. Disease-free five-year survival was influenced by depth of tumor 
infiltration (sm1 89.2%, sm2 76.1%, sm3 58.1%, p<0.001), but did not depend on 
histology (squamous cell carcinoma 79.5% versus adenocarcinoma 76.7%, p=0.47). 
Disease-recurrence was noted in 46 patients (20.7%): TTE 21.2% versus THE 20.0% 
(p=0.83). Type of recurrence was comparable: 9.8% locoregional recurrence and 
14.4% distant metastases in the TTE-group versus 12.2% and 13.3%, respectively, 
in the THE-group. Overall five-year survival (TTE 63.4% versus THE 69.4%, p=0.55; 
Fig 1A) or disease free survival (TTE 76.9% versus THE 78.3%, p=0.65; Fig 1B) did not 
differ between the two groups. In the subgroup of patients with adenocarcinoma (Fig 
2), disease-free five-year survival was also similar for both groups (TTE 77.3% versus 
THE 76.2%, p=0.81). For the subset of patients with N1 disease disease-free five-year 
survival was 49.8% in the TTE-group versus 40.0% in the THE-group; p=0.57 (Fig 3). 
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Figure 1A-B. Overall survival (1A) and disease-free survival (1B) in relation to operation 
technique (TTE versus THE) in 222 patients who underwent primary surgical resection for 
submucosal esophageal cancer.
Figure 1A.
No. at risk 0 months 12 months 24 months 36 months 48 months 60 months
TTE 132 113 97 86 79 73
THE 90 84 74 64 55 51
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Figure 1B.
No. at risk 0 months 12 months 24 months 36 months 48 months 60 months
TTE 132 108 90 86 73 68
THE 90 78 69 61 53 49
Figure 2. Disease-free survival in relation to operation technique (TTE versus THE) in 164 patients 
who underwent primary surgical resection for submucosal esophageal adenocarcinoma.
No. at risk 0 months 12 months 24 months 36 months 48 months 60 months
TTE 86 69 59 52 46 44
THE 78 66 59 52 44 40
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Follow-up in months
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Figure 3. Disease-free survival in relation to operation technique (TTE versus THE) in 56 patients 
who underwent primary surgical resection for submucosal esophageal cancer in whom positive 
lymph nodes were found (pN1).
No. at risk 0 months 12 months 24 months 36 months 48 months 60 months
TTE 35 25 18 16 14 12
THE 21 15 12 9 6 5
Parameters found to be associated with disease-free survival in univariate analyses 
are shown in Table 5. Infiltration depth of the tumor, lymph node involvement (pN-
stage), distant metastatic disease (pM-stage), and lymph node ratio were related to 
survival. On multivariate analysis, pN-stage was the only independent prognostic 
variable for disease-free survival (HR 3.9, 95% CI 1.6 – 9.7; p=0.004). Infiltration 
depth of the tumor (entered as a categorical variable, with sm1 as the reference 
category) appeared to be a borderline independent prognostic factor (sm2 HR 1.2, 
95% CI 0.5 – 3.1; sm3 HR 2.3, 95% 1.1 – 5.1; p=0.07). 
p=0.57
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Table 5. Univariate analyses of variables associated with disease-free survival in 
esophageal cancer patients who underwent surgical resection.
VARIABLE FIVE-YEAR SURVIVAL p-value
Type of surgery
-TTE
-THE
76.9%
78.3%
0.65
Gender
- Male
- Female
76.0%
83.7%
0.24
Age
≤ 64 years
> 64 years
75.2%
80.4%
0.59
ASA classification
- I / II
- III / IV
77.7%
76.5%
0.93
Location of the tumor
- Mid-esophagus
- Distal esophagus / GEJ / gastric cardia
82.1%
76.5%
0.59
Histology
- Squamous cell carcinoma 
- Adenocarcinoma
79.5%
76.7%
0.47
Tumor infiltration depth
- sm1
- sm2
- sm3
89.2%
76.1%
58.1%
<0.001
pN-stage
- N0
- N1
88.4%
45.7%
<0.001
pM-stage
- M0 
- M1
78.3%
64.2%
0.07
Lymph node ratio
≤ 0.05
>0.05
86.4%
46.0%
<0.001
Differentiation grade tumor
- G1 (good)
- G2 (moderate)
- G3 (poor)
83.0%
79.1%
72.3%
0.29
ASA Classification  = American Society of Anesthesiologists Classification
GEJ  = Gastroesophageal junction
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Discussion
Long-term outcome in terms of overall and disease-free five-year survival (68.6% and 
77.5%, respectively) in the present series are at the upper limits of reported survival 
rates for submucosal esophageal cancer (33-79%).13 Lymphatic dissemination was 
related to infiltration depth of the tumor, which is known to decrease patients’ 
disease-free survival.4, 5, 7, 24 Some previous reports have indicated considerably higher 
rates of lymph node involvement and worse disease-free survival inpatients with 
early squamous cell carcinomas.5, 6, 24 However, in the present study the results of 
both submucosal adenocarcinomas and squamous cell carcinomas were combined as 
histology type did not influence pN-stage, M-stage or patients’ disease-free survival. 
The aim of the present study was to compare short-term and long-term outcomes 
of patients who underwent esophagectomy for cancer with submucosal tumor 
infiltration (T1b) through a transthoracic approach with extended lymphadenectomy, 
to those of patients in whom a transhiatal esophagectomy was performed with 
regional lymph node dissection. With regard to the short-term outcome, a well-
known disadvantage of an extended lymphadenectomy is its surgical invasiveness at 
the cost of increased postoperative morbidity particularly pulmonary complications14, 
15 In the present study, overall morbidity was comparable for both groups, but more 
complications were classified as major in patients operated through the transthoracic 
route. This was mainly due to a higher rate of post operative respiratory insufficiency, 
which is in line with the corresponding literature.14, 15 On the other hand, a higher 
incidence of reoperations was noted in the THE group.
A transthoracic approach may be justified if it leads to improved survival. To date 
only one study has shown a favorable long-term outcome in patients with T1b 
carcinoma operated through extended radical esophagectomy (including three-
field lymphadenectomy) compared to a less radical esophagectomy (described as 
‘lesser extent of esophagectomy and lesser extent of lymphadenectomy’).9 However, 
the number of included patients in that particular study was small (n=78) and 30% 
received adjuvant chemo- or radiotherapy. In the present larger study (n=222), 
disease-free survival and overall five-year survival did not differ between the two 
groups.
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The observation that TTE leads to an increased number of severe complications but 
not to improved survival in the current study population suggests that the transhiatal 
approach with regional lymphadenectomy is the preferred operation technique in 
patients with T1b esophageal cancer. Nevertheless, one should take into account 
that the survival curves in the present study include the total population of patients, 
of whom the majority (75%) did not have lymph nodal involvement. pN0-patients are 
unlikely to benefit from an extended lymphadenectomy. However, in the subgroup 
of pN1-patients, a disease-free five-year survival difference of 9.8% was detected in 
favor of an extended lymphadenectomy (TTE 49.8% versus THE 40.0%, p=0.57). Due 
to the relatively small number of T1bN1 patients (n=56), the fact that this difference 
did not reach statistical significance may represent a type-II error as other larger 
studies have found a relationship between the number of resected and positive lymph 
nodes on long-term outcome after esophagectomy for cancer.16, 25, 26 In particular 
the subgroup analysis of a Dutch RCT, in which it was shown that in patients with 
one to eight positive lymph nodes a significant five-year locoregional disease-free 
survival advantage was obtained if operated through TTE, supports the present data 
indicating that T1bN1-patients (of whom the majority has only a limited number of 
positive lymph nodes) might benefit from an extended lymphadenectomy.16 An other 
argument in favor of TTE may be the location of positive lymph nodes in this group: 
for example positive lymph nodes located high in the thorax that would not have 
been removed by a transhiatal procedure. Indeed, in 12 (34%) out of 35 N1-patients 
of the TTE-group, positive lymph nodes were located high in the mediastinum.
Despite major diagnostic advances pretreatment N-staging of early esophageal 
cancer is still unreliable. The accuracy of endosonographic staging for N-stage of early 
esophageal cancer has been reported 71-87%27, 28, although the addition of fine needle 
aspiration (FNA) can improve these results.29 This diagnostic uncertainty implicates a 
therapeutic dilemma in daily practice. Ideally, true N0-patients could be treated with 
organ-preserving endoscopic mucosal resection (EMR) or esophagectomy without 
lymphadenectomy, while N1-patients should undergo surgical resection, probably 
with extended lymphadenectomy. However, surgical resection remains the mainstay 
of submucosal esophageal cancer treatment because of the diagnostic uncertainty.
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A limitation of the present study is its retrospective and non-randomized nature. 
Comparison of TTE with THE for submucosal esophageal cancer remains difficult due 
to the small number of studies and included patients9, as well as the wide variety 
in definition of extended and limited lymphadenectomy. Moreover, studies often 
compare extensive and limited surgery for early esophageal cancer in general, 
considering T1a (mucosal) and T1b (submucosal) cancer as one clinical entity.3, 
8 Due to the relative scarcity of patients with T1bN1 disease, even in the current 
international multicenter study, the number of patients may not be sufficient to 
draw firm conclusions based on statistical evidence. Furthermore, the comparison of 
morbidity and severity of complications between the four participating hospitals is 
subject to bias because of variable definitions of complications and different scoring 
systems.  
In conclusion, for submucosal esophageal cancer TTE with extended lymphadenectomy 
and THE with regional lymphadenectomy had similar short-term outcome and 
long-term survival in general. In the selected group of T1bN1 patients TTE may be 
the preferred operative technique due to a potential disease-free survival benefit; 
in patients with T1bN0 disease THE with en bloc dissection of the esophagus and 
regional lymph nodes offers an oncologically safe and less invasive treatment.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
Surgical management of T1b-tumors
255
13
References
 1. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative 
endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in 
Barrett’s oesophagus. Gut 2008; 57(9):1200-6.
 2. Stein HJ, Feith M, von Rahden BH, Siewert JR. Approach to early Barrett’s cancer. World J Surg 2003; 27(9):1040-
6.
 3. Stein HJ, von Rahden BH, Feith M. Surgery for early stage esophageal adenocarcinoma. J Surg Oncol 2005; 
92(3):210-7.
 4. Westerterp M, Koppert LB, Buskens CJ, et al. Outcome of surgical treatment for early adenocarcinoma of the 
esophagus or gastro-esophageal junction. Virchows Arch 2005; 446(5):497-504.
 5. Stein HJ, Feith M, Bruecher BL, et al. Early esophageal cancer: pattern of lymphatic spread and prognostic 
factors for long-term survival after surgical resection. Ann Surg 2005; 242(4):566-73; discussion 573-5.
 6. Hölscher AH, Bollschweiler E, Schneider PM, Siewert JR. Prognosis of early esophageal cancer. Comparison 
between adeno- and squamous cell carcinoma. Cancer 1995; 76(2):178-86.
 7. Bollschweiler E, Baldus SE, Schroder W, et al. High rate of lymph-node metastasis in submucosal esophageal 
squamous-cell carcinomas and adenocarcinomas. Endoscopy 2006; 38(2):149-56.
 8. Stein HJ, Feith M, Mueller J, et al. Limited resection for early adenocarcinoma in Barrett’s esophagus. Ann Surg 
2000; 232(6):733-42.
 9. Fujita H, Sueyoshi S, Yamana H, et al. Optimum treatment strategy for superficial esophageal cancer: endoscopic 
mucosal resection versus radical esophagectomy. World J Surg 2001; 25(4):424-31.
 10. Ancona E, Guido E, Cutrone C, et al. A new endoscopic technique for suspension of esophageal prosthesis for 
refractory caustic esophageal strictures. Dis Esophagus 2008; 21(3):262-5.
 11. Stein HJ, Feith M. Surgical strategies for early esophageal adenocarcinoma. Best Pract Res Clin Gastroenterol 
2005; 19(6):927-40.
 12. Schröder W, Gutschow CA, Hölscher AH. Limited resection for early esophageal cancer? Langenbecks Arch Surg 
2003; 388(2):88-94.
 13. Tachibana M, Kinugasa S, Shibakita M, et al. Surgical treatment of superficial esophageal cancer. Langenbecks 
Arch Surg 2006; 391(4):304-21.
 14. Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of 
the esophagus: a meta-analysis. Ann Thorac Surg 2001; 72(1):306-13.
 15. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited 
transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347(21):1662-9.
 16. Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal 
resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann 
Surg 2007; 246(6):992-1000; discussion 1000-1.
 17. Lerut T, Coosemans W, Decker G, et al. Surgical techniques. J Surg Oncol 2005; 92(3):218-29.
 18. Lerut T, Nafteux P, Moons J, et al. Three-field lymphadenectomy for carcinoma of the esophagus and 
gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a 
plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 2004; 240(6):962-72; 
discussion 972-4.
 19. Hagen JA, Peters JH, DeMeester TR. Superiority of extended en bloc esophagogastrectomy for carcinoma of the 
lower esophagus and cardia. J Thorac Cardiovasc Surg 1993; 106(5):850-8; discussion 858-9.
 20. Rizzetto C, DeMeester SR, Hagen JA, et al. En bloc esophagectomy reduces local recurrence and improves 
survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma. J 
Thorac Cardiovasc Surg 2008; 135(6):1228-36.
 21. Sobin L. TNM Classification of Malignant Tumors. Vol. 6th edition: John Wiley & Sons, 2002.
 22. Japanese Society for Esophageal Diseases. Guidelines for Clinical and Pathological Studies. Carcinoma of the 
Esophagus. 9th edition: Kanehara, Tokyo, 2001.
 23. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a 
cohort of 6336 patients and results of a survey. Ann Surg 2004; 240(2):205-13.
 24. Ancona E, Rampado S, Cassaro M, et al. Prediction of lymph node status in superficial esophageal carcinoma. 
Ann Surg Oncol 2008; 15(11):3278-88.
 25. Peyre CG, Hagen JA, DeMeester SR, et al. The number of lymph nodes removed predicts survival in esophageal 
cancer: an international study on the impact of extent of surgical resection. Ann Surg 2008; 248(4):549-56.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R11
R12
R13
R14
R15
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
256
 26. Peyre CG, Hagen JA, DeMeester SR, et al. Predicting systemic disease in patients with esophageal cancer after 
esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 
2008; 248(6):979-85.
 27. Buskens CJ, Westerterp M, Lagarde SM, et al. Prediction of appropriateness of local endoscopic treatment for 
high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features. Gastrointest Endosc 2004; 
60(5):703-10.
 28. Rampado S, Bocus P, Battaglia G, et al. Endoscopic ultrasound: accuracy in staging superficial carcinomas of the 
esophagus. Ann Thorac Surg 2008; 85(1):251-6.
 29. Vazquez-Sequeiros E, Wiersema MJ, Clain JE, et al. Impact of lymph node staging on therapy of esophageal 
carcinoma. Gastroenterology 2003; 125(6):1626-35.
Summary
R1
R2
R3
R4
R5
R6
R7
R8
R9
R11
R12
R13
R14
R15
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
258
The incidence of esophageal cancer is rising in the Western world, mainly due to 
the increase in adenocarcinomas of the esophagus and gastroesophageal junction 
over the past decades. Patients are usually diagnosed with esophageal cancer at an 
advanced stage of the disease, as symptoms such as dysphagia and odynophagia 
are experienced when the tumor is large and obstructing the esophageal lumen. 
Moreover, esophageal cancer is an aggressive disease with early lymphatic and 
hematogenous dissemination. Hence, less than half of the newly diagnosed patients 
are eligible for curative therapy due to tumor invasion into adjacent organs, or due 
to the presence of distant metastases. 
The treatment of patients with esophageal cancer is highly complex and requires 
an interdisciplinary approach. New developments such as endoscopic treatment 
of early lesions and application of neoadjuvant chemo(radio)therapy have opened 
novel avenues towards the development of treatment strategies tailored to individual 
patients. However, surgery remains the mainstay in esophageal cancer treatment. 
It offers the best curative option, although it is associated with high morbidity and 
substantial mortality. Therefore, accurate preoperative staging and risk assessment is 
essential to select those patients who will benefit from surgery. Nevertheless, as five-
year survival rates after potentially curative esophagectomy still rarely exceed 40%, 
ongoing research by means of both experimental (e.g. pathogenesis) and clinical 
(e.g. patient selection) studies is required.
This thesis included studies that address various aspects of esophageal cancer: 
pathophysiology, diagnosis, staging and treatment. The thesis consists of three parts: 
part A – pathogenesis of Barrett’s adenocarcinoma, part B – optimization of staging, 
and part C – preoperative risk assessment and surgical treatment. 
Part A – Pathogenesis of Barrett’s adenocarcinoma
There is increasing evidence that a variety of human cancers is driven by a subset of 
cells, the so-called cancer stem cells (CSCs), which sustain tumor growth and underlie 
its malignant behavior. In chapter 1 an overview is given of the current evidence for 
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the existence of CSCs in malignancies, and its potential implications for treatment 
of solid tumors. The CSC model opens new avenues with regard to the treatment of 
cancer. The development of tailor-made targeted therapies may entail great promises 
as several approaches can be developed to specifically target CSCs, such as direct CSC 
eradication by means of therapies directed at CSC-specific surface markers.
Several markers have been employed to isolate CSCs from various malignancies, 
though not from esophageal adenocarcinoma. In chapter 2 we tested whether 
Barrett’s esophagus and esophageal adenocarcinoma might serve as a model for 
the CSC concept. Transplantation assays were performed by injecting serially diluted 
bulk esophageal adenocarcinoma cells into immunodeficient mice to establish the 
presence and frequency of tumor-initiating cells. These were found to be present 
in approximately 1:64,000 cells, and the transplanted tumors fully recapitulated the 
primary lesions. Subsequently, a panel of CSC markers previously established in other 
solid tumor types was employed to sort the corresponding subpopulations of cancer 
cells and transplant them at low multiplicities into mice. However, no increased 
tumor-initiating capacity of sorted cells was observed upon transplantation. These 
results indicate that tumor-initiating cells are present in esophageal adenocarcinoma, 
thus reflecting a hierarchal organization. However, antibodies directed against novel 
surface antigens are needed to detect subpopulations enriched for CSCs.
In chapter 3 an overview is given of the pathogenesis of Barrett’s metaplasia and 
its progression towards esophageal adenocarcinoma. Gastroesophageal reflux 
disease (GERD) has been recognized as the most important risk factor for the onset 
of Barrett’s metaplasia and esophageal adenocarcinoma. Environmental, dietary 
and genetic factors are also likely to play an important role. However, the exact 
mechanism underlying the transition from normal squamous epithelium towards 
metaplastic columnar epithelium has not been elucidated yet. The identification of 
stem cells in the normal squamous esophageal epithelium has lead to speculations 
about the contribution of these cells to the metaplastic process, as these cells are the 
only permanent residents of the epithelium.
Recently, a mouse model for Barrett’s esophagus based on a zinc-deficient diet 
supplemented with deoxycholic bile acids has been published. Chapter 4 comprises 
a short report in which the reproducibility of this non-invasive mouse model of 
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Barrett’s esophagus has been investigated. In this study, all mice showed signs of 
considerable distress and discomfort already 4 weeks after the start of the modified 
diets, and the animals had to be euthanized before the first evaluation time point. 
Therefore, we were not able to reproduce the mouse model according to which 
Barrett’s like lesions could be detected in animals fed with the zinc-deficient 
diet supplemented with deoxycholic bile acids. Notwithstanding their overall 
negative nature, these data are of relevance for the fine-tuning of this animal 
model especially as far as the role of dietary and environmental zinc is concerned. 
 
Part B – Optimization of staging 
In patients with resectable adenocarcinoma of the gastroesophageal junction (GEJ) 
preoperative staging will determine the therapeutic strategy with regard to type of 
surgical procedure and use of neoadjuvant therapy. Tumor location and lymph node 
status play a pivotal role in this tailored strategy. In Chapter 5 we investigated in 
a prospective way the accuracy for determining the location of the primary tumor 
according to the Siewert classification as well as the lymph nodal status per station. 
The preoperative assessment by endoscopy/EUS and CT-scanning were compared 
with the histopathologic findings in the resection specimen (gold standard). However, 
given the frequent discrepancy between the endoscopic and pathologic location of 
the GEJ and the common problem of advanced tumors obscuring the landmarks used 
in the assessment of the Siewert classification, its usefulness in the assessment of 
tumor location appeared to be limited. Furthermore, the overall accuracy for EUS 
and CT in predicting the N-stage per station was only moderate. 
In chapter 6 a study on the feasibility of application of the sentinel node procedure in 
adenocarcinomas of the distal esophagus and GEJ was presented. It was concluded 
that detection of sentinel nodes is technically feasible during esophagectomy 
for cancer. However, given the relatively high false-negative rate and the high 
frequency of sentinel nodes in more than one nodal station, the clinical relevance 
of the sentinel node concept (through application of the blue dye technique) in the 
current treatment of patients with an adenocarcinoma of the distal esophagus or 
gastroesophageal junction seems limited.
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In 2001 the Japanese Society of Esophageal Disease introduced its classification in 
which early cancers are subdivided in six successive layers of the mucosa (m1, m2, 
m3) or submucosa (sm1, sm2, sm3). Subdivision in six, rather than two categories 
has been shown helpful in directing patients to the most optimal treatment 
strategy. In chapter 7 we attempted to address the question whether the presence 
of occult metastases in patients with m3 and sm1 adenocarcinomas could explain 
the variation in reported incidences in lymphatic dissemination in these patients. 
Indeed, lymphatic migration of tumor cells (isolated tumor cells or micrometastases) 
was found in conventionally node-negative m3- and sm1-adenocarcinomas of 
the esophagus (8.0% and 20.0%, respectively). However, the clinical relevance of 
these occult tumor cells (whether this could influence the decision to undertake 
an endoscopic or surgical resection) should become apparent from large series of 
endoscopically treated patients. 
In chapter 8 we evaluated the reproducibility of the Japanese classification of early 
esophageal cancer. The reproducibility was good in terms of inter- and intraobserver 
variability when grading early esophageal adenocarcinoma on surgical resection 
specimens. Nevertheless, dedicated gastrointestinal pathologists with broad 
experience are preferred when grading the resection specimens of patients with 
early esophageal cancer.
Part C – Preoperative risk assessment and surgical treatment
Individual preoperative risk assessment is essential for a proper patient selection in 
the preoperative phase. In chapter 9 patients’ preoperative risk assessment and the 
potential risk factors that can be taken care of both preoperatively and intraoperatively 
in order to prevent postoperative complications in patients with esophageal cancer 
have been reviewed. Age, pulmonary and cardiovascular condition, nutritional 
status, and application of neoadjuvant chemo- and/or radiotherapy have shown 
to be important predictive factors for postoperative morbidity and mortality. Both 
the surgeon (application of appropriate surgical techniques) and the anesthetist 
(adequate fluid management) play an important role in intraoperative risk reduction. 
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In order to improve the short-term outcome of esophagectomy, an optimal 
perioperative treatment strategy can be tailored for the individual patient.
In chapter 10 and 11 the prognostic value of body mass index (BMI) and of delay 
in diagnostic work-up on short-term and long-term outcome after resection of 
esophageal cancer were studied, respectively. BMI was not of prognostic value with 
regard to short-term and long-term outcome in patients undergoing esophagectomy 
for cancer. Therefore, patients oncologically eligible for esophagectomy should not 
be denied surgery on the basis of their BMI class. A longer delay between endoscopic 
diagnosis and surgery resulted in worse patient’s short-term outcome (higher overall 
morbidity and mortality rates), but not in a worse long-term outcome (overall 
survival). This may be explained by a more time-consuming diagnostic work-up in 
patients with a poorer physical status and not by tumor progression.
Furthermore, a recently developed nomogram predicting the occurrence and severity 
of complications in esophagectomy patients was validated externally in a large cohort 
of patients who underwent esophagectomy for cancer in an independent high-
volume center. These results are presented in chapter 12: the model is applicable 
in other high-volume hospitals, but preoperative prediction of complications in 
individual patients remains difficult, most likely due to the complexity of mechanisms 
causing these complications.
Finally, an international multi-center study has been conducted in chapter 13, which 
focused on the best surgical treatment for early esophageal cancer with submucosal 
tumor infiltration (T1b). Outcome of patients who underwent esophagectomy for T1b 
cancer through a transthoracic approach (TTE) with extended lymphadenectomy was 
compared retrospectively to those of patients in whom a transhiatal esophagectomy 
(THE) was performed with regional lymph node dissection only. TTE with extended 
lymphadenectomy did not result in a worse short-term outcome (although more 
complications were graded as severe) and did not improve long-term survival in 
general. However, in the selected patient group of T1bN1 patients TTE might be the 
preferred operation technique due to a potential disease-free survival benefit; in all 
other cases THE will offer an oncologically safe and less invasive treatment.
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In de westerse wereld neemt de incidentie van slokdarmkanker toe. Dit komt 
met name door de stijging van het aantal adenocarcinomen van de slokdarm 
en de slokdarm-maag overgang gedurende de laatste decennia. De diagnose 
slokdarmkanker wordt veelal laat gesteld, als de ziekte zich al in een vergevorderd 
stadium bevindt. Symptomen, zoals pijnlijk en moeizaam slikken, worden meestal pas 
ervaren als de tumor groot is en de slokdarm obstrueert. Tevens is slokdarmkanker 
een agressieve ziekte, waarbij uitzaaiingen via de lymfebanen en bloedvaten al 
vroeg in het ziekteproces kunnen voorkomen. Van de patiënten, bij wie de diagnose 
slokdarmkanker wordt gesteld, komt slechts minder dan de helft in aanmerking voor 
een behandeling waarbij genezing kan worden verwacht. 
De behandeling van patiënten met slokdarmkanker is complex en vereist een multi-
disciplinaire aanpak. Nieuwe ontwikkelingen, zoals endoscopische behandeling van 
vroege tumoren en de toepassing van neoadjuvante chemo(radio)therapie, hebben 
de weg vrijgemaakt voor behandelingsstrategieën die gericht zijn op de individuele 
patiënt. Een operatieve ingreep blijft de belangrijkste peiler binnen de behandeling 
van slokdarmkanker, aangezien deze de grootste kans biedt op genezing. Een 
operatie gaat echter gepaard met een aanzienlijke kans op morbiditeit en mortaliteit. 
Daarom is het van belang om voorafgaand aan de operatie de patiënten te kunnen 
selecteren (door middel van tumorstadiëring en pre-operatieve risico-inschatting) 
die hierbij gebaat zullen zijn. Aangezien de vijfjaarsoverleving na een curatieve 
slokdarmresectie amper boven de 40% uitstijgt, is voortgaand onderzoek door 
middel van experimentele studies (bijvoorbeeld gericht op de ontstaanswijze van 
slokdarmkanker) en klinische onderzoeken (gericht op de patiënt) onontbeerlijk.
Dit proefschrift bevat onderzoeken die verschillende aspecten van slokdarmkanker 
belichten: pathogenese (ontstaanswijze), diagnose, stadiëring en behandeling van 
de ziekte. Het proefschrift bestaat uit drie delen: deel A – Pathogenese van het 
Barrett adenocarcinoom, deel B – Optimaliseren van tumorstadiëring, en deel C – 
Pre-operatieve risico-inschatting en chirurgische behandeling. 
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Deel A – Pathogenese van het Barrett adenocarcinoom
Er is steeds meer bewijs dat verschillende maligniteiten worden aangestuurd 
door slechts een subpopulatie aan cellen, de zogenaamde kankerstamcellen, die 
verantwoordelijk zijn voor de groei van de tumor en zijn maligne kenmerken. Hoofdstuk 
1 biedt een overzicht van de literatuur over het bestaan van kankerstamcellen en 
de mogelijke gevolgen voor de behandeling van tumoren. Het kankerstamcelmodel 
biedt volop nieuwe perspectieven voor de behandeling van kanker, aangezien 
hiermee nieuwe therapieën kunnen worden ontwikkeld, die erop gericht zijn deze 
kankerstamcellen direct aan te pakken. Een voorbeeld hiervan is het uitschakelen 
van kankerstamcellen door middel van een antilichaambehandeling gericht op 
antigenen, die zich op het celoppervlakte van kankerstamcellen bevinden. Meerdere 
celoppervlaktemarkers zijn geïdentificeerd om kankerstamcellen van verschillende 
maligniteiten te isoleren, maar nog niet van het slokdarm adenocarcinoom.
In hoofdstuk 2 hebben we onderzocht of bij het slokdarm adenocarcinoom het 
kankerstamcelmodel ook van toepassing is. Er werden transplantatie-experimenten 
uitgevoerd, waarbij tumorcellen van verse humane slokdarm adenocarcinomen in 
verschillende hoeveelheden werden geïnjecteerd in immunodeficiënte muizen. 
Op deze wijze kon worden bepaald of tumorinitiërende cellen aanwezig zijn in het 
adenocarcinoom van de slokdarm. Uit deze experimenten is gebleken dat ongeveer 1 
op de 64.000 cellen een tumorinitiërende cel is. Bovendien bleken de muis-tumoren 
histologisch identiek te zijn aan de primaire humane tumor. Vervolgens werd een 
panel van (bij andere maligniteiten) bekende kankerstamcelmarkers gebruikt om 
verschillende subpopulaties aan tumorcellen te isoleren en te injecteren in kleine 
aantallen. Er kon echter geen verhoogde tumorinitiërende capaciteit worden 
waargenomen voor een subpopulatie cellen verrijkt aan een specifieke marker. 
Deze resultaten suggereren dat tumorinitiërende cellen aanwezig zijn in het 
slokdarm adenocarcinoom, maar dat reeds bekende kankerstamcelmarkers niet de 
markers lijken te zijn voor dit type tumor. Antilichamen tegen nieuw te ontdekken 
oppervlakte-antigenen zijn nodig om celpopulaties te identificeren, die verrijkt zijn 
aan kankerstamcellen van het slokdarm adenocarcinoom. 
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Hoofdstuk 3 biedt een overzicht van de pathogenese van Barrett metaplasie 
(de voorloper van het adenocarcinoom) en de progressie naar het slokdarm 
adenocarcinoom. Gastro-oesofageale refluxziekte (GORZ) is de belangrijkste 
risicofactor voor het ontstaan van een Barrett slokdarm, waarbij de binnenbekleding 
of epitheel van de slokdarm van celtype verandert (metaplasie). Het exacte 
mechanisme dat ten grondslag ligt aan de omslag van het normale squameuze 
epitheel naar het metaplastische epitheel is echter nog onbekend. De identificatie 
van stamcellen in de basale laag van het normale squameuze slokdarmepitheel 
heeft tot de speculatie geleid dat stamcellen verantwoordelijk kunnen zijn voor 
deze omslag. Het zijn immers de enige cellen zijn die permanent aanwezig zijn in het 
epitheel.
Onlangs is een muismodel voor een Barrett slokdarm gepubliceerd, waarbij muizen 
een zinkdeficiënt dieet kregen, aangevuld met galzouten, en waarbij na enkele 
maanden veranderingen in de slokdarm konden worden geobserveerd, die veel 
gelijkenis vertoonden met een Barrett slokdarm. Hoofdstuk 4 bestaat uit een 
zogeheten ‘short report’ waarin we de reproduceerbaarheid hebben onderzocht van 
dit non-invasieve muismodel. In ons onderzoek kregen alle muizen echter al na vier 
weken vanaf de start van het dieet zoveel ongemak, dat het experiment voortijdig 
moest worden afgebroken. Hierdoor waren wij niet in staat om het muismodel te 
reproduceren waarbij een Barrett slokdarm zou ontstaan na het introduceren van 
een zinkdeficiënt dieet aangevuld met galzouten. Ondanks het negatieve karakter 
van deze uitkomsten, zijn deze data relevant voor het aanpassen van het eerder 
beschreven model. 
 
Deel B – Optimaliseren van tumorstadiëring 
Bij patiënten met een resectabel slokdarm adenocarcinoom van de slokdarm of de 
slokdarm-maag overgang, zal de pre-operatieve tumor stadiëring het uiteindelijke 
behandelplan bepalen voor wat betreft de operatietechniek en de eventuele 
toepassing van pre-operatieve chemo- en/of radiotherapie. De locatie van zowel de 
tumor als de mogelijke betrokken lymfeklierstations speelt een centrale rol in deze 
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op maat gemaakte behandelingsstrategie. In hoofdstuk 5 hebben we prospectief 
de betrouwbaarheid onderzocht van het bepalen van de tumorlocatie volgens de 
classificatie van Siewert en de lymfeklierstatus per klierstation. De pre-operatieve 
inschatting door de endoscopie/endo-echoscopie en de CT-scan werd vergeleken 
met het pathologische eindoordeel vanuit het chirurgische resectiepreparaat 
(‘gouden standaard’). Uit dit onderzoek is gebleken dat door de vaak voorkomende 
discrepantie tussen de endoscopische en pathologische locatie van de slokdarm-
maag overgang en door het frequente voorkomen van grote, stenotische tumoren 
die de markeringspunten van de Siewert classificatie maskeren, de bruikbaarheid van 
deze classificatie in de dagelijkse praktijk in twijfel kan worden getrokken. Daarnaast 
bleek de betrouwbaarheid in het voorspellen van de lymfeklierstatus per klierstation, 
door zowel de endo-echoscopie als de CT-scan, slechts matig. 
In hoofdstuk 6 staat het onderzoek beschreven waarin het gebruik van de zogeheten 
‘sentinel node procedure’ (veelal gebruikt bij borstkanker) tijdens de operatie voor 
slokdarm adenocarcinomen werd onderzocht. Uit deze studie is gebleken dat deze 
poortwachtklieren (‘sentinel nodes‘) inderdaad opgespoord kunnen worden tijdens 
de operatie met behulp van blauwe kleurstof. Echter, gezien de relatief hoge fout-
negatieve uitslag en gezien het vaak voorkomen van meerdere poortwachtklieren 
op verschillende plaatsen, lijkt de klinische toepassing van dit concept bij de huidige 
behandeling van patiënten met een slokdarm adenocarcinoom beperkt.
In 2001 introduceerde de Japanse vereniging voor slokdarmkanker een nieuwe 
classificatie voor vroege tumoren van de slokdarm, waarbij deze vroege laesies 
worden onderverdeeld in zes opeenvolgende categorieën van de slokdarmmucosa 
(m1-, m2- en m3-tumoren) en -submucosa (sm1-, sm2- en sm3-tumoren). Deze 
onderverdeling in plaats van de gebruikelijke twee categorieën is zinvol gebleken 
tijdens het bepalen van de optimale behandelingsstrategie bij deze patiëntengroep. 
In hoofdstuk 7 hebben we geprobeerd de vraag te beantwoorden of de aanwezigheid 
van occulte tumorcellen (geïsoleerde tumorcellen of micrometastasen) in lymfeklieren 
bij patiënten met een m3- of sm1-slokdarmtumor de variatie kan verklaren in de 
gerapporteerde incidentie in lymfogene metastasering in deze subgroepen. Er bleken 
inderdaad in onze serie van m3- en sm1-patiënten, waarbij de lymfeklierstatus in 
eerste instantie als negatief was afgegeven, occulte tumorcellen aanwezig te zijn in de 
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lymfeklieren: 8% in m3-tumoren en 20% in sm1-tumoren. De klinische relevantie van 
deze tumorcellen (oftewel de mogelijke invloed op de beslissing om endoscopisch 
of chirurgisch te behandelen) zal echter in de toekomst duidelijk moeten worden uit 
een grote serie patiënten die endoscopisch zijn behandeld.
Hoofdstuk 8 beschrijft het onderzoek waarin de reproduceerbaarheid van de 
reeds genoemde Japanse classificatie voor vroege tumoren van de slokdarm wordt 
geëvalueerd. De reproduceerbaarheid was goed voor wat betreft de zogenaamde inter- 
en intra-observer variabiliteit bij het beoordelen van chirurgische resectiepreparaten 
op de tumor infiltratiediepte van vroege slokdarm adenocarcinomen. Toegewijde 
en ervaren pathologen blijven echter nodig om deze tumoren zorgvuldig te kunnen 
classificeren.
Deel C – Pre-operatieve risico-inschatting en chirurgische 
behandeling
Een individuele pre-operatieve risico inschatting is essentieel voor een goede 
selectie van patiënten die een operatie zullen ondergaan. In hoofdstuk 9 worden alle 
mogelijke risicofactoren samengevat die zowel voor als tijdens de operatie beïnvloed 
kunnen worden om post-operatieve complicaties te voorkomen bij patiënten met 
slokdarmkanker. Leeftijd, hart- en longconditie, voedingstoestand en toepassing van 
pre-operatieve chemo- en/of radiotherapie, zijn belangrijke voorspellers voor post-
operatieve morbiditeit en mortaliteit. Zowel de chirurg (toepassing van de juiste 
operatietechniek) als de anesthesist (handhaven van een adequate vochtbalans) 
spelen een belangrijke rol tijdens de operatie in het verkleinen van de kans op post-
operatieve complicaties. Om de uitkomst op korte termijn na een slokdarmresectie 
te verbeteren, moet een optimaal behandelingsplan opgesteld worden voor de 
individuele patiënt. 
In de hoofdstukken 10 en 11 is onderzocht wat de voorspellende waarden van de 
parameters body mass index (BMI) respectievelijk de wachttijden voor een operatie 
zijn voor zowel de korte als de lange termijn na een slokdarmresectie. De BMI bleek 
niet van voorspellende waarde voor de uitkomst van een slokdarmoperatie: het aantal 
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en het soort post-operatieve complicaties en de overleving verschilden niet tussen 
patiënten met een lage en hoge BMI. Hierdoor werd uit deze studie de conclusie 
getrokken dat aan patiënten met slokdarmkanker een operatie niet onthouden mag 
worden op basis van een hoge BMI. Een langere wachttijd tussen het stellen van 
de diagnose tijdens endoscopie en de operatie was geassocieerd met een slechtere 
post-operatieve uitkomst op korte termijn (hogere morbiditeit en mortaliteit), maar 
was niet geassocieerd met een slechtere uitkomst op lange termijn (vergelijkbare 
overleving). Het is daardoor meer aannemelijk dat deze associatie tussen wachttijd en 
uitkomst op korte termijn verklaard kan worden door een intensievere en daardoor 
langere pre-operatieve voorbereiding bij patiënten die zich reeds in een slechtere 
lichamelijke conditie bevinden (en dus bij voorbaat al een grotere kans hebben op 
post-operatieve complicaties), dan dat tumorprogressie hiervoor verantwoordelijk 
is.  
In hoofdstuk 11 is een recent ontwikkeld nomogram (een grafisch model) beschreven 
dat het voorkomen en de ernst van complicaties bij patiënten die een slokdarmresectie 
ondergaan kan voorspellen en dat extern gevalideerd is in een groot onafhankelijk 
cohort patiënten van een ander hoogvolume centrum. Het blijkt dat het model 
toepasbaar is in andere ziekenhuizen, maar dat het pre-operatief voorspellen van 
complicaties voor een individuele patiënt moeilijk blijft. Dit is waarschijnlijk het 
gevolg van de complexe mechanismen die deze complicaties veroorzaken. 
Ten slotte is een internationaal multi-center onderzoek uitgevoerd, dat zich richtte 
op de vraag welke chirurgische behandeling het beste is voor patiënten met een 
submucosaal ingroeiende slokdarmtumor (T1b-tumoren). In hoofdstuk 13 zijn in 
retrospectie de uitkomsten van T1b-patiënten die een transthoracale slokdarmresectie 
ondergaan met een uitgebreide lymfeklierdissectie (TTE), vergeleken met de 
patiënten waarbij een transhiatale operatie werd uitgevoerd met een beperkte 
lymfeklierdissectie (THE). Een TTE leidde niet tot een slechtere uitkomst op korte 
termijn (alhoewel meer complicaties als ernstig werden gegradeerd), maar leverde 
ook geen overlevingswinst op voor deze patiënten. Echter, in de geselecteerde groep 
van T1bN1-patiënten, lijkt een TTE wellicht toch de operatietechniek van keuze door 
een mogelijk voordeel in ziektevrije-overleving. In alle andere gevallen zal een THE 
een oncologisch acceptabele en minder invasieve behandeling geven. 
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In high-volume centers, the five-year survival rate (without standard application of 
neoadjuvant therapy) in patients with esophageal cancer after potentially curative 
esophagectomy rarely exceeds 40%. It is possible that a plateau in the effectiveness 
of surgery as primary therapy in esophageal cancer patients may have been reached. 
Therefore, further improvement in survival from this single modality approach seems 
unlikely. The care for patients with esophageal cancer will probably be increasingly 
individualized in the future, with the addition of new therapeutic targets. This 
paragraph describes novel options that might be implemented in the management of 
esophageal cancer, and on which future research should focus in both experimental 
and clinical settings.
Cancer stem cells
Obviously, further studies are needed in order to attempt to identify CSCs in 
esophageal cancer. The identification of CSCs has potentially important implications 
for the treatment of cancer, in specific the therapeutic promise of CSC-directed 
treatment strategies. Potential therapies which are selective to CSCs and not toxic 
to normal stem cells hold great promise for the effective and potentially curative 
therapy of many human cancers. CSC-targeting strategies may include (a) direct 
targeting of CSCs through antibodies directed at CSC-surface markers, (b) blocking 
the essential self-renewal signaling pathways, (c) reversal of CSC resistance to chemo- 
and/or radiotherapy and (d) induction of CSC differentiation.1 Direct targeting of 
CSCs through their CSC-surface markers seems an obvious solution. However, most 
of these markers are also expressed in normal cells, thus finding a therapeutic 
window will be a challenge. Blocking essential self-renewal signaling pathways such 
as Wnt, Hedgehog and Notch is also a promising strategy. In colorectal cancer small-
molecules that inhibit the Wnt- and Notch pathway have recently been identified 
as novel approaches.2 Nevertheless, these pathways are mostly shared by normal 
stem cells, indicating the difficulty of this strategy. An other CSC-directed therapeutic 
strategy might be the targeting of signals that regulate CSC resistance to chemo- 
and/or radiotherapy. Recent findings in colon cancer further support the potential 
utility of CSC chemosensitizing agents: pretreatment of CD133+ colon CSCs with a 
neutralizing antibody enhanced apoptosis mediated by chemotherapy both in vitro 
and in vivo.3
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Following the more recent findings suggesting the interaction between epithelial-
mesenchymal transition (EMT) and CSCs, and more specifically the demonstration 
that the tumor microenvironment may regulate the stemness of cancer cells, a new 
treatment strategy can be proposed. Obviously, if non-CSCs can indeed give rise to 
CSCs, this plasticity would frustrate attempts to cure tumors by eliminating CSCs 
alone. Therefore, cancer therapy should include agents that focus on targeting both 
CSCs and non-CSCs. However, further research is first required to investigate the role 
of EMT in esophageal cancer, and its potential as a prognostic factor for metastases 
and poor survival like in colorectal cancer.4
Molecular tumor biology
The complete sequencing of the human genome in 2003 has enabled systematic 
approaches to identify cancer genome alterations. Molecular targets for therapy 
are becoming widely known and include epidermal growth factors, tyrosine 
kinases, vascular endothelial growth factors and intracellular signaling pathways. 
Microarray analysis to study gene expression is able to identify genes which can 
function as a guide for tailored therapy, i.e. prediction of response to neoadjuvant 
therapy. Recently, a four-gene signature has been discovered and validated that 
independently predicts survival of patients with resected adenocarcinoma of the 
esophagus or gastroesophageal junction.5 Other examples of cancer-targeted 
therapy are Trastuzumab/Herceptin (used to treat Her2/neu overexpressing breast 
cancer) and Gefitinib/Iressa (used to treat lung cancers with EGFR mutations). 
Molecular characteristics of the tumor are becoming more and more important, with 
hopefully in the future the possibility to select the most appropriate treatment for 
the individual patient. 
Neoadjuvant chemoradiotherapy
Improvement in survival may also be expected from neoadjuvant chemoradiotherapy. 
Neoadjuvant chemoradiotherapy is thought to improve primary tumor resectability 
(higher number of radical or R0 resections) and to eliminate (micro)metastatic disease. 
A meta-analysis published in 2007 showed a survival benefit for patients treated with 
neoadjuvant chemoradiotherapy followed by surgery compared to patients treated 
with surgery alone.6 However, most included studies described mainly squamous 
cell carcinomas and had only small sample-sizes. In 2004 a multicenter randomized 
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phase-III trial (including 175 patients in each arm) was initiated in The Netherlands to 
evaluate the effect of neoadjuvant chemoradiotherapy (5-week scheme consisting of 
41.4 Gray in 23 fractions of 1.8 Gray plus a weekly dosis of paclitaxel 50 mg/m2 and 
carboplatin AUC=2) followed by surgery compared to surgery alone in patients with 
potentially curable esophageal cancer.7 Results of this study in terms of long-term 
survival are expected in 2011. 
Patient selection
Better patient selection for esophageal surgery may lead to better survival. Improved 
pre-operative staging (i.e. dedicated gastroenterologists reporting all (tumor) 
landmarks during endoscopy and fine-needle aspiration of all potentially critical 
lymph nodes) will lead to well-considered decision-making with regard to operation 
technique and application of neoadjuvant therapy. Furthermore, preoperative risk 
assessment will supply important information for both patient and surgeon. Potential 
intervention of risk factors (i.e. preoperative respiratory muscle training in case of 
pulmonary dysfunction in order to reduce postoperative pulmonary complications, 
or routine prophylactic combination therapy such as beta-blocker, statin, and aspirin 
to prevent cardiovascular events) hold great promise.
Finally, collaboration between departments (surgery, gastroenterology, medical 
oncology, radiology and pathology) as well as cooperation between hospitals 
(nationwide and on an international basis) will be of utmost importance in future 
research in order to optimize our knowledge in pathogenesis, diagnostics, staging 
and treatment of patients with esophageal cancer. Otherwise, the disease will remain 
a miscellaneous mystery…
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ontwikkeling!
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dit proefschrift staat, dan ben jij het wel. Terwijl we samenwerkten op de afdeling HPB van 
Flinders Medical Centre in Adelaide, zette ik mijn eerste stappen in onderzoeksland. Onder 
jouw voortvarende begeleiding volgden al snel de eerste artikelen èn mijn enthousiasme 
voor het wetenschappelijke onderzoek. Mijn mening over experimenteel onderzoek in een 
laboratorium werd door jou voorzichtig bijgesteld. Bovendien heb ik deze onderzoeksjob 
ten dele ook zeker aan jou te danken. Waar enkele bezoekjes aan de wijnvalleien van South 
Australia al dan niet toe kunnen leiden… Thanks mate! 
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Prof.dr. F.J.W. ten Kate, beste professor, vele coupes hebben wij bekeken aangaande de studies 
over de vroegcarcinomen; ook voor een inter- en intra-observerstudie was u bereid om in de 
vroege uurtjes in het AMC of het UMC met mij de data te verzamelen.
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de werkbezoeken aan Leuven en onze samenwerking aangaande de T1b-studie als zeer prettig 
ervaren. Het kostte wat politieke inspanningen, maar wat is het een mooi artikel geworden!
Leden van de grote commissie, hartelijk dank dat u bereid bent om vandaag plaats te nemen 
in de oppositie. 
Prof.dr. H.W. Tilanus, beste professor, u heeft in het bijzonder bijgedragen aan dit proefschrift. 
De aangewende databases waren door uw inspanningen de afgelopen jaren goed gevuld. Ook 
voor vers onderzoeksmateriaal kon ik altijd bij u terecht. Hopelijk heb ik, wanneer ik voor mijn 
opleiding in het Erasmus MC terug ben, nog een keer het genoegen om met u een buismaag 
te opereren!
Dr. W.N.M. Dinjens, beste Winand, jouw betrokkenheid en interesse voor mijn onderzoek 
waren heel groot. Veel dank wil ik vooral uitspreken voor de wijze waarop jij mij wegwijs 
maakte in het JNI toen ik daar net begonnen was! 
Dr. R.C. Fitzgerald, dear dr Fitzgerald, your attendance today at my PhD-defense is greatly 
appreciated. Hopefully a collaboration between the esophageal research groups in Rotterdam 
and Cambridge will become feasible in the future!
Pieter van Hagen, enorme slokdarmcollega van me! Lieve Piet, allereerst veel dank voor je 
hulp bij het verzamelen van alle data voor onze gezamenlijke studies, maar vooral voor alle 
gezellige momenten tijdens de borrels en congressen. Hopelijk ben je snel weer een directe 
collega van me, maar daar twijfel ik niet over!
Mark van Heijl, slokdarmmattie uit het AMC. We hebben toch maar mooi in een snel tempo 
drie artikelen samen geschreven! Dank voor de gezellige samenwerking en de altijd leuke 
congresbezoeken: Boedapest, Londen, Japan en heel veel Veldhoven… 
Dear colleagues of the Fodde-lab: thanks a lot for your patience in teaching this doctor all 
the laboratory work, but moreover, thanks for your friendship Alex, Andrea (die-hard FACS-
man), Claudia (goddess in explaining), Ingrid, Ivana, Joana B., Joana M. (teaching me the 
transplantation experiments!), Katia, Kim, Lia, Mehrnaz (all-round labteacher, even Western 
Blots), Ron, Rosalie (esospheres rule!), Rubina (Western Blot queen), Sabrina (coffee queen, 
but most of all part of the-best-lab-day-out-ever-team!), Yaser, and Yong-yi. 
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A special thanks for Patrick (missing you already good-old roommate...), Petra (your patience 
and kindness have been greatly appreciated, hopefully we will stay in contact!) and of course 
last-but-not least Marieke, what can we do without you???
Beste collega’s van het Moleculaire Diagnostiek Winand-lab: hartelijk dank voor de gezelligheid 
en jullie interesse in mijn onderzoek! In het bijzonder wil ik nog noemen Jurjen en Ronald voor 
de fijne slokdarmwerkbesprekingen op dinsdagochtend (en Ronald natuurlijk voor zijn hulp bij 
het kweken!) en Ludo voor het ‘in no time’ afleveren van coupes als ik weer eens had gevraagd 
om een serie blokjes te snijden..
Verder bedank ik de mensen van de 2e verdieping van het JNI die mijn onderzoek hebben 
ondersteund: Alex (erg relaxed als ik weer eens een computerprobleempje had), Frank (top 
kwaliteit foto’s!), Kees (uitleg over en gezelligheid tijdens de immuno’s), Hein en Pieter (voor 
als ik weer de fancy apparatuur van jullie IHC-lab mocht gebruiken) en de weefselbank. 
Beste Katharina Biermann, John Hermans, Jan Werner Poley en Manon Spaander, bedankt 
voor jullie inspanningen bij onze prospectieve studie over de Siewert classificatie. De goede 
samenwerking met jullie afdelingen (pathologie, radiologie en MDL) was mij een waar 
genoegen.
Aansluitend wil ik graag van de gelegenheid gebruik maken om de prettige samenwerking met 
het AMC te benoemen. Mark van Berge Henegouwen, Hans Reitsma en Sjoerd Lagarde, dank 
voor jullie enthousiaste medewerking, een aantal mooie artikelen zijn het resultaat!
Alle chirurgische onderzoekscollega’s, wat was het toch een mooie tijd! 
Lieve Bart-Jeroen, de koffiepauzes waren een verademing in de eerste drie maanden van mijn 
bestaan als onderzoeker. Gelukkig volgden daarna nog vele gezellige borrelmomenten bij het 
hockeyen en skiën! Onderzoekers uit de kelder, alias lunch- en koffievrienden, Jan Willem (fijn 
op maandag de uitslagen van het weekend bespreken!), Max (Ditzeltje, hopelijk heb je toch 
een beetje genoten van de opvoeding van Tessa en mij…) en alle anderen. 
Dushi Tamara (fijne skipartner: ja, we kunnen deze piste wel aan, NU een bocht!), Nienke 
(‘Amsterdam rules’ kan ik helaas niet meer zeggen… en jij hopelijk binnenkort ook niet meer!), 
Stephanie (je logeerbed staat klaar!), Zarina, Sanne, Carlijn en alle andere onderzoekers van 
het Z-gebouw: al was het een heel eind om de gang te maken van het lab naar jullie kamers, 
gezellig waren de bezoekjes altijd! Veel succes verder met onderzoeken!
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Mijn favoriete studenten Eric en Gijsbert, mede dankzij jullie inspanningen is het BMI-artikel 
een feit. Succes verder met de co-schappen en wie weet tot snel in de kliniek!
Drie bijzondere mensen verdienen nog een woord van dank: Conny Vollebregt (een betere 
en meer gezellige databasemanager kunnen wij ons niet wensen), Conny van Dooren (vooral 
je bemoedigende woorden rondom de sollicitatieprocedure werden zeer gewaardeerd!) en 
Adrie van Houwelingen (vele gezellige momenten als ik weer eens op de professor stond te 
wachten, dank voor je hulp bij het afronden van dit boekje!). 
Daarnaast wil ik Carla Capel nog bedanken voor de voortvarende hulp bij de administratieve 
procedures aangaande het afronden van mijn promotietraject.
Bazen en collega-assistenten in het Sint Franciscus Gasthuis, ook al werk ik er nog niet zo lang, 
ik weet zeker dat ik een mooie opleidingstijd bij jullie mag volbrengen!
Alle lieve vrienden en vriendinnen van mij, met jullie is het leven zeer aangenaam, dank voor 
jullie vriendschap! Een aantal noem ik in het bijzonder. 
Baukje, Jitske en Riegonda, ook al hebben jullie geen medische achtergrond, altijd bleven de 
vragen komen of ik al wat leuks had ontdekt met mijn onderzoek, hoeveel artikelen ik al had 
geschreven, wat ik nu precies in het lab deed en hoe zo’n proefschrift er uit komt te zien. Jullie 
verregaande interesse heb ik zeer gewaardeerd, et voila, hierbij het resultaat!
Enorm fijne GC’s Jikke, Nina, Sanne en Toesja, geneeskunde-vriendinnen vanaf het eerste uur 
in Maastricht. Allen een andere richting gekozen, maar wat is het heerlijk om met jullie lekker 
bij te praten over ons vak tijdens de weekendjes in Almen of Scheveningen! Dat er nog maar 
veel ‘get-together-momenten’ mogen volgen onder het genot van een spritz-aperolletje…
Lieve Céline, jij weet als geen ander wat de ziekte slokdarmkanker inhoudt en wat voor 
gevolgen het kan hebben. Ik heb veel respect voor de manier waarop jij in het leven staat! 
Lieve (schoon)familie: Heynric en Mira, Margit en Reinout (en favoriete nicht Jasmijn..), 
Marieke (darling Kieks, bedankt voor al je correcties. Erg fijn zo’n neerlandica in de familie!), 
Carla en Paul, Claudia en Gijs (en favoriete neef Timme..). Dank voor jullie interesse in mijn 
promotietraject. Ik bof maar met zo’n familie!
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Zeer gewaardeerde paranimfen! Lieve Heynric, jij als grote broer bent natuurlijk mijn grote 
voorbeeld op vele vlakken, maar vooral op het medische gebied volg ik je trouw: geneeskunde 
studeren in Maastricht, werken in het buitenland en dan nu ook promoveren! Een mooie 
toekomst met Mira, jullie aanstaande gezin en een geweldige baan als kindercardioloog staan 
jou zeker te wachten. 
Lieve Tessa, als er iemand weet hoe mijn promotietraject is verlopen, dan ben jij het wel. 
Veel dank voor je grote interesse in mijn onderzoek. Onder het genot van vele macchiato’s 
en boterkoekjes in de koffiebar van de faculteit, spraken wij elkaar dagelijks. Dat is wel even 
wennen nu we beiden de opleiding in een ander ziekenhuis zijn gestart… Gelukkig heb ik mooie 
herinneringen en vooral een goede vriendin overgehouden aan onze tijd als onderzoeker!
Lieve paps en mams, jullie onvoorwaardelijke liefde is overweldigend, evenals jullie grenzeloze 
steun. Grenzeloos zeker ook in de letterlijke zin van het woord, want waar zijn jullie niet 
geweest om mij op te zoeken als ik weer eens co-schappen liep of werkte aan de andere kant 
van de wereld? Bovenal, jullie hebben mij geleerd te geloven, te hopen en lief te hebben, 
waarvoor ik jullie zeer dankbaar ben (ook al is mijn naam onuitspreekbaar in het buitenland…). 
Mijn proefschrift draag ik dan ook aan jullie op.
Allerliefste Maarten (my dear fiancée!), zeer veel dank voor jouw liefde voor mij. Op vele 
momenten gaf je mij de steun, de rust en het vertrouwen om door te gaan met dit traject. Niet 
alleen aangaande het onderzoek maar het gehele chirurgische pad dat ik nu bewandel, wordt 
op alle vlakken door jou gesteund. Na onze ‘Down Under-experience’ voelt de stap met jou 
naar Rotterdam eigenlijk wederom aan als een fijn avontuur dat wij samen mogen beleven! 
Lief, ik houd met heel mijn hart van jou, op een zeer mooie toekomst samen!
Brechtje
Rotterdam, najaar 2010
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PhD Portfolio
Summary of PhD training and teaching
Name PhD student: Brechtje A. Grotenhuis
Erasmus MC Department: Surgery / Pathology
Research School: Molecular Medicine
PhD period: Oktober 2007 – June 2010
Promotors: Prof.dr. J.J.B. van Lanschot and 
Prof.dr. R. Fodde
1. PhD training
Year Workload
(Hours/ECTS)
General courses 
- Laboratory animal science
- Safety in the laboratory
- Statistics and Methodology:
* Classical Methods for Data-analysis
       * Modern Statistical Methods
       * Survival Analysis for Clinicians
2007
2007
2008
2008
2009
3.0 ECTS
0.3 ECTS
5.7 ECTS
4.3 ECTS
1.9 ECTS
Seminars and workshops
- Erasmus Gastroenterology Day
       “Treatment of M1a-disease in patients with esophageal
        cancer”
2009 1.0 ECTS
Presentations
- Various presentations at research meetings of the 
Department of Surgery and the Department of 
Experimental Pathology
2007 - 2010
Presentations (inter)national conferences
– SEOHS (Utrecht)
   “Kanker stamcel markers van het oesofagus adenocarcinoom”
– Chirurgendagen NVvH (Veldhoven)
   “Analyse naar kankerstamcelmarkers van slokdarmkanker” 
– Chirurgendagen NVvH (Veldhoven)
   “Sentinel node procedure bij patiënten met slokdarmkanker”
– UEGW / Gastro (London)
   “Prognostic value of body mass index on short-term and long- 
term outcome after resection of esophageal cancer“
– UEGW / Gastro (London) 
   “Surgical management of submucosal esophageal cancer:
   extended or limited lymphadenectomy?”
2008
2009
2009
2009
2009
1.0 ECTS
1.0 ECTS
1.0 ECTS
1.0 ECTS
1.0 ECTS
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– UEGW / Gastro (London)
 “Analysis of cancer stem cell markers in esophageal 
adenocarcinoma”
– Najaarsvergadering NVvH (Ede)
   “De prognostische waarde van body mass index op de korte 
en lange termijn uitkomst na resectie voor slokdarmkanker” 
– Voorjaarsvergadering NVGE (Veldhoven)
   “Lymphatic micrometastases in patients with early esophageal 
adenocarcinoma”     
– Chirurgendagen NVvH (Veldhoven)
 “Validatie van een nomogram voor het voorspellen 
van postoperatieve complicaties bij patiënten met 
slokdarmkanker”
– Annual meeting European Surgical Association (Budapest) 
”Surgical management of submucosal esophageal cancer: 
extended or regional lymphadenectomy?”
– European Society of Surgical Research (Geneva) 
 “Lymphatic micrometastases in patients with early esophageal 
adenocarcinoma”
– International Society for Diseases of the Esophagus (Japan)
   “Barrett’s esophageal adenocarcinoma encompasses tumor
    initiating cells that do not express common cancer stem cell
    markers”
– International Society for Diseases of the Esophagus (Japan)
  “Preoperative assessment of tumor location in adenocarcinomas 
   of the gastroesophageal junction according to the Siewert
   classification”
2009
2009
2010
2010
2010
2010
2010
2010
1.0 ECTS
1.0 ECTS
1.0 ECTS
1.0 ECTS
1.0 ECTS
1.0 ECTS
1.0 ECTS
1.0 ECTS
Posterpresentations (inter)national conferences 
– UEGW (Vienna)
   “The sentinel node concept in esophageal adenocarcinoma”
– International Society Diseases of the Esophagus (Budapest)
   “Immunohistochemistry analysis of cancer stem cell markers 
    in esophageal adenocarcinoma”
– Frontiers in Basic Cancer Research (Boston)
   “Barrett’s esophagus and esophageal adenocarcinoma: a
   paradigm for the cancer stem cell model?”
– SEOHS  (Nijmegen)
   “Micrometastasen bij het vroeg-carcinoom van de oesofagus”
– UEGW/Gastro (London)
   “Impact of delay in diagnostic work-up and treatment of
   patients with esophageal cancer” 
2008
2008
2009
2009
2009
0.5  ECTS
0.5  ECTS
0.5  ECTS
0.5  ECTS
0.5  ECTS
2. Teaching
Year Workload 
(Hours/ECTS)
Other
- Supervising second year medical students
   Elective “Kanker: van kliniek tot diagnostiek”
- Supervising third year medical students
   Research elective
2009 / 2010
2008 / 2009
2 x 0.5 = 1.0 
ECTS
1.5 ECTS
Curriculum vitae
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Brechtje Aleid Grotenhuis (April 5th 1980, Zeist) grew up in the neighborhood of the 
Utrechtse Heuvelrug. In 1998 she started her medical studies in Maastricht. Besides 
the challenge of the problem-based learning system propagated by the Maastricht 
University, several chances were offered to explore medicine abroad. Clinical rotations 
were conducted in Adelaide (Australia), Aruba (Netherlands Antilles) and Cape Town 
(South Africa). Her medical degree was obtained in 2005, after which she started 
working as a surgical resident at Tergooiziekenhuizen, Hilversum (supervisors: dr. J.W. 
Juttmann and dr. J.P. Eerenberg). After a year, she decided to take the chance to 
work abroad again, now as a surgical resident in Australia (Flinders Medical Centre, 
Adelaide; supervisors: prof. D.I. Watson and dr. B.P.L. Wijnhoven). Back from the Down 
Under experience, she started her PhD-project in October 2007 at the departments 
of surgery and experimental pathology of the Erasmus MC in Rotterdam (supervisors: 
prof.dr. J.J.B. van Lanschot and prof.dr. R. Fodde). In July 2010 she started her general 
surgical training at the Sint Franciscus Gasthuis in Rotterdam (supervisors: dr. A.J. 
Kerver and prof.dr. J.N.M. IJzermans).
